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ABSTRACT 
 
Epidemiological Burden of Depression and its Impact on Adherence to Oral 
Hypoglycemic Agents and Related Economic Outcomes in Patients with Type 2 
Diabetes 
 
Iftekhar D. Kalsekar 
 
 
Presence of depression in patients with type 2 diabetes may affect their adherence 
to oral hypoglycemics and consequently glycemic control and economic outcomes.  
These potential effects may be more significant when one considers that depression is 
highly prevalent in patients with diabetes.  This study involved two phases.  Phase one of 
the study examined the epidemiological relationship between depression and type 2 
diabetes.   Phase two of the study examined the impact of depression on patterns of use 
and adherence to oral hypoglycemics in newly diagnosed type 2 diabetes patients.  
Impact of depression on expenditures related to type 2 diabetes and overall health care 
was also estimated.  The study also tested the mediating influence of adherence between 
depression and type 2 diabetes expenditures.  Results of phase one of the study indicated 
that depression was more prevalent in patients with type 2 diabetes as compared to a 
control group.  Results also indicated that females with depression were more likely to 
develop type 2 diabetes as compared to those without depression.  Phase two results 
indicated that patients without depression had a more favorable pattern of oral 
hypoglycemic use with a significantly lower proportion of non-depressed patients 
switching, augmenting, or discontinuing their oral hypoglycemics as compared to 
depressed patients.  Depressed patients were also found to have significantly lower 
adherence to oral hypoglycemics as compared to non-depressed patients.  Multivariate 
analyses indicated that patients with depression incurred 21.30% higher type 2 diabetes 
related costs as compared to non-depressed patients.  This difference was primarily due to 
a higher probability of an ER/hospitalization episode in depressed patients.  Similarly, 
patients with depression had 32.10% higher overall health care costs as compared to 
patients without depression.  Depression was associated with increased costs in all areas 
of health care such as ER/hospitalization, outpatient, and prescription costs.  Mediation 
analysis indicated that adherence to oral hypoglycemics was not a mediator between 
depression and type 2 diabetes related expenditures.  Thus, depression could have 
potentially impacted type 2 diabetes related outcomes directly through a physiological 
effect on glycemic levels or indirectly through its impact on adherence to other behaviors 
such as diet or exercise. 
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CHAPTER ONE 
INTRODUCTION 
An estimated 17 million Americans are affected by diabetes.  The American 
Diabetes Association (ADA) has estimated the total cost attributable to diabetes to be 
$132 billion in 2002, which included $ 91.8 billion in direct medical and treatment costs.1 
The prevalence rates of diabetes in Medicaid programs have been reported to be nearly 
twice that of the US population as a whole.  Prevalence based costs of illness studies have 
shown that the per capita mean cost of patients with diabetes in Medicaid were nearly 
$8,000 per year; approximately four times the annual cost of a Medicaid enrollee without 
diabetes.2 
Diabetes mellitus can be divided into type 2 diabetes (formerly called non-insulin 
dependent diabetes mellitus) and type 1 diabetes (formerly known as insulin dependent 
diabetes mellitus).  Type 2 diabetes is more prevalent and accounts for more than 90% of 
diabetes cases.3  Data from the National Medical Expenditure Panel Survey (MEPS) 
showed that inpatient hospital care for diabetes accounted for 63% of the total health care 
expenditure for diabetics.4 Although the cost breakdown estimates for Medicaid are not 
available, one can assume that even in Medicaid programs, diabetic complications 
account for a major fraction of the total costs attributable to type 2 diabetes. 
Over the past decade large-scale studies have demonstrated that tight glycemic 
control greatly reduces the frequency and severity of long-term diabetes related 
complications.  In the 10-year United Kingdom Prospective Diabetes Study (UKPDS), 
intensive glycemic control resulted in A1C levels that were significantly lower than in 
type 2 diabetes patients on conventional therapy.5  The UKPDS data showed a continuous 
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relationship between the risks of microvascular complications and glycemia, such that for 
every percentage point decrease in A1C there was a 35% reduction in the risk of 
complications.   
The importance of tight glycemic control has been also recognized by key US 
organizations.  The National Committee for Quality Assurance (NCQA) and the 
Foundation for Accountability (FACCT) encourage health care delivery systems to 
provide appropriate diabetes care by maintaining tight glycemic control in their enrollees. 
The American Diabetes Association (ADA) recommends measuring A1C every three 
months and maintaining this value below 7% to prevent future complications.6  However, 
in one study, only 20% of health maintenance organization members with diabetes met 
these ADA standards.7 
Studies using measures of adherence such as pill count and refill information have 
demonstrated associations between drug adherence and glycemic control.  Diehl and 
associates8 used pill counts to assess adherence to oral hypoglycemics in patients with 
type 2 diabetes and found a trend towards higher fasting blood glucose in patients taking 
less than 80% of the prescribed doses.  In addition, both Chousa and associates9 and 
Peterson and associates10 used pill count and self-reported measures of adherence to 
demonstrate an association between adherence and A1C levels.  In a recent study 
conducted by Schectman and associates11 in an indigent population using pharmacy 
claims, glycemic control and its improvement over time were strongly associated with 
adherence to diabetes medication measured on the basis of refill information.  Thus, 
evidence in the literature clearly links improved glycemic control through better 
adherence to drug therapy in patients with type 2 diabetes.    
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Adherence to Oral Hypoglycemics 
There is a large literature demonstrating a strong association between adherence 
to medication and outcomes.  Adverse outcomes resulting from non-adherence including 
increased use of emergency room and inpatient services account for a large proportion of 
the drug-related morbidity and mortality estimated to cost $ 76.6 billion in the US 
annually.12   Non-adherence to oral hypoglycemic agents can also result in dire 
consequences for patients with type 2 diabetes.  A review of 13,309 patients with type 2 
diabetes from the UK Mediphys database documented adherence and clinical events 
between 1991 and 1997.13   Patients who discontinued their oral hypoglycemic agents 
were approximately twice as likely to experience an emergency medical event and had a 
mortality rate that was three times that of continuers.  Thus, adherence to oral 
hypoglycemic agents assumes great importance in preventing future complications and 
controlling health care expenditures in patients with type 2 diabetes.   
However, it is increasingly recognized that patients are non-adherent to many 
aspects of diabetes self-management including sufficient intake of appropriate oral 
antidiabetics.  Approximately 10-30% of patients affected by type 2 diabetes withdraw 
from their prescribed regimen within one year of diagnosis.  Of the remaining patients, 
nearly a quarter take insufficient medication thus failing to achieve appropriate glycemic 
levels.14   An observational study of subjects enrolled in an HMO suggested that 31% of 
type 2 diabetes patients on oral hypoglycemic monotherapy did not refill any drug in the 
following year.15  A similar study of a US pharmacy claims database found low 12-month 
persistence ranging from 31% for alpha-glucosidase inhibitors to 60% for metformin.16 
Similar results were found in a study conducted in Scotland which showed that adherence 
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to oral hypoglycemic agents was sub-optimal, with half of patients treated with 
metformin and over one third of those treated with sulphonylureas obtaining insufficient 
drug supplies for adequate drug coverage.17 
Medication non-adherence is a major concern in all chronic conditions especially 
in symptom free patients.  Studies conducted in other Medicaid populations have found 
that newly diagnosed type 2 diabetes patients were less adherent than patients consuming 
oral hypoglycemics for a longer period of time.18  This may be due to the lack of diabetic 
complications and other symptoms in the initial stages of type 2 diabetes.  Newly 
diagnosed patients do not feel as vulnerable to the development of complications and 
hence are less likely to comply with their medication regimen.  Some patients may also 
be in a stage of denial and fail to acknowledge the presence of type 2 diabetes leading to 
decreased medication adherence.  Newer patients may also be less informed and less 
supervised regarding their condition by physicians and other health care providers due to 
lack of diabetic complications.  Thus, newly diagnosed patients are at a considerably 
higher risk for non-adherence with diabetes medication, subsequently leading to 
inadequate glucose control and diabetic complications.       
Impact of Depression on Adherence 
There are a plethora of reasons for patients to be non-adherent to their 
medications.  These reasons may range from their disbelief in the efficacy and adverse 
events associated with treatment to various socio-economic constraints.  A number of 
health behavior models such as the Health Belief Model have tried to examine these 
factors related to adherence.19 Specifically in patients with type 2 diabetes, cost of 
therapy, severity of diabetes, presence of co-morbid conditions, use of insulin therapy, 
 5
interactions with health care providers, and complexity of drug regimens have been 
shown to be factors associated with adherence to oral hypoglycemic therapy, diet and 
exercise.8,20-22 
In addition to these factors, presence of co-morbid depression can be an important 
factor leading to lack of adherence in these patients.  The precise mechanism by which 
depression might affect medication adherence is complex.  Several features of depression 
can have detrimental effects on adherence with medications including poor motivation, 
decrements in attention, memory, and cognition, decreased self-care, and even intentional 
self-harm.23   As depressive symptoms are normally associated with a feeling of 
hopelessness and pessimism, they may hinder adherence to medical regimen.  In addition, 
depression is often accompanied by social isolation and withdrawal thus possibly making 
an individual highly susceptible to non-adherent behavior.  Also, most importantly 
depression may impact an individuals cognitive functioning resulting in forgetfulness to 
adhere to complex treatment regimen.  Some studies have also indicated that depression 
has been associated with greater sensitivity to unpleasant side effects from medications.24 
Depression also adversely affects satisfaction with care, which itself predicts poor 
adherence to medical regimens.25,26 
A few studies have examined the association between depression and treatment 
adherence.  It is well recognized that adherence to antidepressants is very poor; with only 
40% of those receiving an antidepressant prescription completing the nine-month 
recommended treatment.27   There is also a lack of adherence to other medical regimen in 
patients with depression.  A recent meta-analysis of 12 published studies confirmed the 
same demonstrating that depressed patients were three times as likely as non-depressed 
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patients to be non-adherent to physician recommendations.23   In the only study28    
examining the impact of depressive symptoms on adherence in patients with diabetes, the 
depressive symptoms were assessed using the Hopkins Symptom Checklist-90 Revised; 
adherence was assessed by self-report and by using an automated data collection system 
for refills of oral hypoglycemic agents.  The results demonstrated that diabetes patients 
with higher levels of depressive symptoms had more lapses in filling their prescriptions 
for hypoglycemic agents.  Assessing the extent to which non-adherence to a medication 
regimen for a chronic condition such as type 2 diabetes may be a result of a treatable 
condition such as depression can be important in improving patient adherence and finally 
improving outcomes of treatment.  
Epidemiology of Depression and Diabetes 
The potential effects of depression on outcomes associated with management of 
type 2 diabetes may be even more significant when one considers that depression is 
highly prevalent in patients with diabetes.  A recent meta-analysis of 42 studies indicated 
that the odds of depression in patients with diabetes were twice that of a comparison 
group of patients without diabetes.29  A sub-analysis of seven studies including only 
patients with type 2 diabetes indicated that patients with type 2 diabetes were nearly two 
and a half times more likely to have co-morbid depression as compared to patients 
without type 2 diabetes.   
In addition to prevalence of co-morbid depression in patients with type 2 diabetes, 
it is also important to consider the epidemiological measure of incidence.  Incidence has 
the advantage of establishing the temporal order and disentangling the causes of onset 
from influences on chronicity.  Diabetes causes biochemical changes as well as may 
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require psychosocial adjustments that may lead to depression.  On the other hand, 
depression is related to changes in nutrition and exercise that may contribute to risk for 
diabetes; and there may be somatic aspects of depression such as a change in the immune 
or vascular system that contributes to enhanced risk for diabetes onset.30,31 Neuro-
hormonal changes induced by depression such as increase in levels of cortisol and 
catecholamines can lead to insulin resistance and to the development of type 2 diabetes.  
Depressed individuals are less likely to be physically active and eat a healthy diet.  These 
adverse health behaviors may in turn lead to obesity and subsequently to the development 
of diabetes.  Evidence from a few prospective studies indicates that depression doubles 
the risk of incident type 2 diabetes even after controlling for other risk factors.  
Controlling for multiple risk factors, Eaton and colleagues32 have shown that community 
respondents with major depression, diagnosed using the National Institute of Mental 
Health’s Diagnostic Interview Schedule, had an estimated relative risk of 2.23 of 
developing type 2 diabetes over a 13-year period.  Kawakami and associates33 also 
demonstrated in a sample of 2,764 male employees of an electrical company in Japan that 
significant depressive symptoms, measured using the Zung Self-Rating Depression scale, 
were associated with a 2.3 times increased risk of developing type 2 diabetes compared to 
non depressed employees after controlling for known risk factors.  However, these 
studies had a small number of incident case (n= 89 and n = 43, respectively) and thus had 
limited statistical power.  A couple of other studies used data from the National Health 
and Nutrition Examination Epidemiologic Follow-up Study (NHEFS) to test the 
relationship between depression and incidence of diabetes.34,35  These studies used the 
NHEFS cohorts and measured depression using self-reported scales such as the Center 
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for Epidemiologic Studies Depression Scale (CES-D) and the General Well-Being 
Depression subscale.  These studies had variable results with only one of the studies 
demonstrating a significant and independent role of depressive symptoms in the 
development of diabetes.  
Thus, the literature indicates the possibility of higher rates of pre-existing 
depression in patients with type 2 diabetes, which may subsequently lead to lack of 
adherence with anti-diabetic medications resulting in poorer outcomes.  In recent years, a 
number of new oral antidiabetics have been approved including acarbose, glimepride, 
metformin, miglitol, repaglinide, and troglitazone.  These compounds have been shown 
to be effective in achieving tight glycemic control as either monotherapy or in 
combination with other oral antidiabetics.  However, inadequate drug adherence due to 
the presence of pre-existing depression would negate the benefits of these expensive 
antidiabetic agents.  All these findings cause increased concern regarding increased 
morbidity, mortality and expenditures associated with the management of new patients 
with type 2 diabetes. 
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                                     NEED FOR THE STUDY 
Epidemiological studies in the literature regarding the association of depression 
and diabetes were conducted in a mix of type 1 and type 2 diabetes patients.29  These 
issues have not been explored exclusively in type 2 diabetes patients.  Also, most of these 
studies relied on self-reported data for identification of diabetes and depression.29  
Studies in the literature have used a variety of scales to measure the self-report of 
depressive symptoms and each scale measures depressive symptoms over a different time 
interval.29  These self-reported scales can provide an overestimation of depression as 
symptoms related to diabetes may be misclassified as those due to depression.  Also, 
these measures are not accurate predictors of psychiatric diagnosis as transient depression 
symptoms may reflect a situational response to current life events.  Some of the self-
reported depression scales such as the CES-D scale do not distinguish between general 
anxiety and depression and are also inaccurate in identifying patients with major mood 
disorders. 
These epidemiological studies also suffered from selection bias, as they have been 
conducted in specialized settings that treat patients with problematic diabetes.  Moreover, 
potential confounders such as sex, age, race, or concomitant medical illness were not 
addressed.  The published studies also had limited statistical power and generalizability 
due to low sample sizes.  In addition, these prevalence and incidence rates may be 
presumably higher in an indigent population such as enrollees in Medicaid.  Hence, there 
is a need to obtain estimates of clinically diagnosed depression in patients with type 2 
diabetes in a population of lower socio-economic status such as Medicaid enrollees.  
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  Studies of the relationship between depression and adherence have used a variety of 
approaches to assess depression or depressive symptomatology (ranging from 
questionnaires such as the CES-D or the Beck Depression Inventory, to clinical 
interviews).  Also, different aspects of adherence (adherence to diet, exercise, glucose 
monitoring, and medications), different criteria for defining adherence, and different 
approaches to measuring adherence have been used.  It is also possible that the 
association between depression and adherence is artificially created due to the methods of 
measuring adherence.  When asked to self-report their levels of adherence, depressed 
patients may have poor self-perceptions and underestimate their actual level of 
adherence.  Thus, it is important to use objective measures of adherence (such as pill 
counts or refill information) in assessing the relationship between depression and 
adherence.  Also, a lower socio-economic population may have greater barriers to 
adherence thwarting efforts at improving care and outcomes.11 As patients enrolled in 
Medicaid generally have a greater burden of chronic disease, less vigorous treatment, and 
poorer disease outcomes, it will be appropriate to focus efforts on improving adherence in 
such populations.   
Studies in the literature examining the impact of depression on adherence to treatment 
regimen were not necessarily restricted to drug therapy and were all co-relational in 
nature.  Cross sectional studies are not methodologically capable of establishing 
directional effects. The patient population in these studies consisted of a mix of both 
prevalent and incident type 2 diabetes cases.  If such cross-sectional data is used to study 
the relation between adherence and depression, the chicken and egg scenario arises, 
wherein one is not able to assess whether depression caused a decrease in medication 
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adherence or a decrease in adherence with medications aggravated conditions associated 
with type 2 diabetes leading to depression.  This lack of causality and especially the 
biases in model estimation due to presence of endogeneity makes it imperative to observe 
the data longitudinally.  Also, the adherence behavior of those newly diagnosed with 
diabetes and starting treatment for the first time may differ markedly from that of 
survivor cohorts (i.e. those patients who stay under treatment).  The problem of non-
adherence may be especially common in the years immediately after diagnosis when 
many patients with newly diagnosed type 2 diabetes may not yet have accepted or 
adjusted to their diagnosis.18   Hence, there is a need for large longitudinal studies in 
which depression, adherence, and health outcomes are examined and the direct effects of 
depression and the indirect effects of depression through patient adherence on health 
outcomes are explored in patients with newly diagnosed type 2 diabetes.   
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CONCEPTUAL FRAMEWORK 
 
The study will be conducted in two distinct phases.  
• Phase 1 will examine the epidemiological relationship between depression and 
type 2 diabetes 
• Phase 2 will examine the impact of depression on adherence with oral 
hypoglycemics and establish causal pathways for the impact of depression on 
outcomes related to management of type 2 diabetes 
Selection of Database 
The study will be conducted using claims data, which provides a number of 
advantages.  Claims databases are typically used for billing purposes and thus have 
comprehensive information regarding health care utilization and costs.  The presence of 
separate files for outpatient visits, emergency room visits, hospitalizations, and pharmacy 
records allow the examination of all components of health care and the relationships 
between them.  Availability of eligibility information also provides the opportunity to 
conduct longitudinal studies following continuously eligible patients for extended periods 
of time.  One of the biggest advantages of claims data is their non-intrusiveness.  As the 
providers and patients are never contacted, the chances of a Hawthorne effect 
(improvement of performance under observation) in the study are minimized.  Also, 
identification of disease conditions, and utilization parameters are not self-reported and 
hence more likely to be accurate.   Claims data research is less expensive and time 
consuming as compared to other type of research like clinical trials.  It also provides large 
samples for sufficient power in statistical tests.  Thus, claims data provide an opportunity 
 13
for inexpensive, non-intrusive research providing high statistical power in real world 
settings.36 
West Virginia Medicaid claims data will be used to meet the objectives of this 
study.  Medicaid enrollees have comprehensive prescription benefits and out-of system 
use is rare.  Thus, Medicaid prescription data is a more valid and comprehensive source 
than either patient recall or physician’s prescribing records.  Pharmacy refill data thus 
provide a valid approach to measuring drug adherence, which is an important variable in 
the methodological framework of our study.  In measuring adherence from refill 
information, an assumption is made that a filled prescription results in ingestion of a full 
supply of the drug.  However, as in a population enrolled in Medicaid procurement of 
drugs from other sources is highly unlikely, a prescription which is not refilled can be 
considered a good indicator of a prescription not taken and thus of non-adherence.  There 
can also be issues related to the validity of the prescription claims information.  However, 
a validation study that compared Medicaid data with its primary sources such as 
hospitals, physicians, and pharmacies showed that medication data were of high quality.37   
In contrast, self reported adherence is prone to recall bias and tends to be overestimated 
because of desires of social desirability on the part of the respondents.  Also expensive 
adherence assessment methods such as Medication Event Monitoring System (MEMS) 
caps may be subject to the Hawthorne effects.38 
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Phase 1 
The conceptual framework regarding the relationship between pre-existing 
depression and incidence of type 2 diabetes is demonstrated in Figure 1.  Previous 
literature indicates the impact of pre-existing depression on increasing the incidence of 
type 2 diabetes.39  A possible explanation for this relationship is the presence of detection 
bias as individuals with depressive symptoms may be more likely to seek medical care 
than individuals without symptoms, and therefore would have a greater opportunity for 
being diagnosed with diabetes than those without symptoms leading to an increased 
prevalence and incidence of type 2 diabetes among patients with depression.40,41   
Another possible explanation is that depression can lead to increased incidence due to 
physiological reasons such as neuro-hormonal changes leading to insulin resistance and 
increased glucose levels.42,43  Behavioral changes induced by depression such as physical 
inactivity, smoking, and unhealthy diet are also considered risk factors for type 2 
diabetes.44,45  These adverse health behaviors may also lead to obesity and subsequently 
to the development of type 2 diabetes.  Being overweight is associated with onset of type 
2 diabetes and depressed individuals suffer from problems with appetite and weight gain.  
However, one can also view obesity as a mediating variable in the relationship between 
depression and onset of type 2 diabetes.   
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Figure 1:  Conceptual framework for Phase 1 
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Patients with depression will be identified in the year 1997.  As a comparison 
group, a group of Medicaid enrollees without depression will be identified in the year 
1997.  Patients with type 2 diabetes in the baseline year (i.e.1997) will be excluded from 
the analysis.  This cohort of patients will be followed till December 31, 2002 and incident 
cases of type 2 diabetes will be identified in both the groups.  The time frame for 
selection of patients and identification of incident cases for phase 1 of the study is shown 
in Figure 2. 
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Figure 2: Time-line for Phase 1 
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Phase 2 
 
As discussed in the introduction, depression may cause poor adherence to oral 
hypoglycemics.  However, depression can affect type 2 diabetes outcomes in ways other 
than through its impact on adherence to oral hypoglycemic agents.39   Depression may 
oppose efforts to achieve appropriate glycemic levels via both behavioral and 
physiological pathways.  Non-adherence with oral hypoglycemics might be just one of 
the behavioral mediators.   
There is also the issue of aggravation of symptoms wherein patients with 
depression report significantly more physical symptoms on medical review of systems 
than non-distressed populations when controlling for severity of medical illness.40 Since 
co-morbid depression in diabetes is often associated with increased symptom reporting 
and amplification of symptoms, it is possible that physicians may order more testing and 
follow ups in these patients.41  This may explain findings, which have showed that 
diabetes patients with more severe depressive symptoms have significantly higher 
medical costs compared to non-depressed diabetes patients, even after controlling for 
severity of diabetes and other medical illness.28   
 In addition, metabolic alterations associated with depression may disrupt normal 
glucose metabolism.  Studies suggest that depressive disorders lead to increased release 
of hormones such as cortisol, which increase insulin resistance and decrease glucose 
uptake.42,43  Depression may also worsen diabetes outcomes through its effect on 
behavioral pathways.  Depression is associated with increased smoking, alcohol 
consumption, unhealthy eating, and diminished physical activity.44,45   
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In view of the alternate theories of the impact of depression on diabetes, an 
important question that needs to be addressed is whether or not poor adherence actually 
mediates the relationship between depression and outcomes related to type 2 diabetes.  
Our approach to this question is to determine whether the association between depression 
and outcome is weakened after adjusting for level of adherence.   The conceptual model 
in Figure 3 depicts the different factors in addition to pre-existing depression, which may 
impact adherence with oral hypoglycemics and outcomes related to type 2 diabetes.  
These factors identified from the literature such as socio-demographic characteristics, co-
morbid conditions, severity of type 2 diabetes, patient-provider relationship, and 
complexity of regimen will be statistically controlled in the models to help in estimating 
the direct and indirect effects of pre-existing depression on outcomes related to 
management of incident type 2 diabetes. 
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Figure 3: Conceptual framework for Phase 2 
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The study will examine the impact of preexisting depression on patterns of use of 
oral hypoglycemics, drug adherence and outcomes in patients with type 2 diabetes.  
Incident cases of type 2 diabetes will be identified between January 1, 1998 and 
December 31, 2000.  A 12-month pre-period without a diagnosis for type 2 diabetes or a 
prescription for an oral hypoglycemic can confirm that the patient is newly diagnosed 
with type 2 diabetes.  A 12-month pre-period will also be used to identify the diagnosis of 
depressive symptoms in these patients.  Drug utilization patterns and adherence will be 
measured over the period of 12 months post index prescription.  The study population 
will be limited to patients taking at least one oral agent for type 2 diabetes.  Patients will 
have to be continuously eligible in both the pre and post periods.  Incident type 2 diabetes 
patients who do not have preexisting depression but develop depression in the follow up 
period will also be excluded in the analysis.  The time frame and design for enrollment 
and analysis for phase 2 is provided in Figure 4.  
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Figure 4: Timeline for Phase 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
    Enrollment/Index period        
        “Incident cases" 
 
  
Jan 1, 1998 Dec 31, 2000 
12–month pre-period 12-month follow up period NEW CASE OF 
TYPE 2 DIABETES
Dec 31, 2002 Jan 1, 1997 
 23
Evaluation of Outcomes 
 The study aims to examine the effect of pre-existing depression on adherence with 
oral hypoglycemics and subsequently the effect of outcomes related to management of 
type 2 diabetes.  Thus, the selected cohort of newly diagnosed type 2 diabetes patients 
with and without pre-existing depression will be followed for a period of one year to 
detect the impact of depression on adherence with medications and other outcomes. 
 Information on dosage, frequency, length of prescription, and number of tablets 
dispensed from the pharmacy claims of the patients will be used to assess refill 
information and compute patterns of oral hypoglycemic use and adherence indices.  
Examining the pattern of oral hypoglycemic use is especially important in patients newly 
diagnosed with type 2 diabetes.  The following patterns will be examined: 
? Augmentation:  Augmentation refers to a situation where an initial regimen is 
modified by adding another agent of a different class or insulin.   
? Switching:  Switching refers to a situation when an initial regimen of one class of 
oral hypoglycemic agent is changed to another class, or insulin.     
? Discontinuation: Patients discontinuing their oral hypoglycemic therapy 
? Non-modification: Modification in medication regimen may indicate either 
augmentation or switching.  Patients who experience no modification in their 
medication regimens for the entire follow up period (except discontinuers) will be 
designated as non-modifiers.  
Sometimes advancement of type 2 diabetes is associated with a progressive loss of 
beta cell function and increased insulin resistance caused by persistent hyperglycemia 
and possible drug resistance. This is usually referred to as secondary failure wherein there 
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is a loss of glycemic control in patients with type 2 diabetes whose disease has been 
initially well controlled with a single oral hypoglycemic agent.  In our study, 
augmentation or switching will be used as proxies for secondary failure.  In addition, 
survival analysis techniques will be used to estimate the impact of preexisting depression 
on time to secondary failure. 
Another proxy of secondary failure is the switching of type 2 diabetes to insulin, 
as patients are typically switched to insulin therapy if they are on maximum oral 
hypoglycemics and still unable to control their blood glucose levels.  Survival analysis 
techniques will also be used to estimate the impact of pre-existing depression on time to 
insulin switch.   
Adherence indices will be derived separately for the different oral hypoglycemic 
agents used over the follow up period.  Adherence will be modeled as the mean 
adherence for all antidiabetic drugs taken by each patient.  Adherence to insulin will not 
be computed, as utilization of insulin through an administrative dataset is difficult to 
compute due to frequent changes in dosage instructions without proper documentation.  
Adherence indices such as the Medication Possession Ratio (MPR) will be used in the 
study.   
The above adherence related outcomes could be termed as intermediate outcomes, 
which may in turn affect the final outcomes related to management of type 2 diabetes.  
Claims data can be used effectively to measure these final outcomes in terms of 
healthcare service utilization and costs for type 2 diabetes.  Number of physician office 
visits, diabetes prescriptions, and Emergency room/hospitalization episodes specifically 
for type 2 diabetes will be measured.  Overall type 2 diabetes costs and their breakdowns 
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in terms of outpatient, inpatient, and pharmacy costs will also be computed.  However, 
due to the nature of type 2 diabetes, it is highly likely that there is a high proportion of 
healthcare utilization and costs which is diabetes related but not directly attributable to 
type 2 diabetes.  Hence, overall healthcare utilization and costs irrespective of diagnosis 
codes will also be computed.  Appropriate econometric techniques will be used to 
estimate the impact of pre-existing depression on these intermediate and final outcomes 
controlling for the effect of factors mentioned in the conceptual model.  In addition, the 
impact of preexisting depression on final outcomes directly and indirectly in the form of 
drug adherence as a mediating variable will be estimated using path analytic methods.      
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GOALS OF THE STUDY 
? Phase 1:  To estimate the epidemiological burden (in terms of prevalence and 
incidence) of depression and type 2 diabetes. 
? Phase 2:  To estimate the impact of pre-existing depression on adherence with 
oral hypoglycemics and establish causal pathways for the impact of depression on 
outcomes related to management of type 2 diabetes. 
 
SPECIFIC OBJECTIVES 
Phase 1 
Objective 1:  To estimate the prevalence of co-morbid depression in patients with type 2 
diabetes. 
Null Hypothesis A:  There is no difference between the prevalence of co-morbid 
depression in patients with type 2 diabetes and without type 2 diabetes. 
 
Objective 2:  To estimate the incidence of type 2 diabetes in patients with pre-existing 
depression. 
Null Hypothesis B:  There is no difference in the incidence rate of type 2 diabetes in 
patients with pre-existing depression as compared to patients without pre-existing 
depression. 
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Phase 2 
Objective 3:  To examine the impact of pre-existing depression on patterns of oral 
hypoglycemic use in new patients with type 2 diabetes.  
Null hypothesis C:  There is no difference in the pattern of oral hypoglycemic use 
between newly diagnosed type 2 diabetes patients who have pre-existing depression and 
those who do not have pre-existing depression. 
 
Objective 4:  To examine the impact of pre-existing depression on secondary failure with 
oral hypoglycemics. 
Null Hypothesis D:  There is no difference in the rate of secondary failure with oral 
hypoglycemics between newly diagnosed type 2 diabetes patients who have pre-existing 
depression and those who do not have pre-existing depression. 
 
Objective 5:  To estimate the impact of pre-existing depression on initiation of insulin 
therapy in patients with type 2 diabetes. 
Null Hypothesis E:  There is no difference in the rate of initiation of insulin therapy 
between newly diagnosed type 2 diabetes patients who have pre-existing depression and 
those who do not have pre-existing depression. 
 
Objective 6:  To estimate the impact of pre-existing depression on adherence to oral 
hypoglycemic agents. 
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Null Hypothesis F:  There is no difference in adherence to oral hypoglycemics between 
newly diagnosed type 2 diabetes patients who have pre-existing depression and those 
who do not have pre-existing depression. 
 
Objective 7:  To estimate the impact of pre-existing depression on type 2 diabetes related 
utilization and costs.  
Null Hypothesis G:  There is no difference in type 2 diabetes related utilization and costs 
between newly diagnosed type 2 diabetes patients who have pre-existing depression and 
those who do not have pre-existing depression. 
 
Objective 8:  To estimate the impact of pre-existing depression on overall health care 
utilization and costs. 
Null Hypothesis H:  There is no difference in overall health care utilization and costs 
between newly diagnosed type 2 diabetes patients who have pre-existing depression and 
those who do not have pre-existing depression. 
 
 Objective 9:  To examine the causal pathways between pre-existing depression, 
adherence, and outcomes such as resource utilization and costs for type 2 diabetes. 
Null Hypothesis I:  Adherence to oral hypoglycemics is not a mediating variable between 
the presence of pre-existing depression and outcomes related to management of type 2 
diabetes. 
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SIGNIFICANCE OF THE STUDY 
The results of this study can help prioritize risk factors for disorders perhaps 
leading to efforts of prevention.  The results might indicate a benefit to screen a select 
population for adults with diabetes. This is important as screening of all primary care 
patients is not shown to be cost-effective and screening hence should be restricted to only 
a high-risk population.  Also, if the results indicate poorer outcomes and higher costs of 
diabetes management in patients with co-morbid depression then early detection and 
treatment of depression could potentially decrease total cost of diabetes care.   
If a relationship between adherence and depression is demonstrated it may explain 
the high morbidity and mortality rates in depressed patients.  It would also call for 
improving the detection and treatment of depression.  Although a majority of the 
depressed patients present in primary care clinics, there is substantial evidence that 
depression is under detected and inadequately treated in such settings.46,47  Increased 
efforts to detect and treat depression may be associated with better glycemic control.  For 
patients who are beginning their courses of treatment for chronic diseases, screening for 
depression might prove to be a useful identifier of possible future non-adherence and 
might suggest closer monitoring and assistance to achieve adherence.  On the other hand, 
clear non-adherence with a specified treatment regimen should raise suspicion of co-
morbid depression.  Although it remains to be determined whether treating depression 
will result in improved patient adherence, the recognition of depression as a significant 
risk factor for non-adherence with medical treatment carries the potential to improve 
medical practice, reduce patient disability, enhance patient functioning, and improve 
outcomes. 
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Research indicating that depression is associated with health outcomes and 
additive medical costs in specific chronic illness such as diabetes may lead to changes in 
guidelines for diabetes management and encourage national agencies and Health 
Maintenance Organizations (HMOs) to screen for depression in patients with such 
chronic conditions and to improve the clinical management of depression.  
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LIMITATIONS 
Inherent limitations of claims database are applicable to the study as well.36  
Measuring adherence using prescription refills fails to assess the timing and quantity of 
medication taken.  Many patients request refills regularly when reminded, even if they 
have not run out of drugs and some others stockpile medications or have quantities of 
medications in several areas for convenience.  In addition, Medicaid enrollees may lack 
the economic disincentives to purchase only the medications that they will consume.  
However, one can assume that refilling a prescription might be a good indicator of 
willingness to adhere to medications.  Also, as in a population enrolled in Medicaid 
procurement of drugs from other sources is highly unlikely, a prescription which is not 
refilled can be considered a good indicator of a prescription not taken and thus of non-
adherence.  It is also not possible to verify whether the patient discontinued taking the 
medication because of lack of efficacy, adequate control through other methods, or 
change in therapy by physician.  One also misses the most non-adherent patient, i.e. those 
who do not fill any oral hypoglycemic medications. 
Adherence to medications can be affected by a lot of factors, which will not be 
measured in this study such as social support, perceived risk of the outcomes of being 
non-adherent, and others.  Also, severity of disease is an important predictor of adherent 
behavior.48,49  As clinical information is not available, our measures of disease severities 
are proxies and could be subject to measurement bias.  Lack of clinical information also 
prevents us from estimating the impact of adherence on clinical parameters such as blood 
glucose or A1C levels.    In addition to adherence with oral hypoglycemics, diabetes 
control is also affected by factors such as adherence to specified diet and exercise 
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regimen.  Although one can make an assumption that a patient’s adherence to oral 
hypoglycemics can be a valid proxy of adherence to other important self-management 
behaviors such as diet and exercise, studies in literature have demonstrated low 
correlations between these.50,51 
Another major limitation of the study is the issue of undiagnosed/unrecognized 
depression.46  This can potentially lead to misclassification bias as patient classified as 
non-depressed diabetics could be patients with undiagnosed depression and this could 
lead to underestimation of the effect of depression on adherence to medications and 
related outcomes.  However, one can easily assume that diagnosed patients will have 
more severe depressive symptoms as compared to an undiagnosed population.  An 
alternative would be to identify depression in patients through administration of a self 
reported diagnostic measure.  However, self reported depression has been consistently 
shown to be highly unreliable and especially in patients with chronic conditions such as 
diabetes, the severe symptoms of diabetes may be misattributed to depression.  
Depressive symptom inventories such as CES-D are found to be overly sensitive to 
somatic complaints that may be the result of diabetes rather than depressed mood.  Also, 
self-reported measures may identify a broader spectrum of depression disorders (e.g 
dysthymic disorder or minor or subsyndromal depression) or symptoms that reflect co-
morbid psychiatric illness (e.g anxiety or substance abuse disorders) or general 
distress.52,53  
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CHAPTER TWO 
 
LITERATURE REVIEW 
 
Overview of Type 2 Diabetes 
Diabetes is a highly prevalent physiological condition involving high blood 
glucose levels.  There are two classifications of diabetes, type 1 or insulin dependent 
diabetes mellitus, and type 2 diabetes or non-insulin dependent diabetes mellitus. 54  Type 
1 diabetes affects approximately 10% of the diabetic population in the United States.55  It 
is a disease of the beta cells of the pancreatic islets, destroyed by an immunologically 
mediated inflammatory reaction.  In type 1 diabetes, the pancreas loses its ability to 
produce any insulin, resulting in uncontrolled elevations of blood glucose.  Although both 
type 1 and type 2 diabetes share the common feature of elevated blood glucose levels, 
type 2 diabetes typically involves the following three stages in most patients.  The first 
stage involves the principal underlying defect of insulin resistance. Although insulin can 
attach normally to receptors on liver and muscle cells, certain mechanisms prevent 
insulin from moving glucose into these cells.    The ability of beta cells of the pancreas to 
secrete insulin is not affected.  However, as the condition progresses there is subsequent 
beta cell exhaustion and secretion of insulin is affected.  Eventually, the cycle of elevated 
glucose further impairs and possibly destroys beta cells, thereby stopping insulin 
production and causing full-blown diabetes.56-58 
Genetic factors play an important role with regard to both insulin resistance and 
impaired beta cell function.  However, environmental factors such as high calorie intake 
and limited physical activity also play a major role in the incidence and progression of 
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type 2 diabetes.  Type 2 diabetes patients initially have mild symptoms and after years of 
disease may present with complications of diabetes.  Symptoms of type 2 diabetes that 
are typically seen at diagnosis may be thirst, increased urination, fatigue, and blurred 
vision.  However, most of the diagnosis is incidental, and up to 50% of type 2 diabetes 
patients are relatively asymptomatic at diagnosis.55  However, all type 2 diabetes patients 
are at risk of severe complications as the condition progresses.  The life expectancy of 
patients with type 2 diabetes is reduced by 30-40% for those in the age range of 40-70 
years.59  Most of this mortality and morbidity associated with type 2 diabetes can be 
attributed to diabetic complications, which can be divided into the following 2 categories: 
• Microvascular complications: These complications affect the smaller blood 
vessels and are specific complications of diabetes and do not occur in patients 
without diabetes.  Microvascular complications can occur in different body sites 
such as the eye (retinopathy), the kidney (nephropathy), and the nervous system 
(neuropathy).  These complications can lead to debilitating conditions such as 
blindness, renal failure, and foot problems leading to amputations.60   
• Macrovascular complications: These complications are due to the effect of high 
glucose levels on larger blood vessels and are not unique to diabetic patients but 
occur to a greater extent in diabetic patients.  Macrovascular disorders include 
conditions such as cardiovascular disease, cerebrovascular disease, and peripheral 
vascular diseases.60,61   
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Diagnostic Tests for Type 2 Diabetes 
Random plasma glucose or fasting plasma glucose levels are typically used for 
diagnosis of diabetes.  Measurement of fasting plasma glucose requires the patient to fast 
overnight for at least 8 hours.  Another test for diagnosis of diabetes, which is not used as 
frequently in clinical practice, is the oral glucose tolerance test.62  The American Diabetes 
Association (ADA) currently recommends measurement of glycosylated hemoglobin 
(A1C) for monitoring of glycemic control in patients and it is widely used by clinicians 
both for monitoring and diagnostic purposes.63  A1C levels yield a measure of chronic 
glycemia from the slow, posttranslational non-enzymatic glycation of hemoglobin.  A1C 
provides a moving average of blood glucose levels integrated over time, weighted 
proportionally toward recent levels.  Clinical studies have shown a strong correlation 
between A1C levels and the mean level of blood glucose over the preceding one to three 
months.   
Treatment Options 
Type 2 diabetes is a progressive disease and is typically managed using a “stepped 
care approach”.64,65  Patients are initially managed with non-pharmacological options 
such as diet and exercise.  As the disease progresses, oral pharmacological agents are 
used to control blood glucose levels.  Typically, these agents maintain blood glucose 
levels, and some patients can be maintained on single oral agents for a few years.  
However, patients eventually show secondary failure to their treatment regimen, 
requiring therapy with a combination of oral hypoglycemics.  While combination 
therapies lead to better glycemic control, they can also potentially increase the risk of 
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side effects of therapy.  Once oral combination therapies fail, patients progress to insulin 
therapy. 
Non-pharmacological therapy 
Diet, exercise, and weight loss are the initial treatment modalities in the “stepped 
care” approach for type 2 diabetes.  These lifestyle behavioral changes not only lower 
blood glucose levels, but also help in controlling co-existing risk factors for future 
complications.  In a meta-analysis of 14 studies66 examining interventions to increase 
physical activity among diabetes patients, individuals receiving these interventions had a 
mean post study A1C level of 7.7% compared with 8.3% among comparison group 
patients.  In addition to affecting glycemic control, moderate physical activity improved 
other cardiovascular risk factors such as high-density lipoprotein cholesterol and blood 
pressure.  Unfortunately, most patients are unable to achieve adequate control with 
lifestyle changes alone.  However, they can play a pivotal role in diabetes management in 
conjunction with medical regimen.  A controlled diet and regular physical activity are 
therefore, recommended for a majority of patients with type 2 diabetes especially those 
who are overweight.67,68  
Oral hypoglycemic agents  
A variety of oral medications for type 2 diabetes with different mechanism of 
actions are available.  They are typically divided into distinct classes based on their 
mechanism of action.69-73 
Sulfonylureas:  Sulfonylureas have been available in the United States since 1954.  They 
are further classified into: 
 37
First generation sulfonylureas: including drugs such as chlorpropamide, tolbutamide, 
acetohexamide, and tolazamide. 
Second generation sulfonylureas: including drugs such as glyburide, glipizide, and 
glimepiride.  Second generation sulfonylureas are more potent and probably safer than 
first generation sulfonylureas but essentially of equal efficacy.     
Mechanism of action:  Sulfonylureas interact with the pancreatic beta cells leading to a 
closure of voltage-dependent potassium adenotriphosphate channels facilitating cell 
membrane depolarization, calcium entry into the cell, and insulin secretion.  Thus, 
sulfonylureas allow for insulin release at lower glucose thresholds than normal. 
Side effects:  Sulfonylureas are associated with weight gain, typically from five to ten 
pounds, problematic in patients already obese at diagnosis.  Sulfonylureas also cause 
hypoglycemia, especially in elderly, those with worsening renal functioning, and those 
with irregular meal schedules. 
Indications: Sulfonylureas are approved for use as monotherapy and in combination with 
all other oral agent classes (except the non-sulfonylurea secretagogues) and insulin.    
 
Meglitinides:  Meglitinides were introduced in the United States in 1998 and comprise a 
new class of insulin secretagogues derived from benzoic acid that are structurally and 
pharmacologically distinct from oral sulfonylureas.  This class includes drugs such as 
repaglinide, nateglinide, and mitiglinide.   
Mechanism of action: They are also known as non-sulfonylurea insulin secretagogues as 
their mechanism of action is similar to that of sulfonylureas: interaction with voltage 
dependent potassium adenotriphosphate channels on beta cells.  They are different from 
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sulfonylureas in having short metabolic half-lives, which result in brief episodic 
stimulation of insulin secretion.  Thus these newer agents are rapidly metabolized and 
shorter acting and better than sulfonylureas in controlling elevation of glucose levels after 
meals. Also, since less insulin is secreted several hours after the meal, there is decreased 
risk of hypoglycemia during this late postprandial phase. 
Side effects: Side effects include diarrhea and headache.  Some of these agents such as 
repaglinides may pose a slightly increased risk for cardiac events. 
Indications: They are approved for use either as monotherapy or in combination with 
metformin. 
 
Biguanides: Although available internationally for decades, metformin, a biguanide was 
released in the United States only in 1995.   
Mechanism of action:  It reduces glucose production in the liver and increases tissue 
sensitivity to available insulin. These agents may have a beneficial effect on cholesterol, 
blood pressure, and clotting factors.  Metformin does not cause hypoglycemia or weight 
gain and hence is particularly well suited for obese type 2 diabetes patients. 
Side effects: More than 30% of metformin users experience gastrointestinal problems 
including nausea and diarrhea.  Some patients may have excessive weight loss.  Rare but 
life threatening lactic acidosis is seen primarily in persons with renal insufficiency, which 
impairs the clearance of metformin. 
Indications: Approved for use as monotherapy and in combination with sulfonylureas and 
other secretagogues, thiazolidenediones, and insulin. 
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Thiazolidenediones:  In 1997, troglitazone was the first thiazolidenedione that was 
introduced in the United States but was withdrawn after reports of liver toxicity in March 
of 2000.  The other agents in this class, which are currently used, are pioglitazone and 
rosiglitazone. 
Mechanism of action:  Thiazaolidenediones reduce insulin resistance by activating certain 
genes involved in fat synthesis and carbohydrate metabolism.  These agents all improve 
cholesterol levels, including High Density Lipoprotein (HDL) levels and also may reduce 
the risk for blood clots. Thiazolidenediones have a relatively slow onset of action and 
lower the glucose level progressively over 16 weeks.     
Side effects: Troglitazone (rezulin) was removed from the market owing to its 
hepatotoxicity.  Although the other thiazolidenediones do not cause liver toxicity, they 
are associated with side effects such as weight gain, which can be as great or greater than 
that with sulfonylureas.  Some patients may also experience anemia and edema. 
Indications:  Thiazolidenediones are the most expensive class of oral hypoglycemics and 
are indicated as monotherapy and in combination with metformin, sulfonylurea, and 
insulin (pioglitazone only). 
 
Alpha-glucosidase inhibitors: Includes drugs such as acarbose (Precose, Glucobay) and 
miglitol (Glyset). These were introduced in 1996. 
Mechanism of action:  Alpha-glucosidase inhibitors act by a unique mechanism of 
delaying intestinal absorption of carbohydrates. Although their benefit in monotherapy 
and combination therapy has been proved, the incremental reduction in A1C is relatively 
modest.  Their greatest effect is on postprandial glucose levels; whereas, the effect on 
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fasting blood glucose levels is small.  These agents are non-systematic and hence do not 
cause hypoglycemia and weight gain. 
 Side effects: The most common side effects are gastrointestinal side effects such as 
flatulence, bloating, and diarrhea.   
Indications: They are approved for use as monotherapy and in combination with 
sulfonylureas.  However, they are rarely used as monotherapy because of their mild 
efficacy.   
As mentioned previously, initial therapy with oral hypoglycemics fails to control 
blood glucose indefinitely.  Results from the UKPDS indicated that after a period of 3 
years, only 50% of type 2 diabetes patients were adequately controlled with a single drug, 
and after nine years this percentage had decreased to 25%.5  A second oral agent of a 
different class is commonly added when initial glucose control begins to fail.  
Combination of these agents are often used to increase their effectiveness and are 
becoming increasing popular for use before a patient’s transition to insulin therapy.  
However, as failure of oral therapy typically coincides with beta cell exhaustion, insulin 
use eventually is required in most patients with type 2 diabetes.     
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Guidelines for Therapy 
Recent guidelines have stressed the importance of strict glucose control in 
patients with type 2 diabetes.6,74  The UKPDS has shown that for every 1% decrease in 
A1C levels, future micro-vascular complications decrease by 35%.5  The goals of 
treatment of type 2 diabetes are to reduce the symptoms of hyperglycemia and to prevent 
acute and chronic complications of the disease.   
Metformin and sulfonylureas are the mainstay of oral hypoglycemic therapy for 
type 2 diabetes.75   As a high fraction of type 2 diabetes patients in the United States are 
obese, metformin is typically the favored initial therapy.76   For the obese patients in 
whom insulin resistance is a major factor, thiazolidenediones are a suitable alternative 
when metformin is not tolerated or is contraindicated because of renal insufficiency.  
Sulfonylureas are often considered the first choice for patients who are not significantly 
overweight at diagnosis.72 
The initial treatment selection for type 2 diabetes depends on the severity of 
symptoms and the degree of elevation of glucose.70,71   
• Patients presenting with marked symptoms and acute hyperglycemia with Fasting 
Plasma Glucose (FPG) levels greater than 300 mg/dl are most quickly and 
effectively treated with insulin.  With reduction of glucotoxicity and institution of 
a diet and exercise program, insulin therapy can often be withdrawn with 
maintenance of good glycemic control.  Metformin is particularly to be avoided in 
these patients because of the risk of lactic acidosis. 
• Patients with FPG levels of 200 to 300 mg/dl fall in an intermediate group.  One 
option is to treat them with diet and exercise alone with close-follow up.  Failure 
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to respond to non-pharmacological methods should quickly lead to initiation of 
oral agent monotherapy.  If the patient is symptomatic, starting immediately with 
diet, exercise, and oral agent monotherapy is most often a successful and better 
strategy.   
• Patients with FPG levels of less than 200 mg/dl usually can be treated 
successfully with diet and exercise initially.  Although diet and exercise 
eventually lose effectiveness as the sole therapy, reinforcing the importance of 
diet and exercise generally improves the response to oral hypoglycemics.   
 
Treatment Goals 
The American Diabetes Association (ADA) recommended targets for glycemic 
control include a pre-prandial blood glucose level of 80 to 120 mg/dl, a bedtime blood 
glucose level of 100 to 140 mg/dl, and an A1C level of less than 7%.  Change in therapy 
or additional intervention is typically advised at an A1C level of 8% or more.6   However, 
more stringent guidelines have been offered by the American College of Endocrinology 
and the American Association of Clinical Endocrinologists: pre-prandial blood glucose 
levels less than 110 mg/dl, two-hour post-prandial glucose levels less than 140 mg/dl, and 
A1C levels at 6.5%.74   
All these recommendations are based on three landmark studies: Wisconsin 
Epidemiological Study of Diabetic Retinopathy,60 the Kumamoto study,77 and the 
UKPDS,5 which have shown unequivocally that maintaining blood glucose 
concentrations as close to normal decreases the incidence of diabetic complications.  
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Impact of Glycemic Control on Type 2 Diabetes Outcomes 
Epidemiological data from the Wisconsin Epidemiological Study of Diabetic 
Retinopathy60 firmly implicate glycemic control in the development of the microvascular 
complications associated with type 2 diabetes.  In this study baseline A1C levels were 
related to incidence and progression of retinopathy, neuropathy, and nephropathy.  
Benefits of glycemic control on microvascular complications have also been 
demonstrated by a few other randomized trials.  The Kumamoto trial77 was conducted in 
a relatively small sample of 110 lean Japanese patients with type 2 diabetes randomized 
to conventional or intensified insulin therapy.  Intensive therapy was associated with a 
lower incidence of macrovascular events (0.6 versus 1.3 events per 100 patient-years).  
More recently, the results of the large UKPDS5 have confirmed that improved glycemic 
control is associated with reduced rates of microvascular complications.  However, the 
UKPDS did not confirm such a beneficial effect on macrovascular disease.  The UKPDS 
has the advantage over the Kumamoto trial of including typical overweight and obese 
patients who may also have had lesser degrees of insulin deficiency.   
The UKPDS and Kumamoto trials clearly showed that the incidence of 
complications dramatically decreased at approximately five to ten years from initiation of 
intensive glycemic control.  An economic analysis of the UKPDS78 found that increased 
therapy costs of intensive glycemic control in type 2 diabetes patients are offset by 
significantly reduced costs of complications.  The net cost of intensive blood glucose 
control was recently estimated at 1,435 pounds per patient annually, the cost saved on 
complications at approximately 15,000 pounds and the cost per event free year of 
intensive blood glucose control at about 1,166 pounds.  Within the metformin sub study 
 44
of the UKPDS, another pharmacoeconomic study determined that intensive management 
of the overweight was a more cost-effective option. 79  Thus, improving long-term 
glycemic control should reduce the costs of treating diabetes-related complications.  
These savings would more than offset the costs of interventions required to achieve 
glycemic control.  
A number of recent studies have shown that the economic benefits of improved 
glycemic control accumulate much sooner than the seven-ten year trial period examined 
in the UKPDS.  A study conducted by Testa and colleagues demonstrated evidence of 
short-term cost savings.  They compared short-term effects on symptoms, quality of life, 
work productivity, and health care use of active hypoglycemic therapy versus placebo in 
a randomized trial and found that at 15 weeks, patients who controlled their glycemic 
levels reported better health and work productivity and less use of health care services.  
The improvements in quality of life were both consistent and substantial across all 
domains and were partially due to the reduction in adverse events associated with 
hyperglycemia.  The study results demonstrated that improved glycemic control (1.8 
percentage points lower A1C levels) resulted in increased productivity (12%) within a 
period of 12 weeks.80   In a study conducted by Gilmer and associates in a large HMO 
over the period of four years, a strong association was demonstrated between baseline 
glycemic levels in 1992 and subsequent health care expenditures over the next three 
years.  Lower baseline levels of A1C were associated with significantly lower charges for 
care and after adjusting for age, sex, and co-morbidity, higher baseline levels of A1C 
were associated with significantly higher subsequent chares for care.  Their model 
suggested health care savings ranging from $400 to $4000 per patient over a three-year 
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period, with savings increasing depending on the level of baseline A1C.81   Wagner and 
colleagues at Group Health Cooperative of Puget Sound demonstrated reductions in 
health care utilization and costs within one to two years of improvement of A1C levels.  
In a retrospective analysis, better glycemic control (reduction and maintenance of less 
than or equal to one percentage point in A1C level) resulted in average cost savings for 
the HMO of $685 to $950 per patient per year between 1994 and 1997.  The lower end of 
the scale corresponded to patients with uncomplicated diabetes whereas the higher end 
reflected complicated diabetes.82   
Impact of Adherence with Oral Hypoglycemics on Glycemic Control and Type 2 
Diabetes Outcomes 
A number of studies in the literature have empirically evaluated the association 
between medication adherence and diabetes metabolic control. Diehl and colleagues8 
used pill counts to assess adherence in 77 patients with diabetes and found a trend 
towards higher fasting blood glucose levels in those taking less than 80% of prescribed 
dosages.  Chousa and associates9 similarly found adherence assessed by pill count to be 
associated with metabolic control measured by A1C among 107 patients with type 2 
diabetes.  Using self-reported adherence plus the pharmacy records of 65 patients with 
type 2 diabetes, Peterson and colleagues10 also demonstrated an association between 
adherence and a composite measure of metabolic control, including A1C.  However, 
most of these studies relied on small patient samples and self-report as the measure of 
drug adherence.  A recent study conducted by Schectman and associates11 examined this 
issue in a sample of 810 type 2 diabetes patients receiving medical care from a university 
based internal medicine clinic serving low-income population in rural central Virginia.  
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The study used refill data to establish adherence with oral hypoglycemics and found that 
better metabolic control was associated with better medication adherence.  For each 10% 
increment in drug adherence, A1C significantly decreased by 0.16%.  These results were 
duplicated in a prospective assessment of self-reported adherence in a homogenous 
cohort of 11,896 type 2 diabetes patients in Europe.  The study results indicated that A1C 
levels were associated with adherence to medications, with a 1.4% mean difference 
between groups with optimal and worst adherence.83 
However, conflicting results are present for the effect of medication adherence on 
utilization and costs associated with type 2 diabetes.  In a retrospective cohort study 
conducted in a non-managed care setting, a threshold effect was observed where a target 
level of adherence was needed before medical care costs were reduced.  Increased 
pharmaceutical adherence was associated with fewer emergency department visits and 
inpatient admissions, suggesting improved disease control.  Similar costs and utilization 
patterns were evident for both overall health care and diabetes-related care.  The impact 
of medication adherence on decreasing the use and cost of non-pharmacy services was 
observed at a threshold of 20 to 39% adherence.  However, medication adherence was not 
associated with decreased overall healthcare costs because medication costs offset 
medical care costs savings.84  In another study, which examined a longitudinal cohort of 
older adults in the southeastern United States, increased adherence with diabetes 
medications was found to be the strongest predictor of overall health care costs.  Results 
indicated a statistically significant 8.65 to 28.9% decrease in annual costs with every 10% 
increase in medication adherence.85  
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Non-adherence to oral hypoglycemic agents can also result in dire consequences 
for patients with type 2 diabetes.  A review of 13,309 patients with type 2 diabetes from 
the UK Mediphys database documented patient visits to primary care physicians, 
prescription refills, and emergency events between 1991 and 1997.   Patients who 
discontinued their oral hypoglycemics were approximately twice as likely to experience 
an emergency medical event and had a mortality rate that was three times that of 
continuers.13 Thus, adherence to oral hypoglycemics assumes great importance in 
preventing future complications and controlling health care expenditures in patients with 
type 2 diabetes.   
Adherence to Oral Hypoglycemics in Patients with Type 2 Diabetes 
On the basis of the discussion in the sections above, adherence to oral 
hypoglycemics assumes great importance in diabetes management.  However, medication 
non-adherence is a major problem in all therapeutic areas with estimates of non-
adherence rates ranging from 30% to 60% with higher rates in symptom free patients.86  
A similar trend is seen in patients with type 2 diabetes especially those who are newly 
diagnosed with the condition.  A study conducted in Tayside, Scotland of 2,920 type 2 
diabetes patients who received a prescription for oral hypoglycemic drugs for at least 12 
months between January 1993 and December 1995 showed that adherence to these agents 
was suboptimal, with only about one-third of those treated with oral hypoglycemic 
obtaining insufficient drug supplies for “adequate” drug coverage (defined as 90%).17 
These results are consistent with a recent observational study of subjects enrolled in a 
health maintenance organization that suggested that 31% of those receiving sulfonylureas 
alone did not purchase any drug in the following year.15  A similar study conducted by 
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Skaer and associates estimated that 10-30% of patients with type 2 diabetes withdraw 
from their prescribed regimen within one year of diagnosis and of the remainder; nearly 
20% administer insufficient medication to facilitate an adequate reduction in blood 
glucose.14     
A recent analysis of a large administrative pharmacy claims database found 
persistence to oral hypoglycemic therapy over a 12-month period to be low, ranging from 
31% for alpha glucosidase inhibitors to 60% for metformin, with adherence rates of 70-
83%.  The study results also indicated that the addition of a second agent was observed in 
15% of the population with a mean time to augment therapy being approximately four 
months.  When a composite measure of change in therapy including switching or 
augmentation was used, a striking 36% of the patients were found to change therapy over 
a 12-month follow up period.16 Similar studies have found even lower adherence rates, 
although these differences can be explained by methodological and population 
differences.  These studies used refill data for measuring adherence where one assumes 
that every tablet dispensed is actually taken by the patient.  Thus, these adherence rates 
may be overestimates, thus providing further evidence that adherence to diabetic regimen 
is a cause for concern and an important challenge for health care professionals and 
patients with type 2 diabetes. 
Factors Affecting Adherence 
The nature and determinants of non-adherent behavior are complex and not yet 
well understood.  It is commonly believed that adherent behavior is a multidimensional 
issue, which needs to be defined for each population and disease.  The four dimensions 
for determination of adherence identified by most researchers are: treatment regimen 
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complexities, health status and disease-experience factors, characteristics of the 
interaction with healthcare providers, and patient related attributes.18     
Regimen factors 
Regimen factors greatly affect adherence.  Frequency of dosing and the number of 
medications (complexity of regimen) have been shown to reduce adherence.20  Other 
medication related characteristics such as route of administration could also impact 
adherence.  Dezii and colleagues87 evaluated differences in adherence and persistence 
with prescribed therapy of once-daily (OD) dosing compared with twice-daily (BID) 
dosing of glipizide in patients with type 2 diabetes from a pharmacy benefit manager 
claims database.  Patients new to extended-release gastrointestinal therapeutic system 
(GITS) and immediate-release glipizide therapy were identified and followed for one 
year.  The authors concluded that initiation of OD pharmacotherapy results in better 
adherence and persistence compared with a BID regimen, despite a greater daily pill 
burden in the OD cohort.  These data suggest that dosing frequency exerts a greater 
impact on patient adherence and persistence than number of tablets per dose.  Schectman 
and associates11 saw similar results of improved adherence in patients prescribed OD 
dosing as opposed to multiple dosing in the study. 
Conflicting results have been found for the association between number of drugs 
prescribed and mean adherence.  Many studies have reported a positive association 
between number of drugs prescribed and mean adherence.88  It is possible that patients on 
more medications are more likely to adhere because of greater disease severity, concern, 
or knowledge, and a more established regimen.  However, Schectman and associates89 
reported contrasting finding of an inverse association between number of drugs 
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prescribed and minimum adherence levels suggesting lower adherence to individual 
drugs in a complex regimen.  Similar results were found in a retrospective study by 
Dailey and associates,90 comparing patterns of use and persistence in patients with 
diabetes initiated on monotherapy versus those on polytherapy.  For the patients who had 
no modification of their medication regimen, persistence with sulfonylurea or metformin 
monotherapy was 65% greater than with polytherapy over a one-year period.  Similar 
results were seen for adherence with oral hypoglycemics, wherein adherence with 
sulfonylurea or metformin monotherapy was 45% greater than with polytherapy. 
Relationship factors 
Patients may not fear possible medication side effects or drug interaction if they 
understand their prescriptions and have an open, communicative relationship with their 
health care professional.  Researchers have shown that satisfaction with the interpersonal 
quality of the patient provider relationship is significantly associated with adherence to 
diabetes therapy.91,92  Anderson and colleagues93 state that physicians must be aware of 
the likelihood of non-adherence in individual patients and make efforts to persuade 
patients of the importance of adherence to a program designed to reach and maintain 
therapeutic goals.  It is the physician’s responsibility to teach, motivate, and strengthen 
the patient to maximize adherence as part of a “therapeutic partnership”.    
Health status and disease experience 
Anderson and Kirk93 suggested that if an illness has easily recognizable and 
unpleasant symptoms that are improved by following treatment recommendation, 
adherence is more likely.  In diabetes, many of the symptoms are not evident until later in 
life.  Therefore, many individuals will not feel the urgency of undergoing a treatment 
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regimen or making lifestyle changes immediately.  Adherence is also more likely if the 
patient has experienced the illness previously or has known someone impaired by the 
illness in question.  Such experience may make patients more vulnerable and make them 
proactive regarding taking actions to minimize the risk of disease. Studies in patients with 
type 2 diabetes have demonstrated the same showing that newly treated patients are less 
adherent than patients taking antidiabetic medications for a longer period of time.  Newly 
diagnosed patients are usually symptom free and devoid of diabetic complications, thus 
having low perceived susceptibility to complications leading to decreased adherence.  
Also, if the disease does not affect a patient’s functionality and quality of life, and 
diabetes is well controlled through lifestyle changes, then the patient may believe that 
medications are not needed.  Newly diagnosed patients may also remain for prolonged 
periods in a stage of denial and refuse any interventions related to the control of diabetes.  
Additionally, newer patients might be less informed about their condition because 
providers fail to give adequate counseling until negative treatment outcomes and diabetic 
complications become evident.18 
Patient related attributes 
Socioeconomic factors and patient demographics may play an important role in 
non-adherence.  Indigent population without insurance may be non-adherent because of 
the cost of medications.  Lower socioeconomic and minority groups generally have 
greater burdens of chronic disease and poorer outcomes.  Members of these populations 
may also have barriers to adherence that thwart efforts at improving care and outcomes.94-
96  In addition to economic and access factors, these include lack of social support, 
differences in health beliefs and cultural norms, lower disease-specific knowledge and 
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educational background, substance abuse and other physical or mental impairment, and 
care continuity and physician relationship issues.   
Conflicting results have been found in terms of the association between age and 
adherence.  A study by Schectman and associates89 in patients with diabetes found a 1.8% 
increase in mean adherence to oral hypoglycemics per decade of increased age.  The 
association between age and adherence was consistent with that found by both Billups 
and colleagues97 and Bailey and associates98.  However, studies by Monane and 
colleagues99 and Gurwitz and associates100 conflict with respect to an association between 
age and adherence among senior citizens.  The association of age and adherence could 
stem from training and/or maturing effects that facilitate adherence behavior balanced by 
increasing risk for decreased mental and physical functioning that may impair adherence 
with advanced age.   
Race may also play an important role in affecting the adherence to medications.  
Schectman and associates89 reported that African-American diabetes patients averaged 
4.1% lower mean adherence than white patients.  Medicare studies have shown similar 
racial disparities for intervention services after controlling for income.101   African-
American patients may have different perspectives and experiences with respect to health 
care that influences adherence behaviors.102 Others have shown that cultural and 
communication barriers, between African-American patients and Caucasian physicians 
can lead to less participatory decision making and greater mistrust, leading to lower 
adherence.103,104  Lower educational level has also been associated with mistrust of 
medical care and therefore potentially lower adherence.105  Because education status of 
African-American and white low-income patients may differ, education may confound 
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this association between race and adherence. However, a recent survey found that 
minority ethnicity was a strong negative predictor of adherence among elderly patients 
without prescription coverage, independent of income and education.106 
The Sick Role Theory suggests that non-adherent patients do not adopt the sick 
role, and fail to conduct behaviors appropriate to their illness.  An important factor 
involved in the Sick Role Theory is denial, which is in turn associated with a negative 
effect on health outcomes, including regimen adherence.48   A significant relationship 
between self-perception of health and adherence with health care regimes has also been 
demonstrated.  In a cross sectional convenience sample study of 106 subjects with a 
chronic illness for at least two years, Wichowski and Kubsch studied the relationship 
between self-perception of illness and adherence with health care regimens.  There was a 
significant negative correlation between self-perception of illness and adherence for the 
total population.  Adults who do not perceive themselves as ill are unlikely to comply 
with their treatment regimens.107 
Although it is a durable belief that personality traits are predictive of patient 
adherence to treatment regimens, this has not been corroborated by the literature.  
However, depression has been consistently associated with poor adherence.  Depression 
may contribute to low motivation, and it may impact directly on the will of the patients to 
get better, interfering in the patient’s adherence to the treatment regimen. 
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Impact of Depression in Adherence and Outcomes in General 
Adherence to pharmacological regimens for depression is very poor, with less 
than half of those receiving an antidepressant prescription completing the recommended 
treatment.27  However adherence to medications for other conditions is also affected by 
depression.39  Depression can affect cognitive focus, energy, and motivation thus a 
patient’s willingness and ability to adhere to treatment recommendations including 
medication regimens.23  Positive expectations and beliefs in the benefits and efficacy of 
treatment have been shown to be essential to patient adherence.108  Depression often 
involves an appreciable degree of hopelessness and adherence might be difficult for a 
pessimistic patient.  Considerable research has shown that presence of a social support 
network aids in improving adherence with regimens.109,110 Depression is often 
accompanied by social isolation and withdrawal from the very individuals who would be 
essential in providing emotional support and assistance.  Also, depression might be 
associated with reductions in cognitive functioning essential to remembering and 
following through with recommendations. A meta-analysis of 12 published studies 
revealed that depressed patients were three times as likely as non depressed patients to be 
non adherent to recommendations given by physicians.23   Six of these studies involved 
patients with end stage renal disease or renal transplants and six involved other medical 
diseases (angina, cancer, arthritis).  Patients with a recent Myocardial Infarction (MI) 
who dropped out of a recommended cardiac rehabilitation program were found to be 
more depressed and socially introverted than those who participated for the prescribed 
duration of therapy.  Depression and poor motivation were also found to be inversely 
related to smoking cessation and increasing exercise activity for patients hospitalized for 
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unstable angina or acute MI.111 In another study, elderly patients with depression who 
had coronary artery disease adhered less often to prescribed aspirin therapy than patients 
without depression.112  
Recent studies conducted in primary care patients have found significantly higher 
health care costs in patients with depression as compared to patients without depression.  
This increase in costs was seen in primarily all categories such as primary care visits, 
laboratory test, emergency room visits, hospitalizations and pharmacy costs.113-115 Simon 
and associates demonstrated that depressed patients in an HMO had healthcare costs of 
approximately $4,246 as compared to costs of $2,371 in a comparison group.  These 
numbers remained significantly different even after adjustment for presence of other 
chronic medical illnesses.113 Callahan and colleagues also found that patients with 
depression had mean total outpatient charges of $1,210 over a nine-month period 
compared to $752 for a non-depressed population after controlling for medical 
diagnoses.114  Similar results were shown by Unetzer and associates in an elderly cohort 
of 2,588 patients from a large HMO wherein the total median medical costs over a one 
year period for depressed patients was $2,147 as compared to $1,461 for non depressed 
patients.115  Primary care studies have also found that patients with major depression are 
disproportionately represented among high utilizers of medical care.  In a study 
conducted in the Group Health Cooperative, it was found that 10% of patients use more 
outpatient visits, specialty medical visits, and in-hospital days than the 50% of lowest 
utilizers of these clinics.  More than half of these high utilizers had significant depressive 
symptomatology.116                                                                                                                                               
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Impact of Depression on Adherence and Outcomes in Type 2 Diabetes 
Studies have demonstrated that depression can play an important role in affecting 
adherence with prescribed regimen and thus directly or indirectly affect management and 
outcomes of a number of chronic conditions.23 Similar results are also seen in studies 
examining the effect of depression on outcomes related to type 2 diabetes.  A meta-
analysis was conducted to examine the association of depression with glycemic control in 
patients with diabetes.117 The diagnosis of depression was established by using semi-
structured clinical interviews and diagnostic criteria.  Depression was quantified using 
self report instruments such as the Beck Depression Inventory (BDI) and Center for 
Epidemiological Studies-Depression Scale (CES-D) that measure the severity of recent 
depression symptoms, while glycemic control was assessed using a measure of A1C.  
The results of the meta-analysis indicated that depression was significantly associated 
with hyperglycemia.  Although the results demonstrated that depression accounts for a 
small amount (3%) of the variance in A1C levels, this is not trivial in clinical practice.  
Six studies examining the impact of depression on glycemic levels were restricted to 
patients with type 2 diabetes.118-123  Of these, two clearly showed a relationship between 
depression and glycemic control.118,119  Van der Does and associates118 found that higher 
A1C levels were significantly associated with symptom scores of worse mood on the 
Dutch Shortened Profile of Mood states and general well being in the Affect Balance 
Scale.  Lustman and colleagues119 reported that depressed patients as indicated by the 
National Institute of Mental Health Diagnostic Interview Schedule Version Three, had 
higher A1C levels compared with those who were never depressed.  Wilson and 
colleagues120 found that depression as measured by BDI and CES-D was not significantly 
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correlated with glycemic control but was significantly associated with self-care behaviors 
such as medication adherence, glucose testing, diet and exercise. The remaining three 
studies of depression and type 2 diabetes produced equivocal results.121-123 Peyrot and 
Rubin121 found that although scores on the CES-D depression scale were higher in 
individuals with elevated A1C levels, the relationship was not statistically significant.   
   If depression is associated with hyperglycemia and hyperglycemia is associated 
with diabetes complications, then it follows that depression may also be associated with 
diabetic complications.  Previous studies have correlated depression with a variety of 
diabetes complications such as diabetic neuropathy and cardiovascular disease, yet others 
have failed to find an association between depression and diabetic retinopathy and other 
diabetic complications.  A recent meta-analysis of 27 studies was conducted to examine 
the impact of depression on diabetes complications.124  The results of this meta-analysis 
revealed a consistently statistically significant relationship between depression and a 
variety of diabetes complications.  The overall effect size for the meta-analysis was 
statistically significant and in the small to moderate range depending on the specific 
complications.  For each of these complications an increase in depressive symptoms was 
associated with an increase in the severity or number of diabetes complications. 
 These effects of depression on glycemic control and diabetic complications also 
translate into differences in health care costs.  Data from the Medical Expenditure Panel 
Survey (MEPS) 1996 was used by Egede and associates125 to examine differences in 
health care expenditures in diabetes patients with and without depression.  Expenditures 
were adjusted for inflation with the consumer price index to reflect 2001 dollars.  
Expenditures for prescription medication were higher in depressed individuals than in 
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non-depressed individuals with diabetes ($1,392 versus $666, p<0.0001). There were no 
statistically significant differences in other expenditure categories.  Co-morbid depression 
was associated with an almost fivefold significant increase in total health care 
expenditures.  Significant differences were obtained even after controlling for age, sex, 
race, insurance status, and comorbidity.  However, the values reported were unadjusted 
and the number of diabetics with depression was a very small proportion (n=85).  This 
issue was also examined by Black126 in older diabetic Mexican Americans, using 
longitudinal data from the Hispanic Established Population for the Epidemiologic Study 
of the Elderly (EPSE).  The risks of co-morbid myocardial infarction, hypertension, 
arthritis, and angina were significantly higher in the presence of concomitant depressive 
symptoms, as were the risks of diabetic complications, functional disability, incontinence, 
vision impairment, poorer perceived health status, and health care utilization among both 
diabetic and non-diabetic individuals.  Rates were substantially higher among depressed 
individuals with diabetes, however, in comparison to depressed nondiabetic individuals.  
The study also demonstrated that the interaction of diabetes and depression was 
synergistic predicting greater mortality, greater incidence of both macro-and 
microvascular complications over the follow up period of seven years.  The study also 
demonstrated a gradient response such that the risk of adverse events increases with the 
increasing severity of depression.  Importantly, these health burdens were evident even 
when controlling for socio-demographic risk factors, including sex, age, education, 
marital status, immigration status, and living arrangements.  
All these studies used self-reported measures for identification of depression and 
diabetes.  Utilization and costs were also self-reported and were measured and analyzed 
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in terms of total health care costs, which also included costs for mental health treatment.  
Regardless of whether major depression adversely affects an individual’s physical health, 
total costs are expected to be higher for those with major depression due to the costs 
associated with mental health treatment.  A recent study by Finkelstein and associates127 
examined this issue using data from the 1997 Medicare 5% Standard Analytic Files.  This 
was the first study studying the impact of depression on non-mental health care costs in 
patients with diabetes using actual claims data to measure utilization.  The study results 
indicated that controlling for age, gender, race, and comorbidities, non-mental health care 
costs were approximately 21.00% higher for depressed patients with diabetes as 
compared to non-depressed patients with diabetes.  The authors also concluded that 
depressed patients seek treatment for more services and when admitted, spend more time 
in inpatient facilities than patients without depression.  
The only study which examined the effect of depression on both adherence with 
oral hypoglycemics and health care utilization was conducted recently by Ciechanowski 
and associates28 in a primary care based sample of 367 patients with type 1 and type 2 
diabetes in a staff model HMO.  Depressive symptoms were assessed with the Hopkins 
Symptom Checklist-90 Revised.  The patient population was divided into low, medium, 
and high depression tertile categories based on depression scores on the Hopkins 
symptom checklist.  Adherence was assessed by self-report and by using an automated 
data collection system for refills of oral hypoglycemics.  The authors found that 
depressive symptom severity was significantly associated with decreased adherence to 
dietary recommendations and approximately twice as many interruptions in refills of oral 
hypoglycemics.  Depressive severity was associated with a non-significant increase in 
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A1C levels.  After controlling for demographics, medical comorbidity, and diabetes 
severity, higher levels of depression severity were associated with significantly worse 
mental and physical functioning and a significantly greater probability of having an 
emergency department, primary care, specialty care, medical inpatient, and mental health 
costs compared to patients with low severity depression.  The total costs of the high 
tertile group were $3,654 versus $ 2,653 in the medium depression tertile and $2,094 in 
the low tertile groups after adjusting for diabetes severity and medical co-morbidity.    
However, this study was conducted in a small sample of diabetes patients in a 
highly specialized clinical setting.  There was also the issue of non-response bias as only 
62% of the originally contacted diabetes patients agreed to participate in the study.  The 
study included a mix of type 1 and type 2 diabetes patients with varying durations of 
diabetes.  As discussed in detail before, adherence issues might be drastically different in 
newly diagnosed patients as compared to a survivor cohort and hence need to be 
examined separately.  Also, measures used to assess depressive diagnosis and a few other 
control variables were self-reported.  Adherence to oral hypoglycemics was obtained 
through pharmaceutical claims data.  However, refill data to measure adherence was only 
available for a subset of the population (n = 200).  Most importantly, total health care 
utilization and costs were examined rather than specifically examining diabetes related 
outcomes and utilization. 
Most of the studies in literature addressing this issue of depression and diabetes 
were cross sectional in nature thus not indicating whether depression causes aggravation 
of diabetes symptoms or problems with diabetes management lead to depression.  This 
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presence of endogeneity also can lead to statistical biases in the estimates of the impact of 
depression on diabetes related outcomes.   
Theories for Impact of Depression on Type 2 Diabetes Outcomes 
Speculation regarding the pathways by which depression impacts diabetes falls 
into two broad categories: psycho-behavioral and patho-physiological.  Depression may 
influence diabetes through decreased motivation to maintain behaviors that will protect 
against the development or worsening of diabetes, such as proper weight, diet, 
medication adherence and exercise.23,28 Depression is associated with increased smoking, 
alcohol consumption, and unhealthy eating, and with diminished activity.44,45  People 
with diabetes who are depressed care for their diabetes less actively.  Remission of 
depression may improve glycemic control by reducing unhealthy behaviors and 
promoting healthy behaviors.  Diabetes patients who are depressed are more likely to 
report limited physical functioning and increasing physical activity may be one of the 
most important behavioral changes for diabetes patients.  Epidemiologic studies have 
repeatedly found cross sectional association between low levels of physical activity and 
depression.  Studies indicate that patients who are more physically active have better 
depression symptomatology, and that individuals who are less physically active are more 
likely to develop depression.128-130   
Alternatively, metabolic alterations associated with depression may disrupt 
normal glucose metabolism.  The increase risk of negative diabetic outcomes may be the 
result of biological changes such as neurohormonal and neurotransmitter changes.  
Studies suggest that depressive disorders are accompanied by increased sympathoadrenal 
system and hypothalomapituitary adrenal axis activity causing increased release of 
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counter regulatory hormones and cortisol, respectively, which increase insulin resistance 
and decrease glucose uptake.  Lower immune functioning or inhibited cortisol release 
may also increase insulin resistance and thus increase vulnerability to diabetic 
complications.42,43  
It may also be possible that both depression and diabetes share the common 
pathogenesis such as actions of the autonomic or sympathetic nervous systems, or 
polymorphism of genes associated with obesity.  Thus, the link between depression and 
diabetes may be the direct or indirect result of risk factors common to both conditions, 
such as obesity, inactivity, medication use, and other preexisting psychological and 
physical conditions.   
In view of the alternate theories for the impact of depression on diabetes, an 
important question that needs to be addressed is whether poor adherence actually 
mediates the relationship between depression and outcome.  One approach to this 
question is to determine whether the association between depression and type 2 diabetes 
outcomes is weakened after adjusting for adherence.  Gary and associates131 found that 
presence of depression was associated with higher cholesterol, triglycerides, and glucose 
levels in patients with type 2 diabetes.  However, adjusting for adherence to diet, physical 
activity, smoking, glucose monitoring, and medications did not reduce the effect of 
depression.  Another approach to determining the role of adherence as a mediator is to 
examine whether interventions that reduce depression and improve type 2 diabetes 
outcomes also show improvements in adherence.  Lustman and associates122,123 
conducted two such intervention studies for depression in patients with diabetes.  In both 
studies, the intervention reduced depression and improved glucose control relative to the 
 63
control condition.  However, there was no evidence that reducing depression led to 
improved adherence, as measured by the use of home blood glucose monitoring.  
However, the Cognitive Behavioral Therapy (CBT) routinely included homework 
assignments directing patients to record their thoughts and increase various physical and 
social activities.  Thus, it is possible that the participation in CBT complicated an already 
complex regimen and thus decreased adherence with self-monitoring of blood glucose 
levels.  
Thus, based on these few studies there is lack of evidence to support the role of 
adherence as a mediator in the relationship between depression and diabetes outcomes.  
Further research with objective measures of adherence, clear criteria for defining 
adherence and depression, and large samples with longitudinal follow-up need to be 
conducted. 
Epidemiology of Depression and Type 2 Diabetes 
These effects of depression on diabetes related outcomes could be highly 
detrimental, especially if the rate of occurrence of depression in patients with type 2 
diabetes is high.  Hence, the epidemiological burden of depression in patients with type 2 
diabetes needs to be evaluated and the existing literature on this issue will be discussed in 
the following sections. 
Prevalence of Depression in Patients with Type 2 Diabetes 
A number of studies examining the prevalence of depression in patients with 
diabetes have been published in recent years.  These studies have used various patient 
population, research designs, and diagnostic tools.  The varying prevalence rates may 
reflect the differences in assessment methods (self-reported depression scales or 
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structured diagnostic interviews), sample differences (community based or clinical 
samples), and type of diabetes (type 1 or type 2).  Also, a few of these studies were 
conducted without the presence of a control group.  As control groups are essential and 
basic to epidemiological research, the following review will focus exclusively on 
controlled studies performed in patients with type 2 diabetes. 
A recent meta-analysis of 42 studies indicated that the odds of depression in 
patients with diabetes were twice that of a comparison group of patients without 
diabetes.29 A sub-analysis on the basis of seven controlled studies including only patients 
with type 2 diabetes indicated that patients with type 2 diabetes were nearly two and a 
half times more likely to have co-morbid depression as compared to patients without type 
2 diabetes.32, 132-137 Only two of the seven controlled studies used structured diagnostic 
interviews for the assessment of depression.32,137  The structured diagnostic interviews 
used were the National Institute of Health’s Diagnostic Interview Schedule (DIS) and the 
Clinical Interview Schedule (CIS).  The DIS is an instrument for making psychiatric 
diagnoses in accordance with criteria specified in the DSM-III of the American 
Psychiatric Association, while the CIS reports psychiatric diagnoses according the 
International Classification of Disease criteria. Both the interviews have been found to be 
reliable and valid in assessing depressive disorders in patients with type 2 diabetes.  The 
remaining controlled studies used self-reported depression scales such as the Geriatric 
Depression Scale (GDS), Zung scale, and the Beck Depression Inventory (BDI).132-136  In 
these studies, depression prevalence was equal to the percentage of subjects with scale 
scores above a specified threshold value.  However, this threshold value varied across the 
studies.  The method of patient enrollment also differed between the studies.  Five 
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controlled studies32,132,133,135,137  identified the type 2 diabetes patients and their controls 
randomly from a community population, while the remaining two studies134,136 enrolled 
the patients and their controls without diabetes from health care clinics, patient support 
groups, or physician referrals.  The odds of depression were significantly elevated in 
patients with type 2 diabetes as compared to control groups irrespective of the method of 
depression assessment or patient enrollment.  However, only of a few of these studies 
explored the effect of concomitant medical illnesses on the association between 
depression and type 2 diabetes.  This is important as medical conditions in general are a 
risk factor for depressive disorders and the presence of type 2 diabetes may not add any 
additional risk.  Thus, it is possible that the concomitant medical illnesses accompanied 
with type 2 diabetes may contribute to this observed increase in prevalence of depressive 
diagnosis. 
Weyerer and associates137 observed that although patients with type 2 diabetes 
had a higher prevalence of depressive symptoms than those with no somatic illness, no 
differences were found when diabetes patients were compared to patients with other 
somatic illnesses.  A recently published study by Pouwer and associates138 displayed 
similar results.  This community-based study was conducted in elderly Dutch adults.  
Depression was assessed using the CES-D scale and diagnosis of type 2 diabetes was 
obtained from self-reports and data from general practitioners.  The results of this study 
indicated that the 20% of the patients with type 2 and other co-morbid chronic conditions 
suffered from pervasive depression.  Rates of depression were found to be considerably 
lower in patients with type 2 diabetes only (8%) and healthy control subjects (9%).  Thus, 
compared to healthy subjects, the odds for depression are particularly increased in 
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patients with type 2 diabetes and other co-morbid diseases, but not in those with type 2 
diabetes alone.  However, all the studies mentioned above were not population based and 
had relatively small sample sizes leading to doubts regarding the stability of the 
prevalence estimates. 
The only study using claims data to determine prevalence of co-morbid 
depression in patients with type 2 diabetes was conducted among enrollees of Kaiser 
Permanente Northwest (KPNW).139  The study found unadjusted depression prevalence 
rates of nearly 18% in patients with type 2 diabetes.  After controlling for confounders 
such as age, gender, presence of cardiovascular disease, and weight the results indicated 
that patients with type 2 diabetes were slightly more likely to have co-morbid depression 
as compared to patients without diabetes (OR=1.187).  However, the study failed to 
control for co-morbidities other than cardiovascular conditions.  Hence there is a 
possibility of detection bias as individuals with type 2 diabetes are more likely to have 
higher number of co-morbid conditions and thus more likely to seek medical care than 
individuals without type 2 diabetes.  Thus, individuals with type 2 diabetes would have a 
greater opportunity for being diagnosed with depression than those without type 2 
diabetes.  Also, the study did not examine the interaction effects between demographics 
and type 2 diabetes on the prevalence of co-morbid depression.  The impact of age on the 
relationship between type 2 diabetes and depression is important as the peak period of 
onset for depression is generally in the early adult years between 20 and 30 years of age; 
while the onset of type 2 diabetes typically occurs after the age of 50.  Hence, in addition 
to adjusting for age it becomes important to control for a statistical interaction between 
age and presence of type 2 diabetes to provide unbiased estimates.   
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Incidence of Type 2 Diabetes in Patients with Depression 
The studies mentioned in the above section pertained to the concept of prevalence 
of depression and were all cross sectional in nature.  In addition to prevalence of co-
morbid depression in patients with type 2 diabetes, it is also important to consider the 
epidemiological measure of incidence.  In 1684, Thomas Willis, a British physician 
suggested that diabetes results from presence of pre-existing depressive disorders.140   
Evidence from recent prospective studies have confirmed William’s hypothesis and 
indicated that depression doubles the risk of incident type 2 diabetes even after 
controlling for other risk factors.  This finding is of important significance as recent 
research demonstrates the possibility of preventing or delaying the progression from 
impaired glucose tolerance to type 2 diabetes through moderate exercise, weight loss, 
modification of diet, or intake of metformin.  Depressive disorders can affect the 
adherence to each of the above preventive activities and thus lead to increased onset of 
type 2 diabetes.   
Eaton and associates32 conducted the first prospective study examining the effect 
of depression on incidence of type 2 diabetes in adult household residents participating in 
the Epidemiological Catchment Area (ECA) Program Survey in Baltimore, Maryland.  
Results of the study indicated that controlling for age, race, sex, socio-economic status, 
education, use of health services, and body weight, community respondents with major 
depression diagnosed by using the National Institute of Mental Health’s Diagnostic 
Interview Schedule had an estimated relative risk of 2.23 of developing adult onset of 
diabetes mellitus over a 13-year period.  However, the diagnosis of diabetes was by self-
report and the study failed to control for all the important risk factors for incidence of 
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diabetes. Self-reported diagnosis of diabetes could have also led to the problem of 
undetected diabetes.  It is possible that some people enrolled in the cohort may have had 
onset of type 2 diabetes at baseline, thus biasing the study results. 
 Kawakami and associates33 conducted a methodologically superior study in a 
sample of 2,764 male employees of an electrical company in Japan.  The study results 
indicated that significant depressive symptoms measured according to the Zung Self-
Rating Depression scale were associated with a 2.3 times increased risk of developing 
type 2 diabetes compared to non depressed employees after controlling for known risk 
factors over a eight year follow up period. The results of this Japanese study are 
presumably more valid as the study used diagnostic measures such as urine tests and oral 
glucose tolerance testing for identification of type 2 diabetes.  The study also controlled 
for important diabetes risk factors such as body mass index, smoking, alcohol 
consumption, activity level, and family history of diabetes. Biases due to presence of 
undetected diabetes at baseline   were also ruled out by consistent results a sub-analysis 
excluding cases found in the first half of the follow up period.  However, both these 
studies had small number of incident cases (n=89 and 43 respectively) and thus had 
limited power.  The study populations were also not representative of the general US 
population.   
A couple of studies have recently used data from the National Health and 
Nutrition Examination Epidemiologic Follow-up survey (NHEFS) to test the relationship 
between depression and incidence of diabetes.  This data is nationally representative and 
provides a large cohort of participants for follow up over an extended period of time.  
One of the studies used the NHEFS cohort34 from the second examination (1982-1984) 
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and measured depression using the CES-D.  During the follow up period of 
approximately nine years, there were 465 incident cases of diabetes.  After controlling for 
demographic characteristics, the relative hazard (RH) of incident diabetes among those 
with high depressive symptoms was 1.27 as compared to those without symptoms.  
Additional statistical controlling for known diabetes risk factors such as body mass index 
and physical activity further decreased the strength of the association (RH= 1.11). Both 
these values were statistically insignificant at p< 0.05 and thus the study failed to find any 
significant effect of depressive symptoms on diabetes incidence.  However, a subsequent 
study conducted in the NHEFS cohort35 from the first examination (1971-1975) 
measuring depressive symptoms using the General Well-Being Depression subscale 
suggested a significant and independent role of depressive symptoms in the development 
of diabetes.  Over an average of 15.6 years of follow-up, 369 participants developed 
diabetes.  The incidence of diabetes was highest among participants reporting high 
numbers of depressive symptoms (7.3 per 1,000 person-years) and did not differ between 
persons reporting intermediate and low numbers of symptoms (3.4 and 3.6 per 1,000 
person-years, respectively).  The association between depressive symptoms and incidence 
of diabetes was especially stronger in participants with low education levels.  These 
results also persisted in multivariate models after adjusting for demographics (age, 
gender, and race), health behaviors (smoking, alcohol use, and physical activity), and 
baseline body mass index.    
Most of these studies relied on self-reported data for identification of diabetes and 
depression.  Each study exploring the relationship has used a different scale to measure 
the self-report of depressive symptoms and each scale measures depressive symptoms 
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over a different time interval.  Also, the studies using data from the NHEFS cohort were 
not specific to incidence of type 2 diabetes and failed to adequately address the issues of 
undetected diabetes at baseline.  Additionally, studies reported in the literature assessed 
depressive symptoms only once at baseline and hence during the follow-up period a non-
depressed subject could have developed depressive symptoms and subsequent type 2 
diabetes resulting in misclassification bias.  This bias could be significant especially due 
to the long follow-up periods in these studies ranging from eight to 16 years. 
 
Overview of the Medicaid Program 
 
As the study will be conducted using claims data for enrollees of West Virginia 
Medicaid, it will be helpful to understand the structure and functioning of this health care 
system.  Medicaid is a federally sponsored health insurance program for low-income, 
disabled and members of families with dependent children initiated in 1965.  The federal 
government provides the fiscal assistance and the basic framework of regulations, 
guidelines, and operation policies.141 However, the state governments are typically 
responsible for administration of the Medicaid program.  Benefits provided by Medicaid 
include coverage for physician visits, inpatient and outpatient hospitalizations, laboratory 
testing, nursing home care, family planning services and supplies, and home health care. 
The federal government mandates these health care benefits.  Additionally, there are 
optional services that are left to the discretion of each state.  Although optional, all states 
provide reimbursement for prescription costs. 
 In recent years there has been widespread concern regarding the tremendous 
growth in health spending through Medicaid.  Total federal and state Medicaid 
expenditures including administrative costs increased form $58 billion in 1989 to $194.7 
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billion in 2000.  One of the major reasons for this increase in expenditures is the increase 
in size of the Medicaid eligible population.  In 1990, there were 25.3 million enrollees, 
which increased to 36.3 million in 1995 and more than 44 million in 2000.142,143 A similar 
trend is also seen in West Virginia Medicaid with total number of recipients in the 
program increasing from 178,254 in 1982 to 354,326 in 2000.  This growth in number of 
recipients has resulted in a dramatic increase in expenditures from $121 million in 1982 
to over 1.391 billion in 2000.143 This can also be interpreted as an increase in average 
spending per recipient from $678.84 to approximately $3,900.  Thus, it becomes 
important to identify areas of cost-containment; effect of depression on other chronic 
conditions such as type 2 diabetes being one such area.  
West Virginia’s Medicaid program consists of three components: 144 
• Physician Assured Access System (PAAS); a primary care case management 
program wherein individuals enrolled in PAAS receive case management and 
education services not available to individuals enrolled in the fee-for-service 
program.  Under the program, participants select a primary care provider who 
coordinates care and whose approval is required for most health care services. 
• Mountain Health Trust (MHT); a capitated program similar to being enrolled in a 
Health Maintenance organization (HMO). 
• Traditional fee-for-service program  
In 2002, 281,526 individuals were enrolled in West Virginia’s Medicaid program.  As 
of June 2002, 97,174 Medicaid recipients were enrolled in PAAS.  In 1996, Mountain 
Health Trust (MHT) was developed under a subsequent 1915(b) waiver that allowed the 
state to require a majority of its Medicaid recipients including individuals with 
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disabilities to enroll within an HMO.  As of June 2002, 48,189 Medicaid recipients who 
qualify through Temporary Assistance for Needy Families (TANF) were enrolled in 
MHT, and Medicaid recipients who qualified through the supplementary security income 
(SSI) were eligible for the primary care case management program and not the capitated 
program.145 
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CHAPTER THREE 
METHODOLOGY 
 
Data Source 
West Virginia Medicaid claims data 
State Medicaid programs provide health care coverage to poor, aged, and disabled 
individuals.  The Bureau for Medical Services of the West Virginia Department of Health 
and Human Resources has been responsible for the management of the West Virginia 
Medicaid Program (WVMP).   The West Virginia Medicaid Bureau contracts with 
Consultec, Inc. (Atlanta, Georgia), to serve as its claims processor.  Consultec maintains 
and operates the Medicaid Management Information Systems (MMIS), which processes 
provider claims and payments.  MMIS data comprises of three files - provider files, 
recipient files, and claims (medical and pharmacy) files.  The following is a description 
of these files and the specific fields (variables) contained in each file. 
The provider file contains specific information about all health care providers 
eligible to deliver services to Medicaid recipients.  It primarily contains the provider’s 
name, specialty, Medicaid eligibility, and tax related information.  The recipient file 
contains detailed information about Medicaid recipients.  Important fields in this file 
include recipient’s Medicaid number, period of Medicaid eligibility, period of managed 
care eligibility, unique identification number, date of birth, gender, race, and county of 
residence.  The claims file stores detailed information specific to processed claims.  For 
each medical claim, the file contains fields such as invoice type, provider number, 
recipient number, International Classification of Disease 9th edition (ICD-9)146 code of 
diagnosis for which the service was provided, Common Procedural Terminology (CPT) 
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code for procedures and services provided, Diagnostic Related Group (DRG) codes, date 
claim was submitted, date of adjudication, through-date of service, coordination of 
benefit code, primary carrier code, extract indicator, and total amount paid.  The medical 
claims are further classified into two files: outpatient claims and emergency 
room/hospitalization claims.  For pharmacy claims, the file contains fields such as 
number of days supply, metric quantity, National Drug Classification (NDC) code, 
generic code, therapeutic class code, refill number, provider ID number, and amount 
paid. 
Study Population 
West Virginia Medicaid data was extracted for the period 01/01/1997 to 
12/31/2002.  Thus, final data used for the study included all paid claims data for all 
individuals eligible for West Virginia Medicaid during the study period.  Since Medicaid 
recipients aged 65 years and older are eligible for coverage under both Medicaid and 
Medicare, the subjects of this research were limited to all Medicaid recipients who were 
younger than 65 years to avoid the issue of coverage under both Medicaid and Medicare.  
For similar reasons, Medicaid recipients who were part of managed care were not 
included in the study.  
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Data Extraction 
The West Virginia Medicaid claims data obtained from Consultec is loaded on the 
server maintained by West Virginia University’s Rational Drug Therapy Program 
(RDTP).  The data needed for this study was extracted through the software 
BrioIntelligence and converted into Statistical Package for Social Sciences (SPSS) data 
sets.  The extraction process involved identifying the study subjects using specific 
selection criteria and the fields/variables needed were downloaded for the defined study 
time period. 
 
Data Cleaning 
As mentioned previously, the medical claims files are aggregated into two 
separate files of outpatient claims and ER/hospitalization claims.  It is preferable to 
separate the ER claims from the hospitalization claims to get a better distribution of these 
health care costs.  A variable termed as hospitalization Extract Indicator (EXTIND) in the 
ER/hospitalization claims classifies the claims as those belonging to an ER visit or a 
hospitalization episode.  This variable along with the information provided by the 
Diagnosis Related Group (DRG) codes and CPT codes was used to separate ER and 
hospitalization claims.  The following algorithm was used to separate claims into “ER” 
and “Hospitalization” files: 
• Hospitalization claims from the ER/hospitalization file were identified on the 
basis of a DRG code greater than 0.  These claims were separated and classified 
into the “Hospitalization” file. 
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• ER claims were identified on the basis of the EXTIND code.  All claims with 
EXTIND=2 are indicative of an ER visit.  These claims along with all claims with 
the same date of service were separated and classified into the “ER” file 
• The outpatient files contain a few claims, which are related to ER episodes.  
These files were identified on the basis of CPT codes ranging from 99281 to 
99285.  These claims along with all claims with the same date of service were 
separated and transferred to the “ER” file. 
• If the ER events lead to hospitalization, the ER event was considered as a 
component of the subsequent hospitalization episode to prevent double counting.  
Claims from the “ER” file with the same date as a hospitalization claim were 
identified as indicative of ER episodes subsequently leading to hospitalization and 
were transferred to the “Hospitalization” file. 
• A large proportion of claims in the ER/ hospitalization files included services, 
which are outpatient but performed in a hospital setting and hence needed to be 
aggregated as outpatient claims.  After the algorithm mentioned above was used 
to classify claims into ER or hospitalization claims, the remaining claims in the 
ER/hospitalization files were classified as outpatient claims and were transferred 
to the outpatient files. 
In addition, there was also the issue of duplication of claims in the medical and 
pharmacy files that had to be addressed.  These duplications were primarily due to initial 
rejection of claims.  If a claim was rejected, it was followed up with a negative claim.  
Both these negative and positive claims were deleted from the database.  
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Selection Criteria 
Type 2 diabetes 
ICD-9 CM diagnosis codes from medical claims were used to identify patients 
with type 2 diabetes.  The type 2 diabetic patients were identified on basis of ICD-9 CM 
diagnoses codes from 250.0x through 250.9x, where x is the fifth digit with a value of 0 
or 2.  Individuals having diagnosis codes with a missing fifth digit cannot be classified as 
type 1 or type 2 diabetes patients and a decision was made on their inclusion depending 
on their use of oral hypoglycemics.  The following criteria for classification was used: at 
least one inpatient admission for which the principal diagnosis was recorded as type 2 
diabetes, or at least two inpatient admissions or two outpatient facility or physician office 
visit claims for which any diagnoses was recorded as type 2 diabetes.  Claims for 
laboratory, pathology or radiology services were not used to identify individuals with 
diabetes, since their use could incorrectly identify individuals as having diabetes based on 
diagnostic procedures such as screening.   
Depression 
The depressive diagnoses considered in this study included single episode major 
depressive disorder (ICD-9 CM diagnoses codes 296.20 through 296.26), recurrent 
episode major depressive disorder (ICD-9 CM diagnoses code 296.3), neurotic 
depression/chronic depression/dysthymia (ICD-9 CM 300.4), and depression not 
otherwise specified (ICD-9 CM 311).  As mental disorders such as depression are 
associated with issues of initial misdiagnosis, at least one inpatient admission for which 
the principal diagnosis was recorded as depression, or at least two inpatient admissions or 
two outpatient facility or physician office visit claims for which any diagnoses was 
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recorded as depression was needed.  Patients with inadequate number of depressive 
diagnoses were excluded from the analysis to prevent any misclassification bias. 
The methods for the 2 phases of the study are described in more detail below: 
 
Phase 1 
 
Objective 1 
Prevalence of co-morbid depression in patients with type 2 diabetes  
 
              Number of type 2 diabetic patients with  
Prevalence rate =  co-morbid depression during the year 2000   x 100,000   
per 100,000             Number of patients with type 2 diabetes  
                                                during the year 2000 
 
Patients in West Virginia Medicaid with a diagnosis of type 2 diabetes in year 
2000 were identified based on the specified selection criteria.  Among these patients with 
type 2 diabetes, presence of co-morbid depression was identified based on the selection 
criteria for depression.   
In addition, a group of Medicaid enrollees without type 2 diabetes diagnosis or 
prescription of diabetic agents was identified in year 2000.   Presence of co-morbid 
depression was also determined for this group of patients.  In addition to uni-variate chi-
square analyses, multivariate logistic regression analyses were conducted to control for 
effect of confounders such as age, gender, race, and co-morbidity.  Interaction effects of 
the main independent variables with age and gender were also included in the model as 
the associations between type 2 diabetes and depression may differ based on age and 
gender. As interaction terms were used in the model, the independent variable “age” was 
centered about the average age in the population for ease of interpretation.  To separate 
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the effects of type 2 diabetes and the presence of related co-morbidities on the prevalence 
of depression, a block-wise logistic model was created consisting of the following blocks 
of co-variates entered sequentially in the model. 
Block 1: Demographic variables: age, gender, race, interaction term of age and 
diabetes, interaction term of gender and diabetes 
Block 2: Presence of chronic co-morbidities unrelated to type 2 diabetes: Cancer, 
asthma, and chronic liver conditions. 
Block 3: Number of physician office visits and presence of chronic co-morbidities 
related to type 2 diabetes (Cardiovascular conditions, cerebro-vascular conditions, 
nephropathy, retinopathy, neuropathy and endocrine/metabolic disorders). 
The analysis was restricted to patients who were continuously Medicaid eligible 
and had no Medicaid HMO eligibility in the year 2000.  Only patients between the ages 
of 18 and 64 were included in the analysis to exclude children and enrollees who were 
also eligible for Medicare. 
 
Objective 2 
Incidence of type 2 diabetes in patients with pre-existing depression 
 
   Number of new cases of type 2 diabetes in patients with  
Incidence rate =   preexisting depression occurring between 1998-2000 x 100,000    
per 100,000     Number of patients with depression between 1997 
 
Patients with depression were identified on the basis of the inclusion criteria for 
depression in the year 1997.  As a comparison group, a group of Medicaid enrollees 
without depression diagnosis or prescription of antidepressants was identified in the year 
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1997.  Patients with a medical claim for type 2 diabetes or a prescription for a 
hypoglycemic agent in the year 1997 were excluded from the analysis.  These patients 
were then followed till the December 31, 2002 to identify incident cases of type 2 
diabetes in both the groups.  In addition to univariate chi-square analyses, multivariate 
logistic regression analyses were conducted to control for effect of confounders such as 
age, gender, race, and co-morbidity.   
The analysis was restricted to patients who were continuously Medicaid eligible 
and had no Medicaid HMO eligibility in the period 1997-2002.  Only patients between 
the ages of 18 and 60 were included in the analysis to exclude children and enrollees who 
were also eligible for Medicare. 
 
Phase 2 
To examine the impact of preexisting depression on patterns of use of oral 
hypoglycemics, drug adherence, and outcomes in patients with type 2 diabetes, the 
following methodology was employed: 
Incident cases of type 2 diabetes were identified using the selection criteria 
mentioned before.  The first prescription for an oral hypoglycemic agent was treated as 
an index prescription.  A 12-month pre period without a diagnosis for type 2 diabetes or a 
prescription for an oral hypoglycemic was used to confirm that the patient is newly 
diagnosed with type 2 diabetes.  A 12-month pre period was also used to identify the 
diagnosis of depressive symptoms in these patients.  Drug utilization patterns and 
adherence was measured over the period of 12 months post index prescription. Incident 
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type 2 diabetes patients who do not have preexisting depression but develop depression in 
the follow up period were excluded from the analysis. 
 
Exclusion Criteria for Phase 2 
? Troglitazone belongs to the thiazolidenedione class of oral hypoglycemics.  It was 
shown to have liver toxicity and hence required regular monitoring.  Due to its 
toxic side effects the drug was finally removed from the market in the year 
2000.70 Thus, while observing the patterns of use and adherence in the database, 
one might attribute any switch from troglitazone as failure of therapy or lack of 
adherence.  This can lead to misinterpretation of the results and hence patients 
who had any prescription for troglitazone in the study period were excluded from 
the analysis. 
? Patients receiving antidepressant therapy without any depressive diagnoses were 
excluded from the analysis to prevent any misclassification bias. 
? Patients with brief depressive reaction (ICD-9 CM 309.0), prolonged depressive 
reaction (ICD-9 CM 309.1), psychotic depression (ICD-9 CM 298.0) were 
excluded because these are etiologically different from major depressive episodes 
or chronic depression. 
? In addition, patients with a diagnosis of schizophrenia (ICD-9 CM 295.10-
295.30,295.60, 295.90), bipolar disorder (ICD-9 CM 296.0, 296.1, 296.4, 296.6), 
dementia (ICD-9 CM 294.1, 294.9), conditions involving cerebral degeneration 
such as Alzheimer’s disease (330.XX, 331.XX), neurotic disorders such as 
anxiety, hysteria, phobic disorders, obsessive compulsive disorders and others 
(ICD-9 CM 300.XX except 300.4X) were also excluded from the analysis to 
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avoid confounding of the effect of other mental disorders on adherence to oral 
hypoglycemics and related outcomes.  These stringent criteria will help minimize 
misclassification bias for majority of the objectives of the study. 
? Patients in long-term care facility, intermediate care facility or skilled nursing 
facility are a select population who are more severe and may demonstrate a high 
amount of adherence as they are under constant supervision.  Hence, patients in 
such facilities in the follow up period were also excluded from the analysis. 
? Patients who are not continuously eligible in the follow up periods for specific 
objectives were excluded from the study.   
 
Measurement of Variables 
Main independent variable: 
Co-morbid depression 
Co-morbid depression will be a categorical variable classified as follows: 
• No diagnosis of depression  
• Diagnosis of depression 
A multivariate framework was used to estimate the impact of depression on adherence 
and other type 2 diabetes outcomes.  All the multivariate models controlled for 
confounding factors such as demographics, co-morbidity, diabetes severity, complexity 
of regimen, and interaction with health care providers.  Multiple variables were used to 
measure each of these confounding factors and are described in detail below:  
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Demographics 
Age: Age was obtained by calculating the difference between the recipient’s date of birth 
and the index date of the study.   
Gender: The field “recipient gender” in the Medicaid recipient data was utilized to 
identify patient’s gender.  
Race: The field “recipient race” in the Medicaid recipient data was utilized to identify 
patient’s race.  Patient’s race was classified into 2 categories: whites and non-whites 
Geographical location:  Patient’s geographical location was categorized on basis of their 
county of residence. The 2003 Rural-urban Continuum Codes were used to classify the 
county of residence as rural or urban.  
These codes form a classification scheme that categorizes counties by size and 
degree of urbanization and proximity to urban areas. Counties all across the nation have 
been subdivided into three metro and six non-metro categories, resulting in a nine-part 
county codification. This scheme was originally developed in 1974. This scheme of 
coding allows researchers to break county data into finer residential groups as per 
convenience.  The Census Bureau made a radical shift in determining rural-urban 
boundaries by changing and liberalizing the procedures for delineating urbanized areas of 
50,000 or more people, and abandoning place boundaries in measuring urban or rural 
population. The procedures used in defining Urbanized Areas were extended down to 
clusters of 2,500 or more people, based solely on population density per square mile.147  
Year of index date: As our enrollment period spanned a period of three years (i.e. 1998-
2000) a control variable for the year of index date was included to account for differences 
in treatment and diagnosis practices over time.  This variable also accounts for 
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introduction of oral hypoglycemics and marketing strategies that vary and thus affect 
prescribing behavior. 
 
Co-morbidity 
Multiple variables were used to measure baseline co-morbidity for newly diagnosed type 
2 diabetes patients.  The Charlson co-morbidity index148 based on medical claims in the 
12-month period prior to the index date was used to measure co-morbidity.  In addition to 
the Charlson co-morbidity index, co-morbidity was measured using a mix of variables 
identifying the presence of specific co-morbid conditions and those related to utilization 
of health care services in the 12-month pre-period before the index date of an oral 
hypoglycemic agent. 
Charlson co-morbidity index:  The Charlson Index is a list of 19 medical conditions.  
Each condition has a weight assigned from one to six, which is derived from relative risk 
estimates of proportional hazard regression models using clinical data.  The Charlson 
index is the sum of weights for all prevalent conditions during a specified time period.  
The index has been shown to have a strong monotonic association of approximately a two 
fold increase in mortality per increment in index level.  There are a variety of indices that 
are primarily based on the Charlson comorbidity index.  The version by D’Hoore and 
associates,149 which is one of the few Charlson indices for use with administrative claims 
data, was used in our study.  As coding of the ICD-9 codes in administrative databases 
after the decimal places is not reliable, the Charlson index by D’Hoore and associates is 
based on only the first three digits of ICD-9 codes.   Diagnosis codes related to 
depression and diabetes were excluded in the computation of this index. 
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Utilization related variables:  These variables measured overall utilization in the 12-
month pre-period excluding utilization accrued due to depression or antidepressants. The 
following utilization variables were used: 
• Number of ER/hospitalization visits 
• Total health care costs 
• Distinct number of therapeutic medication classes for management of chronic 
conditions. 
Specific co-morbid conditions:  The presence of the following co-morbid conditions was 
identified in the 12-month pre period on the basis of their prevalence in the study 
population and their impact on outcomes related to diabetes management. 
• Presence of cardio-vascular conditions (including hypertension and 
hyperlipidemia) 
• Presence of Asthma 
• Presence of Ulcers 
• Presence of Cancer 
 
Complexity of drug regimen  
The following variables will be used in the model to control for the confounding effect of 
complexity of drug regimen on diabetes related outcomes: 
Mean daily number of pills of oral hypoglycemic agents:  This computation was based 
on the first oral hypoglycemic prescription.  The fields “Qty dispensed” and “days 
supply” were used to compute number of pills per day. 
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Number of prescriptions for chronic medications:  All the available therapeutic classes 
of medication were categorized as those used for acute or chronic conditions on basis of 
clinical literature.  Therapeutic classes such as Non-Steroidal Inflammatory Drugs 
(NSAIDs), which can be used for either chronic or acute purposes, were conservatively 
classified as those for acute conditions. Number of prescriptions for chronic conditions 
other than depression in the pre period was computed. 
Mean daily number of pills of other chronic medications:  Mean number of pills per day 
was computed for chronic medications other than those used for diabetes or depression.  
This analysis was restricted to prescriptions for orally ingested tablets or capsules in the 
60-day period before the index date.  This was computed by multiplying the mean 
number of pills per day for each prescription of a chronic medication with the number of 
prescriptions with unique generic codes in the 60-day pre period.    
 
Interaction with healthcare providers 
Physician Assured Access System (PAAS) enrollment:  Individuals enrolled in PAAS 
receive case management and education services not available to individuals enrolled in 
the fee-for-service program.  Under the program, participants select a primary care 
provider who coordinates care and whose approval is required for most health care 
services.  Hence, a dummy variable indicating whether the patient is enrolled in PAAS or 
is under the traditional fee for service system was used as a proxy for interaction with the 
health care provider.   
Pharmacy patronage:  In addition to interaction with their physician, patient’s interaction 
with their pharmacist can also affect adherence to medications and related outcomes.  
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Pharmacy patronage measured in terms of number of pharmacies visited in the six-month 
pre period was used as a proxy for interaction with pharmacists.  The variable was 
categorized as: 
• No pharmacy use 
• Single pharmacy use 
• Multiple pharmacy use  
 
Severity of diabetes 
Although all patients were newly diagnosed with type 2 diabetes, there might be 
differences in diabetes severity, which was controlled using the following variables:   
Initiation on monotherapy/polytherapy:  A medication regimen was referred to as 
monotherapy when patients received therapy with a single class of oral hypoglycemic 
medication, and polytherapy when patients simultaneously received two or more classes 
of oral hypoglycemics.  A pattern of use was classified as initial poly-therapy if one of 
the following criteria was satisfied: 
• Index prescription was for a fixed combination therapy and the patients received 
at least two more prescriptions for the combination therapy in the follow up 
period; or 
• The patient had a prescription claim for a second oral hypoglycemic agent/insulin 
(different class) within 15 days of the index fill date of the index prescription and 
received at least two more prescriptions for each of the drugs in the follow up 
period. 
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Class of the index oral hypoglycemic agent:  Class of the index oral hypoglycemic 
prescription can indicate the severity of diabetes and also predict diabetes outcomes 
through its efficacy and side effect profile.  The index oral hypoglycemic prescription 
was classified into one of the following class of oral hypoglycemic:   
First generation/second generation sulfonylurea, biguanide, thiazolidenedione, 
meglitinide, or alpha glucosidase inhibitor.   
Specialty of the prescribing physician:  Specialty of the physician who prescribes the 
index oral hypoglycemic prescription can be predictive of diabetes severity, access 
issues, and/or diabetes related outcomes.  This variable was categorized as index 
prescription provided by: a specialist (endocrinologist), an internist, or a family 
physician.  
Gap between diagnosis and medication therapy:  Type 2 diabetes patients in our study 
may have varying lengths of time between initial diagnosis of type 2 diabetes and 
initiation of oral hypoglycemic therapy.  This gap between diagnosis and initiation of 
medication therapy was controlled in our study as a continuous variable measured in 
days. 
Diabetes related utilization:  Although the study population consisted of only patients 
newly diagnosed with type 2 diabetes, the index date of the study period was the date of 
the initial prescription of oral hypoglycemic. Hence, diabetes related utilization was 
available for patients who had a gap in therapy between initiation of pharmacotherapy 
and initial diagnosis of type 2 diabetes and served as a good proxy for diabetes severity.  
The following variables were used to measure diabetes related utilization in the 12-month 
pre period: 
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• Total type 2 diabetes related costs 
• Number of type 2 diabetes related ER/hospitalizations 
The variables described above were used as independent control variables in all 
the multivariate models to examine the impact of depression on type 2 diabetes outcomes.  
A variety of outcomes such as adherence with oral hypoglycemics, and utilization related 
to type 2 diabetes management were evaluated.  The measurement of the outcomes is 
described in detail below: 
Patterns of oral hypoglycemic use 
Patterns of oral hypoglycemic use could be classified in any of the following categories 
based on utilization of prescriptions in the follow-up period. 
• Discontinuation 
A patient was deemed as a discontinuer in the 12-month follow up period after 
initiation of oral hypoglycemic therapy if he/she ends therapy on an oral 
hypoglycemic/insulin and does not receive a refill within x days of supply exhaustion 
where x equals 250% of the days supply of the last fill. 
• Augmentation 
Augmentation refers to a situation where an initial regimen is modified by adding 
another agent of a different class or insulin. Addition of another oral hypoglycemic agent 
was defined as starting a non-index medication belonging to a class other than the index 
prescription, while obtaining a refill for the index drug within a specified window [index 
drug fill date + 2.5 * (days supply of index drug fill)] and at least one more prescription 
for each of the drug classes in the follow up period.  [Patients on initial poly-therapy were 
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initially excluded to facilitate the distinction between augmentation and initial poly-
therapy] 
• Switching 
Agent switching was defined as starting a different class of oral hypoglycemic 
than the index prescription while not obtaining a refill for the index drug in the follow 
up period.    
• Non-modification 
Modification in medication regimen may indicate either augmentation or 
switching.  Patients who experience no modification in their medication regimens for 
the entire follow up period (except discontinuers) were designated as non-modifiers. 
Dose changes were not classified as modification.  Also changing specific drugs 
within the same class of oral hypoglycemic was not defined as modification.   
 
If patients could not be categorized in any of the above patterns, then their 
prescription patterns were manually inspected to determine their status.  Also, the 
outpatient pharmacies do not record prescriptions dispensed during an inpatient 
admission.  These patients may be incorrectly classified as discontinuers due to the lack 
of prescription refill information during the length of their hospitalization.  Hence, during 
the time spent in the hospital it was assumed that the medications are supplied by the 
hospital, and therefore the numbers of days of hospitalization were added as days supply 
in calculating drug utilization patterns.   
 
 
 91
Adherence with oral hypoglycemics 
Patients initiating either mono-therapy or poly-therapy involving insulin were 
excluded from the computation of adherence indices.  For the rest of the patients who 
may have insulin use in the form of a switch or augmentation, all their insulin 
prescriptions were excluded from the calculation of adherence indices. This exclusion 
criterion was used, as only adherence to oral hypoglycemic agents was computed in the 
study.  Also utilization of insulin through an administrative dataset is difficult to compute 
due to frequent changes in dosage instructions without proper documentation.  
Medication Possession Ratios150 were used as proxies for measurement of drug adherence 
in the study.  Two different indices were computed and referred to as MPR-1 and MPR-2.  
• Medication Possession Ratio-1 (MPR-1) 
The Medication Possession Ratio-1 (MPR-1) was a proxy measure of medication 
adherence in the period between the first and last prescription fills. It is defined as the 
sum of days supply for all fills divided by the number of days of therapy between the first 
and last fills plus days supply for the last fill.    
 
MPR-1  =    Sum of days supply 
    (Number of days between the first and last fills) + days supply of the last fill  
 
To account for possible early refills, any excess in the days supply due to early 
refill in the previous interval was allocated to the following interval.   
This index assesses the proportion of days during the treatment that the patient 
possessed an adequate quantity of medication.  Since the denominator of the ratio is the 
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period during which the patient is in possession of medication, this measurement of 
adherence does not capture adherence as a consequence of premature discontinuation of 
therapy. 
Also, as MPR-1 cannot be computed for patients not filling more than one 
prescription, these indices were not computed for patients who discontinue their oral 
hypoglycemic agents.  The above formula for MPR-1 can be easily applied to non-
modifiers. However, if there are drugs from multiple classes consumed over the time 
period (i.e for switchers, augmenters, and those on initial poly-therapy) then MPR-1 
should be computed separately for each class of drug.  This weighted MPR-1 value was 
termed as Reg MPR-1 and was computed as follows:  
 
                           Sum of {MPR-1 * [(Number of days between the first and last fills) days 
Reg MPR-1 =                               supply of the last fill]} for all drugs 
Sum of (Number of days between the first and last fills) + days supply of             
the last fill) for all drugs 
 
If the admit and discharge dates of hospitalizations are included between the first 
and last fill dates of a particular class of drug, then the number of days of hospitalizations 
was added to the days supply of drugs for that particular class. 
The formulas for MPR-1 and Reg MPR-1 mentioned above are restricted to 
computing adherence between two prescription refills.  In addition, adherence indices 
were computed for the period between the index prescription and the end of the follow up 
period.  In the first case, all gaps are embedded within a series of fills.  In the second 
case, a terminal gap may be present after the last refill.  Both measures assume that the 
gaps are due to reduced adherence rather than due to clinician instructions for temporary 
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(in the case of “embedded gaps”) or permanent (in the case of “terminal gaps”) drug 
cessation.   
When computing adherence indices using the end of follow up period as the end 
point instead of last refill, all the patients including discontinuers were used in the 
analysis.  Here, the assumption made would be the fact that discontinuation is because of 
failure to comply and not due to control by diet and exercise. These adherence indices 
were denoted as MPR-2 and included discontinuers in their computation as opposed to 
MPR-1 and Reg MPR-1 wherein all the discontinuers were excluded.   
• Medication Possession Ratio-2 (MPR-2) 
The MPR-2 is a proxy measure of medication adherence in the period between the 
first prescription and end of the follow up period.  It is defined as the sum of days supply 
for all fills divided by the number of days in the follow up period (i.e 365 days).  
 
 MPR-2  =          Sum of days supply 
 Number of days in the follow up period (i.e 365 days) 
 
To account for possible early refills, any excess in the days supply due to early refill in 
the previous interval was allocated to the following interval.   
The above formula for MPR-2 can be easily applied to non-modifiers and 
switchers. However, if there are drugs from multiple classes consumed over the time 
period (i.e for augmenters, and those on initial poly-therapy) then MPR-2 should be 
computed separately for each class of drug. However, these rules might differ a bit for 
MPR-2.   Reg MPR-2 was computed as follows:  
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Sum of {MPR-2* [(Number of days between the first fill and end 
of follow up period) for all drugs} 
Reg MPR-2  =                                 
Sum of (Number of days between the first fill and end of follow    
period) for all drugs 
 
If the admit and discharge dates of hospitalizations are included between the first 
fill date and end of follow up period for a particular class of drug, then the number of 
days of hospitalizations is added to the days supply of drugs for that particular class.    
 
Computation of costs 
• Total health care costs were computed irrespective of the diagnoses codes. The 
components of outpatient, emergency room (ER), hospitalizations, and 
prescription costs were separately computed.   
• Diabetes related costs were computed by summing paid amounts for claims with a 
primary or secondary diagnosis code for type 2 diabetes.  Prescriptions for oral 
hypoglycemics and insulin were identified on basis of National Drug 
Classification (NDC) Code.  Diabetic supplies such as syringes, needles, and 
glucose testing equipment were also identified using NDC codes.  
• In case of outpatient, prescription, and ER costs, costs were computed from 
Medicaid’s perspective using the amount paid by Medicaid for each claim.  In 
case of claims for hospitalizations, the amount reimbursed by Medicaid for each 
claim was not included in the dataset.  Hence, average 2001 West Virginia 
Medicaid reimbursement rates on the basis of Diagnosis Related Groups (DRG) 
were used for computation of hospitalization costs. For DRG codes that did not 
have a reimbursement value from WV Medicaid, the relative weight of the DRG 
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was used to assign hospitalization costs. On the basis of these averages, the 
average reimbursement assigned per unit DRG weight = $ 4,632.66 per unit 
weight. 
The above section discussed in detail the measurement of independent and dependent 
variables examined in the study.  The following sections will describe the methodology 
and statistical methods used to meet each specific study objective: 
 
Objective 3 
Patterns of oral hypoglycemic use 
Univariate analyses such as chi-squares were used to examine the differences in 
patterns of oral hypoglycemic (i.e non-modification, switching, augmentation, or 
discontinuation) between patients with and without depression.  In addition, as the 
dependent variable had four possible categories, multivariate multinomial logistic 
regression techniques were used to estimate the impact of preexisting depression on the 
pattern of oral hypoglycemic use controlling for other confounding factors.  A 
Multinomial logistic regression model simultaneously estimates binary logistic regression 
models for all possible comparisons among the outcomes categories, which enforces the 
logical relationship among the parameters and uses the data more efficiently.151  Patients 
receiving insulin therapy alone or in combination with oral hypoglycemics at the start of 
treatment were excluded from this analysis. 
Pattern (non-modification, switching, augmentation, discontinuation) = constant 
+ β (                                                + Demographics + Drug regimen and complexity  + 
Co-morbidity + Diabetes severity + Interaction with health care providers) + error term 
 
Preexisting depression 
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Objective 4 
Secondary failure with oral hypoglycemic therapy 
Augmenting or switching from the initial class of oral hypoglycemic agent is 
indicative of secondary failure with initial pharmacotherapy.  A chi-square test statistic 
was used to examine the differences in secondary failure with initial oral hypoglycemic 
medication between patients with and without depression.  A multivariate logistic 
regression analysis was used to examine the impact of preexisting depression on 
secondary failure controlling for other confounding factors.  Patients who discontinued 
the use of oral hypoglycemic agents were excluded from the analysis.   
Secondary failure (Yes/No)= constant +β  (                                                + 
Demographics + Drug regimen and complexity  + Co-morbidity + Diabetes severity + 
Interaction with health care providers) + error term 
 
In addition, survival analysis techniques were used to estimate the impact of 
preexisting depression on time to secondary failure.  As the outcome in this scenario is 
time-to-event data, one encounters the issue of censoring where the response is not 
observed for a portion of the subjects due to lack of follow-up time.  Also, the frequency 
distribution of the response measurements is not normally distributed.  Due to these 
characteristics of time-to-event data, the standard statistical methods are not appropriate 
for estimation.  Univariate Kaplan Meier survival analysis and Cox proportional hazard 
models controlling for confounding factors were used for estimation of such data.  
Proportions hazards regression is a semi parametric model wherein the regression 
coefficients are estimated using partial likelihood procedures.152 
Preexisting depression 
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Mathematically, the Cox proportional hazard model can be written as: 
h(t) = ho(t) * exp {βX}   
Where the hazard function h(t) is determined by a set of predictor variables 
collectively represented by X.  Analogous to the intercept in an Ordinary Least Squares 
(OLS) model, the Cox model has a baseline hazard function {ho(t)} which is estimated 
non-parametrically.  Thus, the model is essentially an OLS regression of the logarithm of 
the hazard on the variables X with the baseline hazard being the intercept that varies with 
time.  The covariates act multiplicatively on the hazard at any point in time, thus leading 
to the important assumption of proportional hazards rates between levels of variables.  
Therefore, prior to a multivariate analysis each predictor variable was tested for 
proportionality.  This assumption can be tested by plotting Kaplan Meier survival 
estimates versus time, for the different levels of a variable, and checking whether the 
curves are linear with a constant proportion between each of the levels.  In addition to 
these graphical techniques, significance tests provided by statistical software STATA will 
also be used for testing proportional hazards assumptions. 
Time to Secondary failure  = constant +β (                                                  + 
Demographics + Drug regimen and complexity  + Co-morbidity + Diabetes severity + 
Interaction with health care providers) + error term 
 
 
 
 
 
Preexisting depression
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Objective 5 
Initiation of insulin therapy 
 A chi-square test statistic was used to examine the differences in initiation of 
insulin therapy between patients with and without depression.  A multivariate logistic 
regression analysis was used to estimate the impact of preexisting depression on initiation 
of insulin therapy controlling for other confounding factors. 
Insulin use (Yes/no)  = constant +β  (                                                + 
Demographics + Drug regimen and complexity  + Co-morbidity + Diabetes severity + 
Interaction with health care providers) + error term 
In addition, survival analysis techniques were used to estimate the impact of 
preexisting depression on time to initiate insulin therapy.  Univariate Kaplan Meier 
survival analysis and Cox proportional hazard models controlling for other factors were 
used for estimation.   
Time to insulin use  = constant +β  (                                                    + 
Demographics + Drug regimen and complexity  + Co-morbidity + Diabetes severity + 
Interaction with health care providers) + error term 
 
 
 
 
 
 
 
Preexisting depression 
Preexisting depression 
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Objective 6 
Adherence with oral hypoglycemic therapy 
This objective was examined using different indices for adherence such as the 
Reg MPR-1 and Reg MPR-2.  Univariate analyses such as t-tests were employed to 
examine differences in adherence between patients with and without depression.  
Ordinary Least Squares (OLS) regression techniques were used to estimate the impact of 
preexisting depression on adherence with oral hypoglycemic medications controlling for 
other factors.  If the distributions of the adherence indices were skewed then 
transformations such as log transformations were performed on the indices.   
These adherence scores were also categorized to examine the extremities in 
adherence levels and to estimate the relative impact of extreme adherence behavior on 
outcomes.  Univariate chi-square tests were used to examine differences in adherence.  
As multiple categories of adherence were created, multivariate multinomial logistic 
regression analysis was used to estimate the impact of preexisting depression on these 
categories of adherence controlling for other confounding factors.  Patients receiving 
insulin therapy alone or in combination with oral hypoglycemics at the start of treatment 
were excluded from this analysis.  As insulin use in the follow up period can be a 
consequence of decrease in adherence, it was not controlled in the model.   
Adherence  = constant +β  (                                                  + Demographics + 
Drug regimen and complexity  + Co-morbidity + Diabetes severity + Interaction with 
health care providers) + error term 
 
 
Preexisting depression 
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Objective 7 
Utilization and costs associated with type 2 diabetes 
 Claims including either a primary or secondary diagnosis code for type 2 diabetes 
and prescriptions for insulin, oral hypoglycemics and diabetic supplies were identified in 
assessing total resource utilization associated with type 2 diabetes.  The costs were also 
examined separately in terms of hospitalization/ER costs, outpatient costs, and pharmacy 
costs.   
Parametric and non-parametric univariate tests such as t-tests and Mann-Whitney 
U tests were used depending on the distribution of the dependent variables.  Ordinary 
Least Squares (OLS) regression techniques were used for the estimation of the impact of 
preexisting depression on total costs associated with type 2 diabetes controlling for other 
confounding factors.  As the patients were selected over the period of a few years, the 
costs were inflated to 2002 costs using the medical care and prescription price index.153  
If the distributions of the costs were skewed then transformations such as log 
transformations were performed to normalize the data.  
In case of semi-log OLS models, empirically researchers have misinterpreted the 
estimates of the coefficients of the dummy variables by assuming that the parameter is 
estimated with no uncertainty.  The coefficient of the primary independent variable was 
estimated using the correction of Halverson and Palmquist with a modification by 
Kennedy.154,155  This implies that an estimate for the coefficient of the dummy variable is  
 Corrected Estimate = {Exp (original estimate – 0.5(Standard error of estimate)2 }  - 1   
Estimates from semi-log OLS models also need to interpreted in terms of dollar values.  
However, one cannot simply simulate costs by taking the anti-log of the fitted values.  
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This value is subjected to retransformation bias, which is addressed using a smearing 
estimator.  This estimate for semi-log OLS models is generally the mean of the anti-log 
of the residuals, which is multiplied by the fitted value to correct it for retransformation 
bias. 
In models where the dependent variables are specific costs such as those due to  
ER/hospitalization visits and outpatient costs, there is a possibility of null values for the 
dependent variable for some of the observations.  As a logarithmic transformation cannot 
be employed, a two-part model was used in this case to estimate the impact of depression 
on ER/hospitalization and outpatient costs.  An initial multivariate logistic regression 
model was used to estimate the probability of having an ER/hospitalization or outpatient 
visit and a subsequent semi-logarithmic OLS model was conducted only on those patients 
incurring these specific costs in the follow up period. 
Regression models will be analyzed to examine the impact of preexisting 
depression on events such as number of ER/hospitalization visits, and outpatient visits.  
As the dependent variable in this case is count data, the use of OLS can result in 
inefficient, inconsistent, and biased estimates. Hence, a Poisson regression analysis was 
conducted to meet these objectives.  In a Poisson regression, the probability of a count is 
determined by a Poisson distribution, which has the defining characteristic that the 
conditional mean of the outcome is equal to the conditional variance.  However, if the 
models were overdispersed (i.e the variance being greater than the mean) with a high 
proportion of zero counts, a negative binomial model was used for estimation.  
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Type 2 diabetes related events and expenditures = constant + 
β  (                                                  + Demographics + Co-morbidity + Diabetes 
severity + Interaction with health care providers) + error term 
 
Objective 8 
Overall utilization and health care costs 
All medical and prescription claims in the 12-month follow up period were 
identified for this analysis, irrespective of diagnosis codes.  The costs were also examined 
separately in terms of hospitalization/ER costs, outpatient costs, and pharmacy costs.  
Ordinary Least Squares (OLS) regression analysis was used for the estimation of the 
impact of preexisting depression on total health care costs.  Regression models were also 
used to examine the impact of preexisting depression on events such as number of 
ER/hospitalization visits, outpatient visits, or prescriptions.  Appropriate econometric 
methods as explained in objective 7 were used to estimate the impact of preexisting 
depression on overall utilization and health care costs. 
Overall health care events and expenditures = constant + 
β  (                                                 + Demographics + Co-morbidity + Diabetes 
severity + Interaction with health care providers) + error term 
 
 
 
 
 
Preexisting depression
Preexisting depression
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Objective 9 
Causal pathways between depression, adherence, and type 2 diabetes outcomes 
Mediation analysis was conducted to meet this objective using the criteria 
suggested by MacKinnon.156 The following three equations were estimated to identify 
whether adherence with oral hypoglycemics mediates the relationship between 
depression and type 2 diabetes outcomes. 
 
Equation 1 
Type 2 diabetes related events and expenditures = constant + 
 (α)                                                 + Demographics + Co-morbidity + Diabetes severity + 
Interaction with health care providers + error term 1  
 
Equation 2 
Type 2 diabetes related events and expenditures = constant +  
  (β)                                               + Adherence + Demographics + Co-morbidity + 
Diabetes severity + Interaction with health care providers  + error term 2  
 
Equation 3 
Adherence = constant +                 + Demographics + Co-
morbidity + Diabetes severity + Interaction with health care providers + Complexity of 
regimen + error term 3 
 
 
Preexisting depression 
Preexisting depression
Preexisting depression 
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The following four steps can establish mediation: 
Step 1:  If depression is a significant predictor of outcomes in equation 1 
Step 2:  If depression significantly predicts adherence in equation 3 
Step 3:  If adherence significantly predicts outcomes while controlling for depression in 
equation 2.  It is not sufficient to show that adherence and outcomes are correlated as 
they may be correlated because they are both caused by depression 
Step 4:  To establish that adherence completely mediates the relationship between 
depression and outcomes, the effect of depression on outcomes controlling for adherence 
in equation 2 (i.e. β) should be zero. 
If all the four steps are met then the data is consistent with the hypothesis that 
adherence completely mediates the relationship between depression and outcomes, and if 
the first three steps are met but the fourth step is not met, them partial mediation is 
indicated.  The presence of mediation will be tested by comparing the estimated effects of 
depression on type 2 diabetes outcomes with and without controlling for adherence in the 
estimation models (i.e. α and β).  These differences in the estimates will be statistically 
tested using a Hausman type statistic.157  
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CHAPTER FOUR 
RESULTS AND DISCUSSION 
 Previous chapters provided an overview of the issue of depression in patients with 
type 2 diabetes and discussed the available literature in this area.  The specific objectives 
and the conceptual framework of the study were outlined.  Data sources and detailed 
methodology employed to meet the study objectives were also provided.  This chapter 
presents the results and discusses the findings of each study result.  The results chapter is 
sub-divided on the basis of the two phases of the study.  
 
Phase 1 
Results for Objective 1 
To estimate the prevalence of co-morbid depression in patients with type 2 diabetes 
Patients in West Virginia Medicaid with a diagnosis of type 2 diabetes in the year 
2000 were identified based on the specified selection criteria.  Among these patients with 
type 2 diabetes, presence of co-morbid depression was identified based on the selection 
criteria for depression. 
Patients with type 2 diabetes: 
• Number of patients with continuous Medicaid eligibility and HMO non-eligibility 
between the ages of 18 and 64 in the year 2000: 10,742 
• Number of type 2 diabetes patients who had co-morbid depression in 2000: 2,644 
(24.60%) 
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              Number of type 2 diabetic patients with  
Prevalence rate =  co-morbid depression during the year 2000   x 100,000   
per 100,000                Number of patients with type 2 diabetes  
                                               during the year 2000 
               
Prevalence rate =  2644 x 100,000  = 24,613.66  
per 100,000                   10742 
 
In addition, a group of Medicaid enrollees without type 2 diabetes diagnosis or 
prescription for oral hypoglycemic agent was identified in the year 2000.   Presence of 
co-morbid depression was also determined for this group of patients.   
Patients without type 2 diabetes: 
• Number of patients with continuous Medicaid eligibility and HMO non-eligibility 
between the ages of 18 and 64 in the year 2000: 9,364 
• Number of patients without type 2 diabetes who had co-morbid depression in 
2000: 1,911 (20.40%) 
A Chi-square value of 50.50 was found to be significant (p= 0.001) indicating that 
co-morbid depression was more prevalent in patients with type 2 diabetes as compared to 
Medicaid enrollees without type 2 diabetes.  However, this effect could also be a result of 
confounders such as demographics and presence of co-morbid conditions.  Hence, a 
multivariate logistic regression was also performed controlling for age, gender, race, and 
co-morbidities.  To separate the effects of type 2 diabetes and the presence of related co-
morbidities on the prevalence of depression, a block-wise logistic regression model was 
created consisting of the following blocks of co-variates entered sequentially in the 
model. 
 107
Block 1: Demographic variables: age, gender, race, interaction term of age and 
diabetes, interaction term of gender and diabetes. 
Block 2: Presence of chronic co-morbidities unrelated to type 2 diabetes: Cancer, 
asthma, and ulcer. 
Block 3: Number of physician office visits and presence of chronic co-morbidities 
related to type 2 diabetes (Cardiovascular conditions, cerebro-vascular conditions, 
nephropathy, retinopathy, neuropathy and endocrine/metabolic disorders). 
All three logistic regression models were found to be significant and the model 
results are summarized in Tables 1A-1C. Use of blocks of covariates shows that 
prevalence of depression in patients with type 2 diabetes was significantly higher than 
patients without type 2 diabetes after controlling for demographic characteristics such as 
gender, age, race, and their interactions (Odds Ratio = 1.259; p = 0.000).  The association 
remained significant after additionally controlling for presence of major chronic 
conditions unrelated to type 2 diabetes (Odds Ratio = 1.181; p=0.000).  However, 
presence of type 2 diabetes did not retain its statistically significant impact on presence of 
co-morbid depression when presence of chronic conditions related to type 2 diabetes and 
number of physician office visits were controlled in the model (Odds Ratio = 0.924; p 
=0.089).   
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Table 1A: Logistic regression model to examine the relationship between type 2 
diabetes and presence of co-morbid depression (Model 1) 
 Beta S.E. Sig. 
 (p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
       
Type 2 diabetes 0.230 0.044 0.000* 1.259 1.156 1.371
Block 1 
Age** 0.006 0.002 0.003* 1.006 1.002 1.010
Males (ref: females) 
 
-0.710 0.055 0.000* 0.492 0.441 0.548
Whites (ref: non-whites) 
 
0.347 0.079 0.000* 1.415 1.211 1.653
Interaction of diabetes and 
age 
 
-0.029 0.003 0.000* 0.971 0.966 0.977
Interaction of diabetes and 
gender 
0.029 0.076 0.704 1.029 0.887 1.194
    
Constant -1.374 0.082 0.000 0.253  
*significance at the 0.05 level 
**Age is centered at the average value of age for the sample (40 years) 
 
 
Model fit statistics: 
 
Pseudo R-square = 4.1% 
-2 Log Likelihood = 20411.304; χ2  = 532.630, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 41.850; p=0.000 
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Table 1B: Logistic regression model to examine the relationship between type 2 
diabetes and presence of co-morbid depression (Model 2) 
 Beta S.E. Sig.  
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
       
Type 2 diabetes 0.174 0.044 0.000* 1.190 1.092 1.298
Block 1 
Age** 0.003 0.002 0.188 1.003 0.999 1.007
Males (ref: females) 
 
-0.678 0.056 0.000* 0.507 0.455 0.566
Whites (ref: non-whites) 
 
0.333 0.080 0.000* 1.396 1.193 1.633
Interaction of diabetes and 
age 
 
-0.027 0.003 0.000* 0.973 0.967 0.979
Interaction of diabetes and 
gender 
0.038 0.076 0.622 1.038 0.894 1.206
    
Block 2 
Asthma  0.652 0.042 0.000* 1.919 1.767 2.083
Cancer 0.139 0.077 0.071 1.149 0.988 1.336
Ulcers 0.555 0.075 0.000* 1.742 1.505 2.016
    
Constant -1.518 0.084 0.000 0.219  
*significance at the 0.05 level 
**Age is centered at the average value of age for the sample (40 years) 
 
 
Model fit statistics: 
 
Pseudo R-square = 6.4% 
-2 Log Likelihood = 20098.353; χ2  = 845.581, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 29.280; p=0.000 
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Table 1C: Logistic regression model to examine the relationship between type 2 
diabetes and presence of co-morbid depression (Model 3) 
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
       
Type 2 diabetes -0.072 0.047 0.124 0.931 0.850 1.020
Block 1 
Age** -0.004 0.002 0.067 0.996 0.992 1.000
Males (ref: females) 
 
-0.598 0.057 0.000* 0.550 0.492 0.614
Whites (ref: non-whites) 
 
0.328 0.081 0.000* 1.388 1.185 1.626
Interaction of diabetes and 
age 
 
-0.022 0.003 0.000* 0.978 0.972 0.984
Interaction of diabetes and 
gender 
0.001 0.077 0.991 1.001 0.860 1.165
    
Block 2 
Asthma  -0.111 0.079 0.164 0.895 0.766 1.046
Cancer 0.350 0.077 0.000* 1.419 1.221 1.649
Ulcers 0.483 0.043 0.000* 1.621 1.489 1.764
    
Block 3    
Diabetic complications 0.457 0.049 0.000* 1.579 1.434 1.738
Number of physician office 
visits 
0.040 0.003 0.000* 1.041 1.036 1.046
       
Constant -1.971 0.090 0.000 0.139  
*significance at the 0.05 level 
**Age is centered at the average value of age for the sample (40 years) 
 
Model fit statistics: 
 
Pseudo R-square = 9.5% 
-2 Log Likelihood = 19678.563; χ2  = 1265.371, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 21.570; p= 0.006 
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Discussion for Objective 1 
  Our results demonstrated that 24.6% of type 2 diabetes patients in West Virginia 
Medicaid had co-morbid depression.  Previous studies have found depression prevalence 
rates ranging from 6.1% to 49.3% in patients with type 2 diabetes.29 The population-
based study conducted in KPNW had a prevalence rate of 17.6%.139  Our rates may be 
higher due to an indigent and younger population with a higher proportion of females.  
The association of type 2 diabetes and co-morbid depression was significant after 
controlling for confounders indicating that patients with type 2 diabetes have higher odds 
of co-morbid depression as compared to patients without type 2 diabetes.  However, 
when the logistic regression model was reanalyzed with the presence of type 2 diabetes 
related co-morbidities as independent variables, the odds of co-morbid depression were 
not significantly different for patients with type 2 diabetes as compared to patients 
without type 2 diabetes.  These results are interesting in the fact that they suggest that 
higher observed rates of co-morbid depression in patients with type- 2 diabetes are 
primarily due to the higher number of co-morbid conditions associated with type 2 
diabetes.  However, one can attribute these co-morbid conditions and subsequent 
depression to type 2 diabetes and thus reasonably conclude that type 2 diabetes is 
associated with a higher prevalence of co-morbid depression.  Similar results were 
obtained in a study by Pouwer and associates,138 which suggested that the prevalence of 
co-morbid depression is higher in patients with type 2 diabetes and co-morbid disease(s), 
but not in patients with type 2 diabetes only.   A variety of other studies have found that 
while medical conditions in general are risk factors for psychological disturbance, type 2 
diabetes carries no unique risk.121 The comprehensive review by Anderson and associates 
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contained two studies that compared rates of depression between people with diabetes 
and those with other medical conditions; neither found a significant difference.29 These 
results suggest that factors involved in the general burden of illness contribute to the 
observed elevated prevalence of co-morbid depression in patients with type 2 diabetes. 
 
 
Results for Objective 2 
 
To estimate the incidence of type 2 diabetes in patients with pre-existing depression 
 
Patients with depression were identified on the basis of the inclusion criteria for 
depression in the year 1997.  As a comparison group, a group of Medicaid enrollees 
without depression diagnosis or prescription of antidepressants was identified in the year 
1997.  Patients with a medical claim for type 2 diabetes or a prescription for an oral 
hypoglycemic agent in the year 1997 were excluded from the analysis.  These patients 
were then followed till December 31, 2002, to identify incident cases of type 2 diabetes 
in both the groups.   
Patients with depression: 
• Number of patients with a diagnosis of depression: 12,589 
• Number of depressed patients without type 2 diabetes in 1997: 11,345 
• Number of eligible patients (Medicaid eligible 97-2002; HMO non eligible 97-
2002; age greater than or equal to 18 and age less than or equal to 60 as on 
January 1, 1998): 4,472 
• Number of depressed patients who had incident type 2 diabetes in the follow-up 
period (1998-2002): 704 (15.70%) 
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  Number of new cases of type 2 diabetes in patients with  
Incidence rate =   preexisting depression occurring between 1998-2002 x 100,000    
per 100,000 Number of patients with depression in 1997 
 
Incidence rate =    704 x 100,000      = 15,742.39 
per 100,000         4,472 
 
Patients without depression: 
• Number of patients without a diagnosis of depression: 52,653 
• Number of non-depressed patients without type 2 diabetes in 1997: 50,798 
• Number of eligible patients (Medicaid eligible 97-2002; HMO non eligible 97-
2002; age greater than equal to 18 and age less than equal to 60 as on January 1, 
1998): 5,195 
• Number of non-depressed patients who had incident type 2 diabetes in the follow-
up period (1998-2002): 606(11.70%) 
 
A univariate chi-square analysis was performed to determine the association 
between the presence of pre-existing depression and incidence of type 2 diabetes patients.  
Approximately 15.7% of depressed patients developed type 2 diabetes as compared to 
11.70% of non-depressed patients.  A Chi-square value of 34.104 was found to be 
significant with a p-value of 0.000.  These numbers indicate that the incidence of type 2 
diabetes was slightly higher in patients with pre-existing depression.  However, this effect 
could also be a result of confounders such as demographics and presence of co-morbid 
conditions.  Hence, a multivariate logistic regression was performed to determine the 
association of pre-existing depression and incidence of type 2 diabetes controlling for 
age, gender, race, and presence of cardio-vascular co-morbidities at baseline. 
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The logistic regression model was found to be significant with a Nagelkerke R-
square value of 7.10%.  The model results are summarized in Table 2.  A significant 
adjusted odds ratio indicates that the association between presence of pre-existing 
depression and incidence of type 2 diabetes is still significant and that patients with pre-
existing depression are more likely to develop type 2 diabetes as compared to enrollees 
without pre-existing depression.  
 Due to the use of interaction effects, the odds of developing incident type 2 
diabetes in patients with depression as compared to patients without depression needs to 
be computed separately for males and females.  The interaction term for gender and 
presence of pre-existing depression was significant, suggesting that the odds of 
developing incident type 2 diabetes in patients with depression differs for males and 
females.  The results of logistic regression estimate that a 40 year old female with pre-
existing depression is nearly one and a half times more likely to develop incident type 2 
diabetes as compared to a 40 year old female without depression after controlling for age, 
gender, race, and cardiovascular co-morbidity at baseline.  However, 40 year old males 
do not show a relationship between presence of pre-existing depression and development 
of incident type 2 diabetes (Odds Ratio for Females= 1.479; Odds Ratio for 
Males=0.997). 
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Table 2: Logistic regression model to examine the relationship between pre-existing 
depression and incidence of type 2 diabetes 
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
       
Depression 0.392 0.086 0.000* 1.479 1.250 1.751
Age** 0.039 0.004 0.000* 1.040 1.032 1.048
Males (ref: females) 
 
-0.024 0.091 0.791 0.976 0.816 1.168
Whites (ref: non-whites) 
 
0.135 0.157 0.389 1.145 0.841 1.558
Interaction of depression and 
age 
 
-0.019 0.006 0.001* 0.981 0.969 0.993
Interaction of depression and 
gender 
 
-0.394 0.138 0.004* 0.674 0.515 0.884
Cardiovascular co-morbidity 0.760 0.067 0.000* 2.139 1.877 2.438
 
Constant -2.400 0.166 0.000 0.091  
*significance at the 0.05 level 
**Age is centered at the average value of age for the sample (40 years) 
 
Model fit statistics: 
 
Pseudo R-square = 7.1% 
-2 Log Likelihood = 7003.420; χ2  = 370.605, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 7.142; p= 0.521 
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Table 3: Logistic regression model to examine the relationship between pre-existing 
depression and incidence of type 2 diabetes (excluding cases of incident type 2 
diabetes in the first 2 years of follow up) 
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
   
Depression 0.410 0.114 0.000* 1.507 1.205 1.884
Age** 0.030 0.005 0.000* 1.030 1.019 1.041
Males (ref: females) 
 
0.078 0.121 0.519 1.081 0.853 1.371
Whites (ref: non-whites) 
 
0.212 0.213 0.320 1.236 0.814 1.875
Interaction of depression and 
age 
 
-0.011 0.008 0.155 0.989 0.974 1.004
Interaction of depression and 
gender 
 
-0.371 0.179 0.038* 0.690 0.486 0.979
Cardiovascular co-morbidity 0.704 0.088 0.000* 2.022 1.703 2.401
 
Constant -3.103 0.225 0.000 0.045  
*Significance at the 0.05 level 
**Age is centered at the average value of age for the sample (40 years) 
 
Model fit statistics: 
 
Pseudo R-square = 4.4% 
-2 Log Likelihood = 4592.426; χ2  = 164.520, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 11.245; p= 0.188 
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Discussion for Objective 2 
Evidence from a few prospective studies indicates that depression doubles the risk 
of incident type 2 diabetes even after controlling for other risk factors.  Controlling for 
multiple risk factors in relatively small samples, Eaton and associates32 and Kawakami 
and associates33 have shown that presence of depressive symptoms more than doubled the 
risk of developing type 2 diabetes.  A couple of other studies have used data from the 
NHEFS34,35 to test the relationship between depression and incidence of diabetes. 
However, these studies using the NHEFS cohort were not specific to incidence of type 2 
diabetes and had inconclusive results. 
The study results indicated a significant interaction between gender and presence 
of pre-existing depression.  Pre-existing depression was not significantly associated with 
incident type 2 diabetes in males; while females with pre-existing depression were one 
and a half times more likely to develop incident type 2 diabetes as compared to females 
without pre-existing depression controlling for demographics and presence of 
cardiovascular co-morbidity at baseline.   
However, this impact of pre-existing depression on incidence of type 2 diabetes 
may be confounded by factors such as obesity.  Being overweight is associated with onset 
of type 2 diabetes and depressed individuals suffer from problems with appetite and 
weight gain.  One can also view obesity as a mediating variable in the relationship 
between depression and onset of type 2 diabetes.  However, controlling for the presence 
of chronic medical conditions such as cardiovascular problems, cerebrovascular 
conditions and metabolic/endocrine disorders at baseline failed to attenuate the 
relationship between depression and incidence of diabetes.  Another possible explanation 
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for this relationship is the presence of detection bias as individuals with depressive 
symptoms may be more likely to seek medical care than individuals without symptoms.  
Therefore, they would be more likely to be diagnosed with diabetes than those without 
symptoms leading to an increased prevalence and incidence of type 2 diabetes among 
patients with depression.  In this study, an attempt was made to reduce the bias by 
controlling for the number of physician office visits at baseline (year 1997).  The 
presence of pre-existing depression maintained a significant impact on the incidence of 
type 2 diabetes after controlling for this ascertainment bias. 
Another important limitation of the study is the problem of undetected type 2 
diabetes. Diabetic disturbance in glucose metabolism may start 5-10 years before the 
diagnosis of type 2 diabetes.  It is possible that symptoms due to the presence of 
undetected diabetes could have led to depression at baseline. Also, depressive symptoms 
may worsen glycemic control exclusively among those who already had diabetic 
metabolic disturbance.  These factors can lead to an artificial effect of a higher incidence 
of type 2 diabetes in patients with depression as compared to patients without depression.   
To avoid this problem of undetected diagnosis, a sub-analysis was conducted by 
excluding cases of incident diabetes in the first two years of the follow-up period.  The 
results of this sub-analysis were highly comparable to the original results confirming the 
higher incidence of type 2 diabetes in female patients with depression (Table 3). 
Also, the peak onset of depression usually occurs during early adulthood between 
the ages of 20 and 30; while the onset of type 2 diabetes typically occurs much later.158,159  
On the basis of this alone, one would expect depressive symptoms to precede the 
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incidence of type 2 diabetes.  Hence, a statistical interaction between presence of 
depression and age at baseline become highly important control variables in the model.   
There is also the possibility of misclassification bias as there might be individuals 
at baseline who have depression symptomatology but have not sought treatment or 
medical attention and are hence classified as patients without depression.  However, this 
misclassification would only lead to an underestimation of the effect of depression on 
incidence of type 2 diabetes.  As significant results are obtained even with 
underestimation we can easily conclude that there is a significant positive relationship 
between presence of pre-existing depression and incidence of type 2 diabetes. 
 
 
Phase 2 
 
 In phase 2 of the study, patients newly diagnosed with type 2 diabetes were 
identified. The date of the first prescription for an oral hypoglycemic agent was identified 
for these patients and treated as the index date for the study.  Patients were then followed 
for a period of 12 months post index date.   
Sample selection 
 In the three-year enrollment period between January 1, 1998 and December 31, 
2000, 27,676 patients with a medical diagnosis for type 2 diabetes were identified.  Of 
these, 9,116 patients were newly diagnosed with type 2 diabetes in the enrollment period.  
Only about 50% of these newly diagnosed patients received any type of oral 
hypoglycemic prescription in the period between January 1, 1998 and December 31, 
2002.  Of these 4,459 newly diagnosed type 2 diabetes patients, 1,021 patients had pre-
existing depression and the remainder had no diagnosis of depression in the entire study 
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period.  After excluding patients on the basis of other criteria, the final cohort consisted 
of 1,326 type 2 diabetes patients (471 patients with depression and 855 patients without 
depression).  A detailed algorithm of sample attrition for the cohort followed for 12 
months post index date is provided in Figure 5.   
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Figure 5: Algorithm for sample attrition of patients with newly diagnosed type 2 
diabetes (12 month follow up period) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Incident diabetes is identified by absence of diagnosis codes for diabetes or antidiabetic medications in the 12 month period prior to 
index date of diabetes in 98-2000; coupled with Medicaid eligibility and non-HMO eligibility in the 12 month pre-index date  
**Pre-existing depression is identified by the presence of a depression diagnosis or use of an antidepressant in the period before 
incidence of type 2 diabetes 
Diagnosis of type 2 diabetes between 1998-2000
(N= 27,676) 
Patients with incident type 2 diabetes* 
(N= 9,116) 
Patients receiving oral hypoglycemic therapy 
(N= 4,459) 
Patients with pre-existing depression** 
(N =1,021) 
Medicaid eligibility; HMO non-eligibility; 
Age > 18 and < 64 years   (N= 774) 
Absence of other mental disorders 
(N= 544) 
Patients with no depression diagnosis 
(N=3,296) 
Medicaid eligibility; HMO non-eligibility; 
Age > 18 and < 64 years   (N= 1,756) 
Absence of other mental disorders 
(N= 981) 
Absence of a prescription for Rezulin 
(N= 943) 
Absence of a prescription for Rezulin 
(N= 510) 
Absence of nursing home visits 
(N= 505) 
Absence of nursing home visits 
(N= 922) 
Prescription of index oral hypoglycemic 
prescription in 1998-2001  
(N= 471) 
Prescription of index oral hypoglycemic 
prescription in 1998-2001  
(N= 855) 
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Baseline characteristics of newly diagnosed type 2 diabetes patients 
 To meet the study objectives of examining differences in adherence and health 
care expenditures between patients with and without depression, a number of baseline 
demographic and clinical variables were controlled to prevent any bias in the validity of 
the study results.  The comparison of these baseline characteristics between patients is 
provided in Table 4.  The baseline characteristics were grouped into factors such as 
demographic characteristics, complexity of regimen, co-morbid conditions, provider 
interaction, and diabetes severity.  A Mann Whitney U test was used to compare 
continuous variables, while a chi-square test was used to compare differences between 
categorical variables.  
Demographic characteristics: 
 Patients with pre-existing depression were significantly younger as compared to 
patients without pre-existing depression.  Mean age for patients with depression was 
46.87 years (+9.35) as compared to a mean age of 49.12 years (+10.65) for patients 
without depression.  A significantly higher percent of depressed patients were female 
(81.5%) as compared to non-depressed patients (53.6%).  Depressed and non-depressed 
patients did not differ significantly on other demographic characteristics such as race, 
geographical location, and year of index prescription.    
Complexity of regimen 
 Patients with depression consumed significantly higher number of pills per day 
for chronic medications (3.72 +3.62) as compared to non-depressed patients (2.74 +3.31).  
Depressed patients also filled a greater number of prescriptions for chronic medications 
(11.63 +10.07) as compared to non-depressed patients (9.27 +3.30).  However, the two 
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groups did not differ significantly in the number of pills per day for oral hypoglycemic 
agents. 
Co-morbid conditions 
 Baseline co-morbid conditions other than depression were evaluated for patients 
with type 2 diabetes.  Health care utilization variables identifying the presence and 
severity of co-morbid conditions (excluding those due to depression) such as total health 
care costs, number of ER/hospitalization episodes, and number of therapeutic classes of 
chronic medications indicated that patients with depression had a significantly higher 
presence of co-morbid conditions as compared to patients without depression.  Scores on 
the Charlson co-morbidity index indicated greater co-morbidity in depressed patients 
(0.76 +1.22) as compared to non-depressed patients (0.55 +1.19).  Also co-morbid 
conditions such as asthma, ulcer, and cardiovascular conditions occurred more frequently 
in depressed patients as compared to non-depressed patients.   
Provider interaction 
 There were no differences in the fraction of patients enrolled in PAAS between 
depressed and non-depressed patients.  However, a greater fraction of non-depressed 
patients (52.3%) used a single pharmacy in the last six months as compared to depressed 
patients (38.9%), implying greater pharmacy patronage for non-depressed patients.             
Diabetes severity 
As the study population consisted of a group of newly diagnosed type 2 diabetes 
patients, drastic differences in terms of diabetes severity were not expected.  However, as 
our study index date was the date of the first prescription for an oral hypoglycemic, there 
could be potentially a gap between initiation of oral hypoglycemic therapy and initial 
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diagnosis of type 2 diabetes thus leading to differences in diabetes severity.  Baseline 
comparisons demonstrated that depressed and non-depressed patients did not have 
significant differences in diabetes severity as measured on the basis of type of prescribing 
physician, initiation on polytherapy, gap between diagnosis and therapy, and number of 
diabetes related ER/hospitalization episodes.  The only differences were seen in terms of 
diabetes related costs in the pre 12-month period and the class of the index oral 
hypoglycemic agent.  Depressed patients had significantly higher diabetes related costs 
($899.35 + 3,275.30) than non-depressed patients ($629.42 + 2,751.92).  Also, in terms 
of the class of index oral hypoglycemic agent, the most notable difference was that a 
higher fraction of depressed patients (2.8%) were prescribed an alpha-glucosidase 
inhibitor as compared to non-depressed patients (0.8%).  Also, a slightly higher fraction 
of depressed patients (2.5%) were prescribed meglitinides as compared to non-depressed 
patients (1.1%). 
 Overall, the results demonstrated distinct differences between patients with and 
without pre-existing depression. Depressed patients were significantly younger and 
included a higher proportion of females.  Depressed patients had a significantly higher 
number of co-morbid conditions and a more complex drug regimen at baseline.  Level of 
diabetes severity was not too different between the two groups.  However, differences in 
the index class of oral hypoglycemic agent was possibly indicative of a higher fraction of 
depressed patients being obese as compared to non-depressed patients.  This was deduced 
on the basis of clinical information indicating that alpha-glucosidase and meglitinides are 
typically prescribed to obese patients as opposed to sulfonylurea due to the absence of 
any side effects of weight gain due to these medications.   
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These baseline variables were used in the multivariate framework to estimate the 
impact of depression on type 2 diabetes outcomes adjusting for these baseline 
characteristics.  The effect of the individual constructs such as demographics, co-
morbidity, provider interaction, complexity of regimen, and diabetes severity on type 2 
diabetes outcomes were not an objective of the study.  Hence, in all the results and 
discussions of study objectives, the effect of these baseline control variables on type 2 
diabetes outcomes will not be discussed.  Only the effect of depression on type 2 diabetes 
outcomes controlling for these baseline variables will be examined and discussed. 
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Table 4: Baseline characteristics of newly diagnosed type 2 diabetes patients 
 
              Depressed         Non-depressed              Test            Sig.         
          (n=471)                      (n=855)                        Statistic               (p)                                   
                         
 
Demographic Characteristics 
 
Age (in years)            46.87 +9.35*  49.12 +10.65*      M=169467.00       0.000** 
 
Gender 
• Males  18.53%  46.63%      χ2 = 101.30           0.000** 
• Females 81.47%  53.37%    
 
Race 
• Whites  95.91%  93.64%     χ2 = 3.11                 0.078 
• Non-whites   4.09%    6.36% 
 
Residence 
• Urban   93.03%  92.05%     χ2 = 0.39            0.534 
• Rural    6.97%    7.95% 
 
Year of index prescription 
• 1998  21.00%  25.32%     χ2 = 4.81            0.186 
• 1999  32.11%  32.04% 
• 2000  36.83%  35.14% 
• 2001  10.06%    7.50% 
 
Complexity of regimen 
 
Number of pills per day      3.72 + 3.62* 2.74 + 3.31*      M= 164214.00        0.000** 
for chronic medications 
 
Number of prescriptions   11.63 + 10.07* 9.27 + 3.30*      M= 165250.00        0.000** 
for chronic medications  
 
Number of pills per day      1.49 + 0.73*        1.44 + 0.69*     M=195228.00          0.301 
for oral hypoglycemics 
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Table 4: Baseline characteristics of newly diagnosed type 2 diabetes patients 
(Contd.) 
 
               Depressed         Non-depressed             Test              Sig.   
              (n=471)                      (n=855)                     Statistic                  (p)                                 
                      
 
Baseline Co-morbid conditions 
 
Number of ER/             2.03 +3.47*            1.09+2.16*            M=162948.00      0.000** 
hospitalizations      
(Excluding those  
due to depression) 
  
Total health costs             7,623.21                 5,318.42               M=136320.00       0.000** 
(Excluding those         + 10,942.62*         + 11,378.92*    
due to depression) 
 
Charlson                      0.76 + 1.22*        0.55 + 1.19*             M= 177512.00      0.000** 
co-morbidity   
   
Number of                   2.86 + 1.90*          2.12 + 1.82*       M=153958.00       0.000** 
therapeutic classes  
of medications 
 
Presence of co-morbid conditions 
• Cardio-vascular     64.10%  58.13%  χ2 = 4.55        0.033** 
• Cancer          5.92%    3.91%  χ2 = 3.01        0.083 
• Asthma       21.24%  14.62%  χ2 = 9.42        0.002** 
• Ulcers          5.12%    1.83%  χ2 = 11.88      0.001** 
 
Provider interaction 
 
PAAS enrollment        12.74%  11.13%  χ2 = 0.78        0.377 
 
Number of pharmacies seen 
in last 12 months 
• No pharmacy          0.82%    7.05% 
• Single         38.91%             52.22%  χ2 = 59.93      0.000* 
• Multiple        60.27%  40.73%  
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Table 4: Baseline characteristics of newly diagnosed type 2 diabetes patients 
(Contd.) 
 
                 Depressed            Non-depressed               Test              Sig. 
                    (n = 471)                  (n = 855)                Statistic            (p)                                     
    
Baseline diabetes severity 
 
Index oral hypoglycemic 
prescribed by: 
• Endocrinologist     1.92%    1.52%     
• Internal medicine   31.53%  30.14%        χ2 = 0.70           0.705 
• Family practitioner   66.55%  68.44% 
 
Number of diabetes            0.21 + 0.59*             0.14 + 0.44*    M=194630.00    0.080 
related ER/hospitalizations  
 
Total diabetes related                899.35               629.42       M=186703.00    0.020** 
costs                      + 3,275.30*               + 2,751.92*    
 
Gap between diagnosis            117.16                  97.29     M= 191107.50   0.105 
and index prescription          + 236.23*                      + 214.15*      
   
Initial polytherapy      6.21%    8.92%        χ2 = 3.11           0.078 
 
Index class of oral hypoglycemic 
• Sulfonylurea     49.72%  55.02% 
• Thiazolidenedione      7.22%    5.81% 
• Biguanides     35.00%  34.60%        χ2 = 14.40        0.013** 
• Alpha-glucosidase      2.81%    0.82% 
• Sulfonylurea-biguanide    2.83%    2.72% 
• Meglitinides       2.42%    1.13% 
 
 
 
*Mean + S.D.       
**significance at the 0.05 level           
M= Mann-Whitney U Test; χ2 = Chi-square test 
PAAS = Physician Assured Access System 
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Results for Objective 3 
To examine the impact of pre-existing depression on patterns of oral hypoglycemic use in 
new patients with type 2 diabetes 
Patients initiating polytherapy or insulin therapy were excluded from this 
analysis.  Univariate results for patterns of oral hypoglycemic therapy are presented in 
Table 5.  Results indicated that a significantly higher fraction of depressed patients 
(39.50%) discontinued oral hypoglycemic therapy as compared to non-depressed patients 
(32.90%).  Only 37.20% of depressed patients non-modified their index oral 
hypoglycemic therapy as compared to 50.90% of non-depressed patients who remained 
on their original therapy for the entire 12 month follow up period.  Of the patients who 
modified their index oral hypoglycemic therapy, 9.20% depressed patients switched 
therapy as compared to 6.30% non-depressed patients.  The fraction of patients 
augmenting their index therapy by adding another oral hypoglycemic agent or insulin to 
their drug regimen was also significantly higher for depressed patients (14.1%) as 
compared to non-depressed patients (9.9%).  A univariate chi-square value of 22.95 was 
found to be significant with a p-value of 0.000.  These numbers indicate that the patterns 
of oral hypoglycemic use were significantly favorable for non-depressed patients 
indicating better management of type 2 diabetes.   
However, this effect could also be a result of confounders such as demographics, 
co-morbidity, diabetes severity, complexity of regimen, and interaction with health care 
providers.  Hence, a multivariate multinomial logistic regression was performed to 
determine the impact of depression on patterns of oral hypoglycemic use controlling for 
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baseline confounding factors.  Non-modification was used as the reference category for 
all comparisons in the multinomial logistic model framework. 
The multinomial logistic regression model was found to be significant with a 
Nagelkerke R-square value of 16.1%.  The model results are summarized in Table 6A-
6C.  Results of the multivariate model indicated that controlling for confounding 
covariates, patients with depression were nearly one and a half times more likely to 
discontinue oral hypoglycemic therapy in the 12 month follow up period as compared to 
patients without depression (p= 0.004).  Results also demonstrated that depressed patients 
were 1.7 times more likely to switch (p=0.046) and two times more likely to augment 
therapy (p=0.003) as compared to patients without depression.  
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Table 5: Pattern of use of oral hypoglycemics in the 12-month follow up period 
 
         Depressed     Non-depressed      Total           Test           Sig. 
                                 (n= 446)          (n= 791)          (n= 1237)     statistic         (p) 
 
 
Non-modification           37.22%           50.95%              46.00%  
         (166)                (403)                  (569) 
Modification 
 
• Switching             9.19%            6.32%                7.36% 
           (41)                 (50)                   (91)           χ2 = 22.95    0.00* 
  
• Augmentation           14.13%            9.86%            11.40%  
           (63)            (78)            (141) 
 
Discontinuation          39.46%           32.87%             35.25%  
         (176)               (260)                  (436) 
 
*significance at the 0.05 level 
χ2 = Chi-square test 
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Table 6A: Multinomial Logistic regression for the impact of depression on pattern 
of oral hypoglycemic use (Switching vs. Non-modification) 
 Beta S.E. Sig. 
 (p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Depression 0.544 0.270 0.044* 1.724 1.016 2.924
Demographic characteristics 
Age (in years) 0.006 0.013 0.674 1.006 0.980 1.032
Males (ref: females) 
 
0.223 0.260 0.391 1.249 0.751 2.078
Whites (ref: non-whites) 
 
1.156 0.777 0.137 3.178 0.692 14.588
Urban (ref: rural) 
 
0.180 0.462 0.697 1.197 0.484 2.957
Year of index prescription (ref: 2001) 
• 1998  -0.911 0.634 0.151 0.402 0.116 1.394
• 1999 -0.614 0.589 0.297 0.541 0.171 1.716
• 2000 -0.261 0.559 0.640 0.770 0.258 2.301
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.051 0.064 0.428 1.052 0.928 1.193
Total health costs 
     
0.000 0.000 0.256 1.000 1.000 1.000
Charlson co-morbidity 
            
-0.051 0.144 0.722 0.950 0.716 1.260
Number of therapeutic classes 
of medications 
 
0.077 0.131 0.556 1.080 0.835 1.397
Cardio-vascular 
 
-0.395 0.274 0.149 0.674 0.394 1.152
Cancer 
 
0.446 0.630 0.479 1.563 0.455 5.372
Asthma 
 
0.290 0.358 0.418 1.336 0.662 2.696
Ulcers 
 
0.728 0.601 0.225 2.072 0.638 6.724
Provider interaction in the pre period 
PAAS enrollment 0.413 0.347 0.234 1.512 0.765 2.986
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.568 0.801 0.479 0.567 0.118 2.726
• Single pharmacy -0.212 0.249 0.395 0.809 0.496 1.318
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Beta S.E. Sig. 
 (p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
-0.035 0.059 0.557 0.966 0.859 1.085
Number of prescriptions for 
chronic medications 
 
-0.005 0.024 0.849 0.995 0.949 1.044
Number of pills per day for 
oral hypoglycemics 
 
0.122 0.217 0.575 1.129 0.738 1.728
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 1.355 0.885 0.126 3.876 0.684 21.956
• Internal medicine          0.335 0.255 0.189 1.398 0.848 2.305
Total diabetes costs 0.000 0.000 0.720 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.311 0.305 0.309 1.364 0.750 2.481
Gap between index diagnosis 
and prescription 
 
-0.001 0.001 0.167 0.999 0.998 1.000
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.327 0.447 0.465 1.386 0.577 3.331
• Biguanides  -0.324 0.330 0.327 0.724 0.379 1.383
• Alpha-glucosidase 1.166 0.739 0.115 3.208 0.753 13.658
• Meglitinides 0.377 0.808 0.641 1.457 0.299 7.107
Constant -3.118 1.302 0.017   
   
 
 
 
 
 
 
 
 
 
 
 
 
Table 6A: Multinomial Logistic regression for the impact of depression on pattern 
of oral hypoglycemic use (Switching vs. Non-modification) (Contd.) 
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Table 6B: Multinomial Logistic regression for the impact of depression on pattern 
of oral hypoglycemic use (Augmentation  vs. Non-modification) 
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Depression 0.659 0.220 0.003* 1.933 1.256 2.975
Demographic characteristics 
Age (in years) -0.008 0.011 0.452 0.992 0.972 1.013
Males (ref: females) 
 
-0.018 0.218 0.933 0.982 0.640 1.507
Whites (ref: non-whites) 
 
0.744 0.552 0.178 2.104 0.713 6.207
Urban (ref: rural) 
 
0.436 0.406 0.283 1.547 0.698 3.429
Year of index prescription (ref: 2001) 
• 1998  -0.328 0.559 0.558 0.720 0.241 2.156
• 1999 -0.007 0.523 0.989 0.993 0.356 2.767
• 2000 0.335 0.502 0.505 1.398 0.523 3.738
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.141 0.047 0.003* 1.151 1.051 1.262
Total health costs 
     
0.000 0.000 0.052 1.000 1.000 1.000
Charlson co-morbidity 
            
-0.248 0.154 0.108 0.781 0.577 1.056
Number of therapeutic classes 
of medications 
 
0.201 0.109 0.065 1.222 0.988 1.512
Cardio-vascular 
 
-0.152 0.226 0.503 0.859 0.551 1.339
Cancer 
 
0.143 0.617 0.817 1.153 0.344 3.867
Asthma 
 
0.049 0.336 0.885 1.050 0.543 2.029
Ulcers 
 
0.367 0.635 0.564 1.443 0.416 5.012
Provider interaction in the pre period 
PAAS enrollment 0.325 0.300 0.279 1.384 0.769 2.489
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.650 0.532 0.222 1.915 0.675 5.429
• Single pharmacy 0.060 0.208 0.773 1.062 0.706 1.598
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
-0.018 0.048 0.705 0.982 0.895 1.078
Number of prescriptions for 
chronic medications 
 
-0.014 0.020 0.486 0.986 0.947 1.026
Number of pills per day for 
oral hypoglycemics 
 
0.307 0.168 0.067 1.359 0.978 1.887
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 1.469 0.698 0.035* 4.347 1.107 17.072
• Internal medicine          0.152 0.217 0.484 1.164 0.761 1.781
Total diabetes costs 0.000 0.000 0.032* 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
-0.348 0.291 0.232 0.706 0.399 1.250
Gap between index diagnosis 
and prescription 
 
0.000 0.001 0.508 1.000 0.998 1.001
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.133 0.419 0.750 1.143 0.503 2.598
• Biguanides  -0.089 0.257 0.730 0.915 0.553 1.515
• Alpha-glucosidase -0.505 0.888 0.569 0.603 0.106 3.442
• Meglitinides -1.095 0.926 0.237 0.335 0.054 2.056
Constant -3.016 1.048 0.004   
       
 
 
 
 
 
 
 
 
 
 
 
 
Table 6B: Multinomial Logistic regression for the impact of depression on pattern 
of oral hypoglycemic use (Augmentation  vs. Non-modification) (Contd.) 
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Table 6C: Multinomial Logistic regression for the impact of depression on pattern 
of oral hypoglycemic use (Discontinuation  vs. Non-modification) 
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Depression 0.454 0.157 0.004* 1.575 1.157 2.144
Demographic characteristics 
Age (in years) -0.013 0.007 0.065 0.987 0.973 1.001
Males (ref: females) 
 
-0.053 0.150 0.723 0.948 0.706 1.273
Whites (ref: non-whites) 
 
-0.056 0.295 0.850 0.946 0.531 1.685
Urban (ref: rural) 
 
0.077 0.259 0.767 1.080 0.650 1.795
Year of index prescription (ref: 2001) 
• 1998  -0.782 0.385 0.042* 0.458 0.215 0.973
• 1999 -0.859 0.366 0.019* 0.424 0.207 0.869
• 2000 -0.518 0.351 0.140 0.596 0.299 1.186
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.148 0.037 0.000* 1.159 1.079 1.246
Total health costs 
     
0.000 0.000 0.218 1.000 1.000 1.000
Charlson co-morbidity 
            
0.077 0.082 0.343 1.080 0.921 1.268
Number of therapeutic classes 
of medications 
 
0.083 0.080 0.300 1.087 0.929 1.271
Cardio-vascular 
 
-0.311 0.156 0.046* 0.732 0.539 0.995
Cancer 
 
0.429 0.392 0.273 1.536 0.713 3.310
Asthma 
 
0.290 0.215 0.178 1.337 0.877 2.038
Ulcers 
 
0.051 0.415 0.903 1.052 0.467 2.370
Provider interaction in the pre period 
PAAS enrollment 0.043 0.216 0.843 1.044 0.683 1.595
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.377 0.340 0.267 1.458 0.749 2.838
• Single pharmacy -0.186 0.145 0.201 0.830 0.624 1.104
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
0.032 0.033 0.327 1.033 0.968 1.102
Number of prescriptions for 
chronic medications 
 
-0.060 0.016 0.000* 0.942 0.913 0.971
Number of pills per day for 
oral hypoglycemics 
 
0.103 0.126 0.414 1.109 0.866 1.421
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.312 0.694 0.653 1.366 0.350 5.321
• Internal medicine          0.171 0.151 0.259 1.187 0.882 1.597
Total diabetes costs 0.000 0.000 0.639 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
-0.296 0.222 0.182 0.744 0.481 1.149
Gap between index diagnosis 
and prescription 
 
-0.001 0.000 0.027* 0.999 0.998 1.000
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.094 0.300 0.753 1.099 0.610 1.980
• Biguanides  0.127 0.183 0.487 1.136 0.793 1.627
• Alpha-glucosidase -0.366 0.633 0.564 0.694 0.201 2.400
• Meglitinides -0.254 0.586 0.664 0.776 0.246 2.444
Constant 1.042 0.667 0.118   
    
*significance at the 0.05 level 
PAAS = Physician Assured Access System 
 
 
Model fit statistics: 
 
Pseudo R-square = 16.1% 
-2 Log Likelihood = 2616.299; χ2  = 189.814; p= 0.00 
 
 
 
 
Table 6C: Multinomial Logistic regression for the impact of depression on pattern 
of oral hypoglycemic use (Discontinuation  vs. Non-modification) (Contd.) 
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Discussion for Objective 3 
Depression can play an important role in diabetes management as it can decrease 
adherence with medications leading to inadequate glucose control and thus affect patterns 
of use of oral hypoglycemics.  Results from our study indicated the same with a 
significantly higher fraction of depressed patients switching, augmenting, and 
discontinuing therapy.  There are no studies in literature to compare these results as no 
other study has examined the impact of depression on patterns of oral hypoglycemic use.  
However, there are a few studies, which examine the patterns of oral hypoglycemic use in 
newly diagnosed type 2 diabetes patients.   
A large administrative database study by Boccuzzi and associates16 using 
pharmacy claims of millions of Americans, found that the rate of discontinuation for 
newly diagnosed type 2 diabetes patients in the 12-month follow up period was 11.3%.  
Nearly 15% augmented therapy while 10% switched from the index oral hypoglycemic 
agent in the 12-month follow up period.  A similar study conducted by Skaer and 
associates14 estimated that 10-30% of patients with type 2 diabetes withdraw from their 
prescribed regimen within 1 year of diagnosis.  In a study conducted by Dailey and 
associates90 in Medi-Cal patients who were newly diagnosed with type 2 diabetes, 
patterns of oral hypoglycemic use indicated that nearly 16% of patients failed to refill 
their index oral hypoglycemic prescription in the one-year follow up period.  Donnan and 
associates17 conducted a population-based study in Tayside, Scotland following up newly 
diagnosed type 2 diabetes patients for varying time periods with a median follow up time 
of 588 days.  Results from the study indicated that nearly 70.00% of patients did not 
modify their original oral hypoglycemic therapy, 5.40 % augmented therapy, and around 
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18.00% switched therapy in the follow up time period.  Surprisingly, only 0.50% of the 
newly diagnosed type 2 diabetes patients discontinued pharmacotherapy.   
The overall rates of switching (7.40%) and augmentation (11.40%) found in this 
study are comparable to the findings in literature.  The results showed lower rates of non-
modification with 46.00% of newly diagnosed patients maintaining therapy on the index 
oral hypoglycemic agent, as compared to non-modification rates of 60-70% in the 
literature.  The largest discrepancy, however, was in terms of discontinuation rates.  The 
rates of 35.00% were much higher than most reported studies. The differences in these 
patterns can be attributed to differences in algorithm used for classification of these 
patterns and/or variations in length of follow-up periods.  These differences can also be 
attributable to a difference in the health care system, as some of the studies in literature 
were based in Europe.  Also, a number of these studies had the strict inclusion criteria of 
at least two prescriptions for oral hypoglycemics in the follow up as opposed to our 
criteria of a diagnosis of type 2 diabetes and at least one prescription for an oral 
hypoglycemic agent.  This difference in inclusion criteria can possibly be the most logical 
reason for higher discontinuation rates in this study.  However, similar studies conducted 
to examine patterns of use for antihypertensive medications have detected high 
discontinuation rates comparable to this study results with 40-50% of new users of 
antihypertensive medications discontinuing use by 6 months.160   
Patterns of use of oral hypoglycemics have been used in the literature to examine 
management of patients with newly diagnosed type 2 diabetes.  They can be highly 
indicative of success of oral hypoglycemic therapy in controlling blood glucose levels in 
these patients.  Non-modification of the initially prescribed oral hypoglycemic therapy 
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can be an indication of adequate blood glucose control.  Modification of therapy in terms 
of either switching or augmenting therapies is typically seen when the index oral 
hypoglycemic therapy fails to maintain blood glucose levels.  This inadequate control of 
blood glucose can occur due to the natural course of the disease over time.  However, 
frequently it is a result of lack of adherence to either medications, diet or exercise 
regimen.  The act of switching/augmentation typically indicates secondary failure with 
initial therapy.  However, such a conclusion cannot be drawn for patients discontinuing 
pharmacotherapy.  The reasons for discontinuing therapy are not captured in a claims 
database.  The adverse effects of oral hypoglycemic agents can affect patient’s quality of 
life, which in turn can result in discontinuation of treatment.  Thus, these patients may be 
discontinuing therapy in spite of inadequate blood glucose control, which may cause a 
number of diabetic complications in the future.  It is also possible that patients 
discontinue pharmacotherapy as their blood glucose levels are controlled through other 
methods such as diet and exercise.   However, a review of 13,309 patients with type 2 
diabetes from the UK Mediphys database, demonstrated that patients who discontinued 
their oral hypoglycemics were approximately twice as likely to experience an emergency 
medical event and had a mortality rate that was three times that of continuers.13  These 
results indicate that a large fraction of type 2 diabetes patients who discontinue therapy 
need to maintain pharmacotherapy for adequate management of their diabetes.   
Although no studies are available in the literature to examine the impact of 
depression on patterns of oral hypoglycemic use, studies have demonstrated an 
association between depression and adherence to diabetes medications.28  Patterns such as 
switching, augmentation, and especially discontinuation can be indicative of lack of 
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adherence.  Results of this study demonstrated that patterns of oral hypoglycemic use 
were much more favorable in non-depressed patients as compared to depressed patients 
after adjusting for the effect of confounders.   This study demonstrates that even in a 
population with complete insurance coverage, there may be issues of avoidance of 
therapy partly due to presence of co-morbid depression. 
 
Results for Objective 4 
To examine the impact of pre-existing depression on secondary failure with oral 
hypoglycemics 
Augmenting or switching from the initial class of oral hypoglycemic agent can be 
considered together as modification of therapy, indicative of secondary failure with initial 
pharmacotherapy.  Objective 4 was to estimate the impact of depression on the rate of 
modification and the time to modification with index therapy in the 12-month follow up 
period.  Patients initiated on polytherapy or insulin therapy were excluded from the 
analysis.  Patients who discontinued therapy in the 12-month follow up period were also 
excluded from the analysis. 
Univariate results are presented in Table 7.  The results indicated that a 
significantly higher percent of depressed patients (38.47%) modified their index oral 
hypoglycemic therapy as compared to non-depressed patients (24.08%).  Higher rates of 
modification were also accompanied with a relatively shorter time period to modification 
for depressed patients (282.57 + 7.54) compared to non-depressed patients (307.63 + 
4.99).  A univariate Kaplan Meier analysis indicated that this time to modification was 
significantly higher for depressed patients with a log rank test statistic of 16.65 
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(p=0.000).  These results can also be seen in terms of a better survival distribution for 
non-depressed patients in the Kaplan Meier survival curves for time to modification of 
pharmacotherapy (Figure 6).  However, this effect could also be a result of confounders 
such as demographics, co-morbidity, diabetes severity, complexity of regimen, and 
interaction with health care providers.  Hence, a multivariate logistic regression and Cox 
proportional hazards model was performed to determine the impact of depression on rate 
and time to modification of oral hypoglycemic use controlling for baseline confounding 
factors.   The logistic regression model was found to be significant with a Nagelkerke R-
square value of 11.40%.  The model results are summarized in Table 8.  Results of the 
multivariate model indicated that controlling for confounding covariates, patients with 
depression were nearly 1.7 more likely to modify oral hypoglycemic therapy in the 12 
month follow up period as compared to patients without depression (p= 0.003).  An 
initial multivariate Cox proportional hazards model to estimate the impact of depression 
on time to modification of index oral hypoglycemic therapy failed to satisfy the 
proportional hazard assumption.  Hence, on the basis of the cumulative Kaplan Meier 
survival functions that indicated 2 different hazards, an extended Cox-proportional 
hazards model was estimated to examine the effect of depression on time to modification 
in the first six months and the latter six month follow up period. The extended Cox 
proportional hazards model was found to be significant and the model fit and results are 
summarized in Table 9.  The model indicated that the hazard to modify therapy was 2.4 
times more for depressed patients as compared to non-depressed patients in the latter six 
months of the follow-up period (p=0.001).  No significant differences were observed 
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between the patients for the first six months after the index oral hypoglycemic 
prescription.   
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Table 7: Modification of oral hypoglycemics in the 12-month follow up period 
 
         Depressed    Non-depressed      Total           Test           Sig. 
                                 (n= 270)          (n= 531)         (n= 801)     statistic         (p) 
 
 
Non-modification           61.53%           75.92%           71.02%  
         (166)                (403)               (569) 
    χ2 = 18.07    0.000* 
Modification            38.47%          24.08%          28.98%  
                      (104)               (128)              (232) 
             
Time to modification            282.57          307.63           299.18     LR=16.65   0.000* 
(in years)               (+ 7.54)        (+ 4.99)         (+ 4.19) 
(Mean + Standard Error)       
 
*significance at the 0.05 level 
χ2 = Chi-square test 
LR = Log rank test 
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Figure 6: Kaplan-Meier Survival Curves for time to modification of oral 
hypoglycemic therapy 
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Table 8: Logistic regression for the impact of depression on modification of oral 
hypoglycemic agents 
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Depression 0.568 0.188 0.003* 1.764 1.220 2.551
Demographic characteristics 
Age (in years) 
 
-0.004 0.009 0.663 0.996 0.978 1.014
Males (ref: females) 
 
0.071 0.180 0.694 1.073 0.754 1.528
Whites (ref: non-whites) 
 
0.801 0.485 0.098 2.228 0.861 5.763
Urban (ref: rural) 
 
0.321 0.332 0.333 1.379 0.719 2.643
Year of index prescription (ref: 2001) 
• 1998  -0.721 0.470 0.125 0.486 0.194 1.221
• 1999 -0.426 0.438 0.331 0.653 0.277 1.541
• 2000 0.007 0.418 0.986 1.007 0.444 2.284
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.110 0.045 0.015* 1.116 1.022 1.219
Total health costs 
     
0.000 0.000 0.028* 1.000 1.000 1.000
Charlson co-morbidity 
            
-0.174 0.119 0.145 0.840 0.665 1.062
Number of therapeutic classes 
of medications 
 
0.174 0.095 0.068 1.190 0.987 1.434
Cardio-vascular 
 
-0.257 0.196 0.190 0.773 0.527 1.135
Cancer 
 
0.295 0.512 0.564 1.344 0.493 3.665
Asthma 
 
0.125 0.273 0.647 1.133 0.663 1.937
Ulcers 
 
0.594 0.494 0.229 1.810 0.688 4.764
Provider interaction in the pre period 
PAAS enrollment 0.420 0.253 0.097 1.522 0.927 2.499
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.075 0.472 0.874 1.077 0.427 2.716
• Single pharmacy -0.060 0.175 0.732 0.942 0.668 1.328
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
-0.030 0.040 0.465 0.971 0.897 1.051
Number of prescriptions for 
chronic medications 
 
-0.012 0.018 0.514 0.988 0.954 1.024
Number of pills per day for 
oral hypoglycemics 
 
0.292 0.153 0.056 1.340 0.993 1.808
Diabetes severity  
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 1.533 0.647 0.018* 4.633 1.303 16.473
• Internal medicine          0.212 0.183 0.245 1.237 0.865 1.769
Total diabetes costs 0.000 0.000 0.200 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
-0.030 0.232 0.896 0.970 0.615 1.530
Gap between index diagnosis 
and prescription 
 
-0.001 0.001 0.187 0.999 0.998 1.000
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.181 0.344 0.598 1.199 0.611 2.351
• Biguanides  -0.234 0.227 0.302 0.791 0.507 1.234
• Alpha-glucosidase 0.348 0.663 0.600 1.416 0.386 5.191
• Meglitinides -0.261 0.664 0.694 0.770 0.210 2.829
Constant -2.093 0.893 0.019 0.123  
    
*significance at the 0.05 level 
PAAS = Physician Assured Access System 
 
 
Model fit statistics: 
 
Pseudo R-square = 11.4% 
-2 Log Likelihood = 871.997; χ2  = 64.944, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 8.157; p=0.418 
 
 
 
Table 8: Logistic regression for the impact of depression on modification of oral 
hypoglycemic agents (Contd.) 
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Table 9: Extended Cox proportional hazards model for the impact of depression on 
time to modification of oral hypoglycemic agent 
 Beta S.E. Sig. 
(p) 
Hazard 
ratio 
95% C.I. for 
Hazard ratio
     Lower Upper
Depression (0 –6 months) 0.168 0.181 0.353 1.183 0.829 1.688
Depression (6 –12 months) 0.855 0.246 0.001* 2.350 1.451 3.806
 
Demographic characteristics 
Age (in years) 
 
-0.004 0.008 0.623 0.996 0.982 1.011
Males (ref: females) 
 
0.028 0.150 0.852 1.028 0.767 1.379
Whites (ref: non-whites) 
 
0.749 0.434 0.084 2.115 0.904 4.948
Urban (ref: rural) 
 
0.319 0.286 0.265 1.375 0.785 2.409
Year of index prescription (ref: 2001) 
• 1998  -0.607 0.385 0.115 0.545 0.256 1.160
• 1999 -0.329 0.358 0.358 0.720 0.357 1.451
• 2000 0.043 0.343 0.901 1.044 0.532 2.045
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.108 0.033 0.001* 1.114 1.044 1.189
Total health costs 
     
0.000 0.000 0.018* 1.000 1.000 1.000
Charlson co-morbidity 
            
-0.200 0.102 0.048* 0.818 0.671 0.999
Number of therapeutic classes 
of medications 
 
0.137 0.076 0.072 1.147 0.988 1.333
Cardio-vascular 
 
-0.172 0.158 0.276 0.842 0.617 1.148
Cancer 
 
0.221 0.403 0.583 1.248 0.567 2.747
Asthma 
 
0.191 0.224 0.396 1.210 0.779 1.879
Ulcers 
 
0.623 0.373 0.095 1.865 0.897 3.878
Provider interaction in the pre period 
PAAS enrollment 0.289 0.199 0.147 1.335 0.904 1.970
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.022 0.392 0.955 1.022 0.474 2.205
• Single pharmacy -0.077 0.144 0.590 0.926 0.698 1.227
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Beta S.E. Sig. 
(p) 
Hazard 
ratio 
95% C.I. for 
Hazard  ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
-0.020 0.033 0.543 0.980 0.918 1.046
Number of prescriptions for 
chronic medications 
 
-0.009 0.015 0.541 0.991 0.962 1.020
Number of pills per day for 
oral hypoglycemics 
 
0.217 0.118 0.066 1.242 0.986 1.566
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 1.037 0.424 0.015* 2.821 1.228 6.481
• Internal medicine          0.135 0.147 0.359 1.144 0.858 1.526
Total diabetes costs 0.000 0.000 0.101 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
-0.014 0.180 0.938 0.986 0.693 1.404
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.246 1.000 0.999 1.000
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.152 0.274 0.580 1.164 0.680 1.994
• Biguanides  -0.236 0.187 0.207 0.790 0.547 1.139
• Alpha-glucosidase 0.198 0.485 0.682 1.219 0.472 3.153
• Meglitinides -0.238 0.517 0.645 0.788 0.286 2.171
    
   
* significance at the 0.05 level 
PAAS = Physician Assured Access System 
 
 
Model fit statistics: 
 
-2 Log Likelihood = 2863.587; χ2  = 72.07, p= 0.001 
Global test of proportional hazards : χ2  = 43.45, p= 0.467 
 
 
 
 
Table 9: Extended Cox proportional hazards model for the impact of depression on 
time to modification of oral hypoglycemic agent (Contd.) 
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Discussion for objective 4 
Modification to treatment regimens may be indicative of poor blood glucose 
control, lack of tolerance of the drug, or the onset of concomitant conditions.  Failure to 
achieve glycemic control or the onset of co-morbid conditions may prompt physicians to 
step up the treatment regimen by: (1) substituting a more potent medication or (2) adding 
another oral hypoglycemic agent, or (3) initiating insulin therapy.   
Depression can decrease adherence with medications leading to inadequate 
glucose control and thus lead to modification of oral hypoglycemic therapy.  The study 
results indicated the same with a significantly higher percent of depressed patients 
modifying their index oral hypoglycemic therapy as compared to non-depressed patients.  
No studies examining the impact of depression on modification of therapy are available 
in the literature.  However, one can compare our overall rates of modification with 
findings from other studies.  Results from the study conducted by Donnan and 
associates17 in Tayside Scotland, indicated that around 28.00% of newly diagnosed type 2 
diabetes patients modified their index oral hypoglycemic therapy over the median follow 
up time period of 588 days.   A similar rate for modification of therapy (32.00%) was 
observed over a 12-month follow up period in a study conducted in Medi-Cal.90 A more 
recent study conducted by Bocuzzi and associates16 in a large administrative dataset used 
a composite measure of change in therapy including switching or augmentation and 
found that a striking 36.00% of the patients changed therapy over a 12-month follow up 
period with a crude time to modification of therapy being around 170 days.  Overall rates 
from this study for modification of 29.00% were similar to findings from previous 
studies.  However, time to modification of therapy was longer (300 days) in this study as 
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compared to the crude rates estimated from the study by Bocuzzi and associates16 (~ 170 
days). 
 Multivariate results indicated that controlling for baseline characteristics, patients 
with depression were nearly 1.8 times more likely to modify index therapy as compared 
to non-depressed patients.  Similarly, the hazard to modify therapy was 2.4 times more 
for depressed patients as compared to non-depressed patients in the latter six-month 
follow-up period.      
 
 
Results for Objective 5 
To estimate the impact of pre-existing depression on initiation of insulin therapy in 
patients with type 2 diabetes 
The univariate results are presented in Table 10.  Results indicated that a 
significantly higher percent of depressed patients (5.30%) initiated insulin therapy as 
compared to non-depressed patients (2.90%).  Higher rates of insulin initiation were also 
accompanied with a relatively shorter time period to begin insulin therapy for depressed 
patients (355.92 days) compared to non-depressed patients (358.71 days).  A univariate 
Kaplan Meier analysis indicated that this time to insulin initiation was significantly 
higher for depressed patients with a log rank test statistic of 4.68 (p = 0.030).  These 
results can also be seen in terms of a better survival distribution for non-depressed 
patients in the Kaplan Meier survival curves for time to initiation of insulin therapy 
(Figure 7).   
However, these differences between the two groups were not found to be 
significant in the multivariate framework after adjusting for confounders such as 
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demographics, co-morbidity, diabetes severity, complexity of regimen, and interaction 
with health care providers.  The logistic regression model to predict the impact of 
depression on the likelihood of initiating insulin therapy was found to be significant with 
a Nagelkerke R-square value of 14.40%.  The model results are summarized in Table 11.  
Results of the multivariate model indicated that controlling for confounding covariates, 
there were no significant differences in the rate of initiation of insulin therapy in the 12-
month follow up period.  The Cox proportional hazards model was found to be 
significant and satisfied the assumptions of proportional hazards.  The model fit and 
results are summarized in Table 12.  The model indicated that the time to initiate insulin 
therapy was not significantly different between depressed and non-depressed patients 
after adjusting for baseline covariates.  
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Table 10: Initiation of insulin therapy in the 12-month follow up period 
 
         Depressed    Non-depressed      Total           Test           Sig. 
                                 (n= 471)          (n= 855)        (n= 1326)    statistic         (p) 
 
Initiation of insulin therapy 
• Insulin use             5.30%             2.90%             3.80%  
            (25)                 (25)                 (50) 
    χ2 = 4.76     0.030* 
• No insulin use           94.70%          97.10%          96.20%  
                      (446)               (830)              (1276) 
 
             
Time to initiation of          355.92         358.71           357.71     LR = 4.68   0.032* 
insulin         (+ 2.09)         (+ 1.43)         (+ 1.17) 
(in years) 
(Mean + Standard Error)      
 
*significance at the 0.05 level 
χ2 = Chi-square test 
LR = Log Rank test 
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Figure 7: Kaplan-Meier Survival Curves for time to initiation of insulin therapy 
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Table 11: Logistic regression for the impact of depression on initiation of insulin 
therapy 
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Depression 0.521 0.341 0.126 1.684 0.864 3.283
Demographic characteristics 
Age (in years) 
 
-0.015 0.017 0.355 0.985 0.953 1.017
Males (ref: females) 
 
-0.164 0.349 0.637 0.848 0.428 1.680
Whites (ref: non-whites) 
 
1.029 1.040 0.323 2.798 0.364 21.505
Urban (ref: rural) 
 
0.243 0.588 0.679 1.275 0.403 4.039
Year of index prescription (ref: 2001) 
• 1998  -0.449 0.908 0.621 0.638 0.108 3.785
• 1999 0.363 0.826 0.660 1.438 0.285 7.255
• 2000 -0.096 0.807 0.905 0.908 0.187 4.421
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.005 0.047 0.920 1.005 0.916 1.102
Total health costs 
     
0.000 0.000 0.200 1.000 1.000 1.000
Charlson co-morbidity 
            
0.292 0.158 0.064 1.340 0.984 1.825
Number of therapeutic classes 
of medications 
 
0.255 0.163 0.117 1.290 0.938 1.775
Cardio-vascular 
 
-0.455 0.350 0.194 0.634 0.319 1.261
Cancer 
 
-2.187 1.281 0.088 0.112 0.009 1.381
Asthma 
 
-0.498 0.457 0.276 0.608 0.248 1.489
Ulcers 
 
-1.009 1.098 0.358 0.365 0.042 3.137
Provider interaction in the pre period 
PAAS enrollment 0.169 0.448 0.705 1.185 0.492 2.852
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.517 0.644 0.422 1.677 0.474 5.930
• Single pharmacy -0.759 0.350 0.030* 0.468 0.236 0.929
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
-0.071 0.079 0.369 0.932 0.798 1.087
Number of prescriptions for 
chronic medications 
 
-0.034 0.035 0.338 0.967 0.902 1.036
Number of pills per day for 
oral hypoglycemics 
 
0.379 0.232 0.102 1.461 0.927 2.301
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.568 1.094 0.604 1.765 0.207 15.068
• Internal medicine          0.582 0.315 0.065 1.789 0.965 3.318
Total diabetes costs 0.000 0.000 0.777 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
0.197 0.349 0.573 1.218 0.614 2.414
Gap between index diagnosis 
and prescription 
 
0.000 0.001 0.655 1.000 0.998 1.002
Initial polytherapy 0.917 0.499 0.066 2.502 0.941 6.653
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.491 0.508 0.333 1.635 0.604 4.424
• Biguanides  -1.046 0.443 0.018* 0.351 0.147 0.837
• Alpha-glucosidase -0.762 1.133 0.501 0.467 0.051 4.301
• Sufonylurea biguanide  -19.08 6477.240 0.998 0.000 0.000 .
• Meglitinides -0.728 1.167 0.533 0.483 0.049 4.755
Constant -4.174 1.710 0.015 0.015  
   
*significance at 0.05 level 
PAAS = Physician Assured Access System 
 
Model fit statistics: 
 
Pseudo R-square = 14.4% 
-2 Log Likelihood = 370.174; χ2  = 53.058, p= 0.015 
Hosmer and Lemeshow’s goodness of fit: χ2  = 2.828; p=0.945 
 
 
Table 11: Logistic regression for the impact of depression on initiation of insulin 
therapy (Contd.) 
 157
Table 12: Cox proportional hazards model for the impact of depression on time to 
initiation of insulin therapy 
 Beta S.E. Sig. 
(p) 
Hazard 
ratio 
95% C.I. for 
Hazard ratio
     Lower Upper
Depression  0.494 0.328 0.132 1.639 0.861  3.118
Demographic characteristics 
Age (in years) -0.015 0.016 0.355 0.985 0.955 1.017
Males (ref: females) 
 
-0.170 0.335 0.613 0.844 0.437 1.629
Whites (ref: non-whites) 
 
0.993 1.024 0.332 2.698 0.363 20.079
Urban (ref: rural) 
 
0.183 0.550 0.739 1.201 0.409 3.532
Year of index prescription (ref: 2001) 
• 1998  -0.607 0.385 0.115 0.545 0.256 1.160
• 1999 -0.329 0.358 0.358 0.720 0.357 1.451
• 2000 0.043 0.343 0.901 1.044 0.532 2.045
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.000 0.042 0.997 1.000 0.921 1.086
Total health costs 
     
0.000 0.000 0.241 1.000 1.000 1.000
Charlson co-morbidity 
            
0.260 0.144 0.071 1.297 0.978 1.719
Number of therapeutic classes 
of medications 
 
0.238 0.155 0.124 1.269 0.937 1.719
Cardio-vascular 
 
-0.414 0.334 0.215 0.661 0.343 1.272
Cancer 
 
-1.997 1.229 0.104 0.136 0.012 1.510
Asthma 
 
-0.435 0.431 0.314 0.647 0.278 1.508
Ulcers 
 
-0.948 1.067 0.375 0.388 0.048 3.138
Provider interaction in the pre period 
PAAS enrollment 0.176 0.429 0.681 1.193 0.515 2.763
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.487 0.616 0.428 1.628 0.487 5.441
• Single pharmacy -0.718 0.336 0.033* 0.488 0.252 0.942
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Beta S.E. Sig. 
(p) 
Hazard 
ratio 
95% C.I. for 
Hazard  ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
-0.062 0.076 0.414 0.940 0.811 1.090
Number of prescriptions for 
chronic medications 
 
-0.032 0.034 0.347 0.968 0.906 1.035
Number of pills per day for 
oral hypoglycemics 
 
0.393 0.218 0.071 1.481 0.966 2.270
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.562 1.041 0.589 1.755 0.228 13.491
• Internal medicine          0.559 0.301 0.063 1.749 0.969 3.156
Total diabetes costs 0.000 0.000 0.712 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.157 0.329 0.633 1.170 0.614 2.232
Gap between index diagnosis 
and prescription 
 
0.000 0.001 0.639 1.000 0.998 1.001
Initial polytherapy 0.856 0.465 0.066 2.354 0.946 5.854
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.386 0.477 0.419 1.471 0.577 3.750
• Biguanides  -1.042 0.436 0.017* 0.353 0.150 0.828
• Alpha-glucosidase -0.708 1.086 0.515 0.493 0.059 4.142
• Meglitinides -0.797 1.130 0.481 0.451 0.049 4.132
    
    
*significance at the 0.05 level 
PAAS = Physician Assured Access System 
 
 
Model fit statistics: 
 
-2 Log Likelihood = 662.481; χ2  = 54.049, p= 0.012 
Global test of proportional hazard: χ2   = 31.86; p= 0.5237 
 
 
 
Table 12: Cox proportional hazards model for the impact of depression on time 
to initiation of insulin therapy (Contd.) 
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Discussion for Objective 5 
 
Initiation of insulin therapy can be a proxy for failure to control blood glucose 
with oral hypoglycemic therapy.  Depression can decrease adherence with medications 
leading to inadequate glucose control and cause a subsequent need for insulin therapy.  
Although significant differences were observed at the univariate level, these differences 
were not seen when the objective was examined in a multivariate framework.  One reason 
for this may be the length of the follow up period.  Usually insulin therapy is initiated 
when oral hypoglycemics and their combinations fail to control blood glucose and is not 
seen in a large fraction of newly diagnosed type 2 diabetes within a year of therapy.         
There are no studies in literature examining the role of depression in initiation of 
insulin therapy in patients with type 2 diabetes.  However, studies have examined the 
issue of insulin initiation extensively.  These studies have reported a high variation in 
rates of progression to insulin therapy in newly diagnosed patients.  This was primarily 
due to studies having a small sample sizes and being conducted in specialized settings 
such as diabetes clinics.  In a study conducted by Spoelstar and associates161 in a Dutch 
general health care system, the cumulative incidence of switching to insulin therapy was 
36% over a 4.5-year period.  Results from the United Kingdom Prospective Database 
study report insulin initiation rate of 30% over a nine year follow up period.162  One of 
the large population based studies examining this issue was conducted by Donnan and 
associates163 using retrospective claims data  in incident type 2 diabetes patients in 
Tayside, Scotland.  The newly diagnosed type 2 diabetes had varying times of follow up 
with a median length for the total cohort being 588 days.  Overall, 9.40% of subjects 
switched to insulin with a median time of switching being approximately six months after 
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initiation of oral hypoglycemic therapy.  The annual rate of switching was computed to 
be 5.84%.   These rates in literature are comparable to annual insulin initiation rate of 
3.80% found in this study. 
 
 
Results for Objective 6 
To estimate the impact of pre-existing depression on adherence to oral hypoglycemic 
agents 
Adherence to oral hypoglycemics was computed using refill information from claims 
data.  Patients initiating either mono-therapy or poly-therapy involving insulin were 
excluded from the computation of adherence indices.  All insulin prescriptions were 
excluded from the calculation of adherence indices.  This objective was examined using 
different indices for adherence such as the Reg MPR-1 and Reg MPR-2.  Univariate t-
tests were conducted to examine the differences in adherence indices.   
Univariate results are presented in Table 13.  Results indicated that patients with 
depression had significantly lower adherence to oral hypoglycemics than non-depressed 
patients on the basis of both Reg MPR-1 and Reg MPR-2.  However, although the 
differences were significant the magnitude of difference was not large with patients with 
depression being only 3% and 6% less adherent to oral hypoglycemics than non-
depressed patients on the Reg MPR-1 and Reg MPR-2 index respectively.  A multivariate 
Ordinary Least Squares (OLS) regression was performed to determine the impact of 
depression on adherence (Reg MPR-1 and Reg MPR-2) to oral hypoglycemic use 
controlling for baseline confounding factors.  Results of the multivariate OLS models are 
presented in Tables 14 and 15.  The multivariate results were exactly similar to the 
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univariate analysis wherein the depressed patients were found to be significantly less 
adherent than non-depressed patients.  The magnitude of difference in adherence after 
adjusting for baseline covariates was similar to unadjusted differences with depressed 
patients being approximately 3% and 7% less adherent than non-depressed patients as 
measured by Reg MPR-1 and Reg MPR-2.   
However, this multivariate OLS model was estimated on the assumption that 
depression has a linear effect on adherence.  Also, in objective 9, which estimates the 
impact of adherence on health care expenditures, a continuous adherence score could not 
be used as the independent variable as literature indicates a possible non-linear 
relationship between adherence to medications and health care expenditures.   Hence, we 
categorized Reg MPR-1 and Reg MPR-2   to examine the impact of depression on 
categories of adherence levels.  Categories of adherence were computed on the basis of 
recommendations from clinical experts and on the basis of distribution of adherence rates 
in the study data.   
Adherence measured by both Reg MPR-1 and Reg MPR-2 was divided into the 
following categories: 
• Very low adherence:  (Reg MPR-1 and Reg MPR-2 greater than or equal to 0 and 
less than or equal to 0.55)  
• Low adherence:  (Reg MPR-1 and Reg MPR-2 greater than 0.55 and less than or 
equal to 0.7) 
• Average adherence:  (Reg MPR-1 and Reg MPR-2 greater than 0.70 and less 
than or equal to 0.85) 
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• Good adherence:  (Reg MPR-1 and Reg MPR-2 greater than 0.85 and less than or 
equal to 1.0) 
• Over adherence:  (Reg MPR-1 and Reg MPR-2 greater than 1.0).   
Univariate distributions of depressed and non-depressed patients on the basis of these 
categories are presented in Table 13. 
As multiple categories of adherence were created, multivariate multinomial 
logistic regression analysis was used to estimate the impact of preexisting depression on 
these categories of adherence controlling for other confounding factors.  Good adherence 
was used as the reference category for all comparisons in the multinomial logistic model 
framework.  Separate multinomial logistic regression models were estimated for the 
impact of depression on Reg MPR-1 and Reg MPR-2.  The multinomial logistic 
regression model for the impact of depression on Reg MPR-1 and Reg MPR-2 were 
found to be significant with a Nagelkerke R-square value of 26.10% and 20.00%, 
respectively.  The model results are summarized in Tables 16A-16D and Table 17A-17D.  
Results of the multivariate model for Reg MPR-1 indicated that controlling for 
confounding covariates, patients with depression were 1.9 times more likely to have low 
adherence to oral hypoglycemics as compared non-depressed patients in the 12 month 
follow up period (p= 0.031).  Results from the model for Reg MPR-2 demonstrated that 
depressed patients were 1.6 times more likely to be in the very low adherence group as 
compared to non-depressed patients (p=0.004).  No other comparisons in the multinomial 
logistic regression models were found to be significant. 
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Table 13: Adherence indices in the 12-month follow up period 
 
Reg MPR-1: Based on adherence between index prescription and the last oral 
hypoglycemic prescription fill  
               Depressed        Non-depressed       Total              Test            Sig. 
                  (n = 295)             (n=595)             (n=890)      Statistic         (p)    
 
Mean Reg MPR-1  0.86 + 0.14         0.89 + 0.13        0.88 + 0.13    t = -3.38      0.001* 
(Mean + S.D.)     
 
Categories of Reg MPR-1 
 
Very low adherence   3.05%(9)         1.85%(11)          2.25%(20) 
 
Low adherence            11.53%(34)             7.39%(44)         8.76%(78) 
      χ2 = 8.98     0.060 
Average adherence     26.10%(77)       22.18%(132)     23.48%(209) 
 
Good adherence          55.59%(164)         64.37%(383)     61.46%(547) 
 
Over adherence   3.73%(11)         4.20%(25)         4.04%(36) 
 
 
Reg MPR-2: Based on adherence between index prescription and the end of the follow 
up period   
               Depressed        Non-depressed       Total              Test            Sig. 
       (n = 471)             (n=855)            (n=1326)    Statistic         (p)    
 
Mean Reg MPR-2     0.66 + 0.31           0.73 + 0.32      0.73 + 0.34       t = -3.82     0.000* 
(Mean + S.D.)  
 
Categories of Reg MPR-2 
 
Very low adherence  35.46%(167)      27.02%(231)      30.02%(398) 
 
Low adherence            12.31%(58)            9.82%(84)       10.71%(142) 
       χ2 = 20.57   0.060 
Average adherence     14.43%(68)     14.15%(121)       14.25%(189) 
 
Good adherence          32.70%(154)       39.30%(336)      24.51%(325) 
 
Over adherence   5.10%(24)       9.71%(83)          8.07%(107) 
   
* significance at the 0.05 level 
t = t -test 
χ2 = Chi-square test 
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Table 14: Ordinary Least Squares (OLS) regression model for the impact of 
depression on adherence (Reg MPR-1) to oral hypoglycemics  
 Beta       S.E. Test 
statistic (t) 
Sig. 
(p) 
     
Depression  -0.028 0.010 -2.880 0.004* 
Demographic characteristics 
Age (in years) 0.001 0.000 2.012 0.045* 
 
Males (ref: females) 
 
-0.013 0.009 -1.381 0.168 
Whites (ref: non-whites) 0.061 0.020 3.061 0.002* 
 
Urban (ref: rural) 
 
0.004 0.016 0.260 0.795 
Year of index prescription (ref: 2001) 
• 1998  0.013 0.023 0.559 0.577 
• 1999 -0.003 0.022 -0.152 0.879 
• 2000 0.014 0.020 0.698 0.485 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
-0.003 0.002 -1.234 0.217 
Total health costs 
     
0.000 0.000 2.437 0.015* 
Charlson co-morbidity 
            
0.006 0.006 1.167 0.244 
Number of therapeutic classes 
of medications 
 
-0.027 0.005 -5.627 0.000* 
Cardio-vascular 
 
-0.004 0.010 -0.434 0.665 
Cancer 
 
-0.009 0.026 -0.351 0.726 
Asthma 
 
-0.019 0.014 -1.380 0.168 
Ulcers 
 
0.000 0.028 -0.002 0.998 
Provider interaction in the pre period 
PAAS enrollment 0.017 0.014 1.226 0.221 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.021 0.024 -0.892 0.373 
• Single pharmacy 0.004 0.009 0.496 0.620 
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Beta     S.E. Test 
statistic (t) 
Sig. 
(p) 
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
0.000 0.002 -0.161 0.872 
Number of prescriptions for 
chronic medications 
 
0.005 0.001 5.881 0.000* 
Number of pills per day for 
oral hypoglycemics 
 
-0.018 0.008 -2.188 0.029* 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.011 0.033 0.328 0.743 
• Internal medicine          0.004 0.010 0.402 0.688 
 
Total diabetes costs 0.000 0.000 1.971 0.049* 
 
Number of diabetes related 
ER/Hosp visits 
 
-0.015 0.013 -1.156 0.248 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.387 0.699 
Initial polytherapy -0.050 0.017 -2.978 0.003* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -0.007 0.018 -0.389 0.697 
• Biguanides  -0.005 0.012 -0.417 0.677 
• Alpha-glucosidase 0.008 0.036 0.226 0.821 
• Meglitinides 0.073 0.030 2.422 0.016* 
   
Constant 0.814 0.042 19.225 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
Model fit statistics: 
 
R-square: 13.8%; F = 4.026; P = 0.000 
Durbin-Watson: 1.980 
White test for heteroskedasticity: Chi-square = 480.33   p=0.7073 
   
 
 
Table 14: Ordinary Least Squares (OLS) regression model for the impact of 
depression on adherence (Reg MPR-1) to oral hypoglycemics (Contd.) 
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Table 15: Ordinary Least Squares (OLS) regression model for the impact of 
depression on adherence (Reg MPR-2) to oral hypoglycemics  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
     
Depression -0.057 0.019 -2.916 0.004* 
Demographic characteristics 
Age (in years) 0.002 0.001 2.115 0.035* 
 
Males (ref: females) 
 
0.004 0.020 0.209 0.834 
Whites (ref: non-whites) 0.062 0.041 1.512 0.131 
 
Urban (ref: rural) 
 
0.018 0.034 0.527 0.598 
Year of index prescription (ref: 2001) 
• 1998  0.064 0.050 1.276 0.202 
• 1999 0.102 0.047 2.170 0.030* 
• 2000 0.059 0.044 1.320 0.187 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
-0.018 0.004 -4.727 0.000* 
Total health costs 
     
0.000 0.000 2.467 0.014* 
Charlson co-morbidity 
            
-0.008 0.011 -0.755 0.450 
Number of therapeutic classes 
of medications 
-0.018 0.010 -1.700 0.089 
Cardio-vascular 
 
0.030 0.021 1.406 0.160 
Cancer 
 
-0.075 0.052 -1.433 0.152 
Asthma 
 
-0.053 0.029 -1.843 0.066 
Ulcers 
 
-0.060 0.056 -1.072 0.284 
Provider interaction in the pre period 
PAAS enrollment                   0.018
  
0.029 0.631 0.528 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.057 0.048 -1.195 0.232 
• Single pharmacy 0.025 0.019 1.276 0.202 
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 Beta       S.E. Test statistic 
(t) 
Sig. 
(p) 
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
-0.003 0.004 -0.782 0.434 
Number of prescriptions for 
chronic medications 
 
0.009 0.002 4.724 0.000* 
Number of pills per day for 
oral hypoglycemics 
 
-0.004 0.017 -0.227 0.820 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.089 0.075 1.185 0.236 
• Internal medicine          -0.009 0.020 -0.423 0.673 
 
Total diabetes costs 0.000 0.000 1.854 0.064 
 
Number of diabetes related 
ER/Hosp visits 
 
0.013 0.027 0.487 0.626 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 1.509 0.131 
Initial polytherapy 0.007 0.041 0.167 0.867 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.004 0.040 0.101 0.919 
• Biguanides  -0.057 0.025 -2.287 0.022* 
• Alpha-glucosidase 0.091 0.078 1.162 0.245 
• Meglitinides -0.017 0.079 -0.213 0.832 
   
Constant 0.473 0.089 5.306 0.000 
* significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
Model fit statistics: 
 
R-square: 11.4%; F = 4.906; P = 0.000 
Durbin-Watson: 1.934  
White test for heteroskedasticity: Chi-square=540.83;  p= 0.2963 
 
 
 
 
Table 15: Ordinary Least Squares (OLS) regression model for the impact of 
depression on adherence (Reg MPR-2) to oral hypoglycemics (Contd.) 
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Table 16A: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-1) to oral hypoglycemics  
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Very low adherence vs. Good adherence 
Depression 0.648 0.626 0.301 1.911 0.560 6.521
Demographic characteristics 
Age (in years) -0.035 0.029 0.216 0.965 0.913 1.021
Males (ref: females) 
 
0.281 0.594 0.636 1.324 0.414 4.240
Whites (ref: non-whites) 
 
-0.836 1.142 0.464 0.433 0.046 4.063
Urban (ref: rural) 
 
-0.388 0.925 0.675 0.678 0.111 4.159
Year of index prescription (ref: 2001) 
• 1998  -3.088 1.378 0.025* 0.046 0.003 0.680
• 1999 -3.542 1.364 0.009* 0.029 0.002 0.419
• 2000 -3.686 1.366 0.007* 0.025 0.002 0.365
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.253 0.127 0.047* 1.287 1.003 1.652
Total health costs 
     
0.000 0.000 0.411 1.000 1.000 1.000
Charlson co-morbidity 
            
-0.319 0.555 0.566 0.727 0.245 2.156
Number of therapeutic 
classes of medications 
 
1.086 0.323 0.001* 2.961 1.571 5.583
Cardio-vascular 
 
-0.499 0.629 0.428 0.607 0.177 2.082
Cancer 
 
0.922 1.527 0.546 2.514 0.126 50.158
Asthma 
 
0.798 0.981 0.416 2.222 0.325 15.197
Ulcers 
 
-18.067 0.000 . 0.000 0.000 0.000
Provider interaction in the pre period 
PAAS enrollment -19.477 9459.151 0.998 0.000 0.000 .
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 1.129 1.357 0.405 3.093 0.216 44.207
• Single pharmacy 0.803 0.627 0.200 2.232 0.653 7.625
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
0.045 0.147 0.758 1.046 0.784 1.396
Number of prescriptions for 
chronic medications 
 
-0.265 0.076 0.001* 0.767 0.660 0.891
Number of pills per day for 
oral hypoglycemics 
 
0.684 0.381 0.073 1.983 0.939 4.187
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist -17.438 0.000 . 0.000 0.000 0.000
• Internal medicine         0.050 0.632 0.937 1.051 0.304 3.628
Total diabetes costs 0.000 0.000 0.879 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
-0.986 1.455 0.498 0.373 0.022 6.468
Gap between index diagnosis 
and prescription 
 
-0.003 0.002 0.201 0.997 0.993 1.001
Initial polytherapy 1.455 0.777 0.061 4.284 0.934 19.642
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -0.387 1.251 0.757 0.679 0.059 7.877
• Biguanides  0.010 0.684 0.988 1.010 0.264 3.863
• Alpha-glucosidase -18.235 0.000 . 0.000 0.000 0.000
• Sulfonyl-biguanides -20.527 0.000 . 0.000 0.000 0.000
• Meglitinides 2.739 1.593 0.086 15.464 0.681 351.022
Constant 0.631 2.535 0.804    
       
 
 
 
 
 
 
 
 
Table 16A: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-1) to oral hypoglycemics (Contd.) 
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Table 16B: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-1) to oral hypoglycemics 
  Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
Low adherence vs. Good adherence 
Depression 0.649 0.301 0.031* 1.913 1.061 3.448
Demographic characteristics 
Age (in years) -0.013 0.015 0.388 0.987 0.958 1.017
Males (ref: females) 
 
0.408 0.293 0.163 1.504 0.848 2.669
Whites (ref: non-whites) 
 
-1.243 0.522 0.017* 0.288 0.104 0.803
Urban (ref: rural) 
 
0.309 0.530 0.560 1.362 0.482 3.850
Year of index prescription (ref: 2001) 
• 1998  -0.076 0.753 0.919 0.927 0.212 4.050
• 1999 0.191 0.703 0.786 1.211 0.305 4.807
• 2000 0.145 0.661 0.826 1.157 0.316 4.229
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.050 0.070 0.475 1.052 0.916 1.207
Total health costs 
     
0.000 0.000 0.325 1.000 1.000 1.000
Charlson co-morbidity 
            
-0.488 0.265 0.066 0.614 0.365 1.033
Number of therapeutic 
classes of medications 
0.651 0.149 0.000* 1.917 1.433 2.565
Cardio-vascular 
 
0.202 0.317 0.523 1.224 0.658 2.278
Cancer 
 
0.334 0.927 0.718 1.397 0.227 8.591
Asthma 
 
1.206 0.424 0.004* 3.341 1.454 7.676
Ulcers 
 
0.088 0.930 0.924 1.092 0.177 6.757
Provider interaction in the pre period 
PAAS enrollment -0.340 0.457 0.458 0.712 0.291 1.744
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.105 0.832 0.900 1.110 0.217 5.671
• Single pharmacy 0.062 0.282 0.827 1.064 0.612 1.848
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Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
-0.039 0.070 0.575 0.962 0.839 1.102
Number of prescriptions for 
chronic medications 
 
-0.110 0.031 0.000* 0.896 0.843 0.952
Number of pills per day for 
oral hypoglycemics 
 
0.568 0.220 0.010* 1.765 1.146 2.717
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 1.060 0.926 0.252 2.886 0.470 17.720
• Internal medicine         0.068 0.300 0.821 1.070 0.594 1.926
Total diabetes costs 0.000 0.000 0.356 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.383 0.431 0.374 1.467 0.630 3.418
Gap between index diagnosis 
and prescription 
 
0.000 0.001 0.795 1.000 0.999 1.002
Initial polytherapy 1.393 0.418 0.001* 4.028 1.775 9.141
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.427 0.518 0.410 1.532 0.555 4.232
• Biguanides  0.141 0.356 0.692 1.151 0.573 2.315
• Alpha-glucosidase -0.802 1.284 0.532 0.448 0.036 5.555
• Sulfonyl-biguanides -1.440 0.836 0.085 0.237 0.046 1.219
• Meglitinides 1.569 1.112 0.158 4.801 0.543 42.439
Constant -2.570 1.321 0.052  
       
 
 
 
 
 
 
 
 
Table 16B: Multinomial Logistic regression for the impact of depression on adherence 
(Reg MPR-1) to oral hypoglycemics (Contd.) 
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Table 16C: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-1) to oral hypoglycemics 
  Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
Average adherence vs. Good adherence  
Depression 0.338 0.201 0.092 1.403 0.946 2.079
Demographic characteristics 
Age (in years) -0.018 0.010 0.056 0.982 0.964 1.000
Males (ref: females) 
 
0.242 0.187 0.196 1.273 0.883 1.837
Whites (ref: non-whites) 
 
-0.803 0.390 0.039* 0.448 0.209 0.962
Urban (ref: rural) 
 
0.188 0.343 0.582 1.207 0.617 2.364
Year of index prescription (ref: 2001) 
• 1998  -0.084 0.517 0.870 0.919 0.334 2.532
• 1999 0.321 0.487 0.509 1.379 0.531 3.584
• 2000 -0.001 0.464 0.997 0.999 0.402 2.478
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.069 0.054 0.204 1.071 0.963 1.192
Total health costs 
     
0.000 0.000 0.016* 1.000 1.000 1.000
Charlson co-morbidity 
            
-0.063 0.125 0.613 0.939 0.735 1.199
Number of therapeutic 
classes of medications 
0.300 0.103 0.004* 1.350 1.103 1.653
Cardio-vascular 
 
-0.181 0.203 0.374 0.835 0.560 1.243
Cancer 
 
0.388 0.557 0.487 1.474 0.494 4.394
Asthma 
 
0.212 0.291 0.467 1.236 0.698 2.188
Ulcers 
 
-0.104 0.572 0.856 0.901 0.294 2.764
Provider interaction in the pre period 
PAAS enrollment 0.035 0.266 0.896 1.035 0.615 1.742
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.196 0.441 0.658 1.216 0.512 2.888
• Single pharmacy -0.145 0.184 0.433 0.865 0.603 1.242
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Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
0.046 0.042 0.270 1.047 0.965 1.136
Number of prescriptions for 
chronic medications 
 
-0.074 0.021 0.000* 0.929 0.892 0.967
Number of pills per day for 
oral hypoglycemics 
 
-0.021 0.173 0.902 0.979 0.697 1.374
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.703 0.719 0.328 2.020 0.494 8.260
• Internal medicine         0.065 0.198 0.741 1.068 0.724 1.574
Total diabetes costs 0.000 0.000 0.202 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.478 0.287 0.096 1.613 0.919 2.832
Gap between index diagnosis 
and prescription 
 
0.000 0.001 0.772 1.000 0.999 1.001
Initial polytherapy 0.171 0.390 0.662 1.186 0.552 2.548
  
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -0.726 0.451 0.107 0.484 0.200 1.170
• Biguanides  -0.051 0.247 0.835 0.950 0.586 1.541
• Alpha-glucosidase 0.751 0.681 0.270 2.120 0.558 8.054
• Sulfonyl-biguanides -0.712 0.707 0.314 0.491 0.123 1.963
• Meglitinides 2.282 0.845 0.007* 9.797 1.871 51.297
Constant 0.441 0.897 0.623  
       
 
 
 
 
 
 
 
 
 
Table 16C: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-1) to oral hypoglycemics (Contd.) 
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Table 16D: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-1 ) to oral hypoglycemics 
  Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Over adherence vs. Good adherence 
Depression 0.304 0.422 0.472 1.355 0.593 3.097
Demographic characteristics 
Age (in years) 
 
-0.012 0.020 0.559 0.988 0.950 1.028
Males (ref: females) 
 
0.556 0.384 0.148 1.744 0.821 3.704
Whites (ref: non-whites) 
 
15.777 0.000 .   
Urban (ref: rural) 
 
1.293 1.051 0.218 3.644 0.465 28.588
Year of index prescription (ref: 2001) 
• 1998  -0.250 1.018 0.806 0.779 0.106 5.730
• 1999 0.005 0.954 0.996 1.005 0.155 6.524
• 2000 -0.102 0.893 0.909 0.903 0.157 5.198
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.040 0.118 0.736 1.041 0.825 1.312
Total health costs 
     
0.000 0.000 0.648 1.000 1.000 1.000
Charlson co-morbidity 
            
-0.210 0.313 0.502 0.811 0.439 1.497
Number of therapeutic 
classes of medications 
0.080 0.212 0.705 1.083 0.716 1.640
Cardio-vascular 
 
-0.212 0.436 0.627 0.809 0.344 1.902
Cancer 
 
-0.421 1.308 0.748 0.656 0.051 8.527
Asthma 
 
0.190 0.616 0.758 1.209 0.362 4.043
Ulcers 
 
-18.605 0.000 . 0.000 0.000 0.000
Provider interaction in the pre period 
PAAS enrollment 0.078 0.582 0.894 1.081 0.346 3.380
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.323 1.151 0.779 0.724 0.076 6.906
• Single pharmacy 0.328 0.399 0.412 1.388 0.634 3.035
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
-0.120 0.106 0.257 0.887 0.721 1.091
Number of prescriptions for 
chronic medications 
 
0.013 0.040 0.749 1.013 0.937 1.095
Number of pills per day for 
oral hypoglycemics 
 
0.208 0.322 0.518 1.232 0.655 2.316
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 2.342 0.895 0.009* 10.407 1.800 60.166
• Internal medicine         0.836 0.400 0.036* 2.307 1.054 5.049
Total diabetes costs 0.000 0.000 0.243 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
-0.400 0.625 0.522 0.670 0.197 2.281
Gap between index diagnosis 
and prescription 
 
0.000 0.001 0.769 1.000 0.997 1.002
Initial polytherapy 1.558 0.512 0.002* 4.752 1.742 12.957
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -1.011 1.064 0.342 0.364 0.045 2.926
• Biguanides  -0.474 0.501 0.345 0.623 0.233 1.663
• Alpha-glucosidase 0.651 1.280 0.611 1.917 0.156 23.543
• Sulfonyl-biguanides -1.847 1.216 0.129 0.158 0.015 1.711
• Meglitinides -20.581 0.000 . 0.000 0.000 0.000
Constant -19.894 1.814 0.000   
   
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
Model fit statistics: 
 
Pseudo R-square = 26.1% 
-2 Log Likelihood = 1609.302; χ2  = 226.003; p= 0.00 
 
Table 16D: Multinomial Logistic regression for the impact of depression on adherence 
(Reg MPR-1) to oral hypoglycemics (Contd.) 
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Table 17A: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-2) to oral hypoglycemics 
  Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
  Lower Upper
Very low adherence vs. Good adherence 
Depression 0.484 0.167 0.004* 1.623 1.169 2.252
Demographic characteristics 
Age (in years) -0.011 0.008 0.150 0.989 0.974 1.004
Males (ref: females) 
 
0.156 0.162 0.333 1.169 0.852 1.605
Whites (ref: non-whites) -0.413 0.357 0.248 0.662 0.328 1.333
Urban (ref: rural) 
 
-0.018 0.268 0.948 0.983 0.581 1.663
Year of index prescription (ref: 2001) 
• 1998  -0.662 0.404 0.101 0.516 0.234 1.139
• 1999 -0.889 0.383 0.020* 0.411 0.194 0.871
• 2000 -0.489 0.361 0.175 0.613 0.303 1.244
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.188 0.041 0.000* 1.207 1.113 1.309
Total health costs 
     
0.000 0.000 0.022* 1.000 1.000 1.000
Charlson co-morbidity 
            
0.119 0.092 0.198 1.126 0.940 1.350
Number of therapeutic 
classes of medications 
0.156 0.086 0.069 1.169 0.988 1.384
Cardio-vascular 
 
-0.359 0.168 0.033* 0.698 0.502 0.971
Cancer 
 
0.543 0.434 0.211 1.721 0.736 4.026
Asthma 
 
0.417 0.229 0.069 1.518 0.968 2.380
Ulcers 
 
0.336 0.465 0.470 1.399 0.563 3.478
Provider interaction in the pre period 
PAAS enrollment -0.013 0.232 0.954 0.987 0.626 1.555
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.551 0.370 0.137 1.735 0.839 3.584
• Single pharmacy -0.176 0.156 0.260 0.839 0.618 1.139
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 Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
0.062 0.037 0.095 1.064 0.989 1.144
Number of prescriptions for 
chronic medications 
 
-0.087 0.017 0.000* 0.916 0.886 0.948
Number of pills per day for 
oral hypoglycemics 
 
-0.006 0.132 0.964 0.994 0.767 1.289
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.266 0.630 0.673 1.304 0.380 4.481
• Internal medicine         0.082 0.165 0.619 1.085 0.786 1.499
Total diabetes costs 0.000 0.000 0.221 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
-0.254 0.241 0.293 0.776 0.484 1.245
Gap between index diagnosis 
and prescription 
 
-0.001 0.000 0.092 0.999 0.998 1.000
Initial polytherapy -0.023 0.344 0.947 0.978 0.498 1.918
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.211 0.324 0.515 1.235 0.654 2.333
• Biguanides  0.449 0.198 0.023* 1.566 1.062 2.309
• Alpha-glucosidase 0.776 0.761 0.308 2.174 0.489 9.663
• Sulfonyl-biguanides -0.081 0.572 0.888 0.923 0.300 2.832
• Meglitinides 0.777 0.688 0.258 2.175 0.565 8.370
Constant 1.321 0.728 0.070  
   
 
 
 
 
 
 
 
 
 
Table 17A: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-2) to oral hypoglycemics (Contd.) 
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Table 17B: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-2) to oral hypoglycemics 
  Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Low adherence vs. Good adherence 
Depression 0.389 0.227 0.086 1.475 0.946 2.300
Demographic characteristics 
Age (in years) 0.001 0.011 0.905 1.001 0.980 1.023
Males (ref: females) 
 
0.010 0.222 0.963 1.010 0.654 1.560
Whites (ref: non-whites) -0.998 0.396 0.012* 0.369 0.170 0.801
Urban (ref: rural) 
 
0.354 0.409 0.387 1.425 0.639 3.177
Year of index prescription (ref: 2001) 
• 1998  -0.117 0.557 0.834 0.890 0.299 2.650
• 1999 -0.335 0.530 0.527 0.715 0.253 2.022
• 2000 -0.235 0.503 0.641 0.791 0.295 2.119
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.083 0.055 0.133 1.086 0.975 1.210
Total health costs 
     
0.000 0.000 0.973 1.000 1.000 1.000
Charlson co-morbidity 
            
-0.002 0.131 0.988 0.998 0.773 1.289
Number of therapeutic 
classes of medications 
0.262 0.110 0.017* 1.299 1.048 1.611
Cardio-vascular 
 
0.067 0.234 0.773 1.070 0.677 1.691
Cancer 
 
0.293 0.600 0.625 1.341 0.413 4.349
Asthma 
 
0.243 0.310 0.433 1.275 0.695 2.339
Ulcers 
 
0.271 0.626 0.665 1.311 0.385 4.470
Provider interaction in the pre period 
PAAS enrollment -0.366 0.349 0.294 0.693 0.350 1.374
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.368 0.545 0.499 1.445 0.497 4.205
• Single pharmacy -0.019 0.211 0.929 0.981 0.649 1.484
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
0.025 0.048 0.608 1.025 0.933 1.126
Number of prescriptions for 
chronic medications 
 
-0.068 0.022 0.002* 0.934 0.895 0.975
Number of pills per day for 
oral hypoglycemics 
 
0.117 0.171 0.493 1.124 0.804 1.572
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist -19.987 0.000 . 0.000 0.000 0.000
• Internal medicine         0.292 0.215 0.174 1.339 0.879 2.039
Total diabetes costs 0.000 0.000 0.123 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.152 0.321 0.636 1.164 0.621 2.182
Gap between index diagnosis 
and prescription 
 
-0.001 0.001 0.256 0.999 0.998 1.001
Initial polytherapy 0.617 0.395 0.118 1.854 0.856 4.018
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.358 0.431 0.407 1.430 0.614 3.328
• Biguanides  0.464 0.265 0.080 1.590 0.946 2.675
• Alpha-glucosidase 0.412 0.977 0.673 1.509 0.223 10.237
• Sulfonyl-biguanides -0.359 0.718 0.617 0.698 0.171 2.853
• Meglitinides 1.044 0.793 0.188 2.841 0.600 13.452
Constant -1.167 0.977 0.232   
       
 
 
 
 
 
 
 
 
 
Table 17B: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-2) to oral hypoglycemics (Contd.) 
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Table 17C: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-2) to oral hypoglycemics 
  Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
Average adherence vs. Good adherence 
Depression 0.308 0.205 0.133 1.360 0.911 2.033
Demographic characteristics 
Age (in years) -0.005 0.009 0.583 0.995 0.976 1.013
Males (ref: females) 
 
0.249 0.194 0.199 1.283 0.877 1.878
Whites (ref: non-whites) -0.659 0.393 0.093 0.517 0.239 1.117
Urban (ref: rural) 
 
0.325 0.360 0.366 1.385 0.684 2.804
Year of index prescription (ref: 2001) 
• 1998  -0.219 0.523 0.675 0.803 0.288 2.238
• 1999 -0.243 0.494 0.623 0.784 0.298 2.065
• 2000 -0.204 0.472 0.666 0.816 0.324 2.055
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.091 0.055 0.100 1.095 0.983 1.220
Total health costs 
     
0.000 0.000 0.004* 1.000 1.000 1.000
Charlson co-morbidity 
            
0.148 0.115 0.199 1.159 0.925 1.452
Number of therapeutic 
classes of medications 
0.042 0.103 0.686 1.043 0.852 1.276
Cardio-vascular 
 
-0.260 0.204 0.201 0.771 0.517 1.149
Cancer 
 
0.004 0.557 0.994 1.004 0.337 2.990
Asthma 
 
-0.040 0.296 0.892 0.961 0.537 1.717
Ulcers 
 
-0.285 0.645 0.658 0.752 0.213 2.659
Provider interaction in the pre period 
PAAS enrollment 0.498 0.259 0.054* 1.645 0.991 2.730
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.050 0.489 0.919 0.951 0.365 2.480
• Single pharmacy -0.341 0.189 0.072 0.711 0.491 1.030
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Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
0.074 0.042 0.082 1.076 0.991 1.169
Number of prescriptions for 
chronic medications 
 
-0.032 0.020 0.107 0.969 0.933 1.007
Number of pills per day for 
oral hypoglycemics 
 
-0.152 0.169 0.367 0.859 0.616 1.196
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.636 0.690 0.356 1.889 0.489 7.306
• Internal medicine         0.015 0.204 0.940 1.016 0.681 1.515
Total diabetes costs 0.000 0.000 0.860 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.137 0.274 0.618 1.146 0.670 1.961
Gap between index diagnosis 
and prescription 
 
-0.001 0.001 0.086 0.999 0.998 1.000
Initial polytherapy 0.119 0.416 0.775 1.126 0.498 2.543
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.334 0.396 0.399 1.397 0.642 3.037
• Biguanides  0.510 0.245 0.038* 1.666 1.030 2.695
• Alpha-glucosidase 1.675 0.789 0.034* 5.338 1.136 25.077
• Sulfonyl-biguanides 0.181 0.694 0.794 1.199 0.308 4.669
• Meglitinides 1.244 0.777 0.109 3.469 0.757 15.901
Constant 0.058 0.906 0.949  
       
 
 
 
 
 
 
 
 
Table 17C: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-2) to oral hypoglycemics (Contd.) 
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Table 17D: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-2) to oral hypoglycemics 
  Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
  Lower Upper
Over adherence vs. Good adherence 
Depression -0.399 0.281 0.156 0.671 0.386 1.164
Demographic characteristics 
Age (in years) 0.018 0.013 0.144 1.019 0.994 1.044
Males (ref: females) 
 
0.228 0.235 0.333 1.256 0.792 1.991
Whites (ref: non-whites) 0.002 0.581 0.997 1.002 0.321 3.129
Urban (ref: rural) 
 
0.084 0.397 0.833 1.087 0.500 2.367
Year of index prescription (ref: 2001) 
• 1998  -0.529 0.562 0.347 0.589 0.196 1.773
• 1999 -0.621 0.526 0.238 0.537 0.192 1.506
• 2000 -0.145 0.485 0.765 0.865 0.335 2.236
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.137 0.054 0.011* 1.147 1.032 1.274
Total health costs 
     
0.000 0.000 0.565 1.000 1.000 1.000
Charlson co-morbidity 
            
0.002 0.127 0.986 1.002 0.781 1.286
Number of therapeutic 
classes of medications 
-0.053 0.126 0.678 0.949 0.741 1.216
Cardio-vascular 
 
-0.284 0.260 0.275 0.753 0.452 1.253
Cancer 
 
0.515 0.621 0.407 1.673 0.495 5.653
Asthma 
 
-0.277 0.368 0.452 0.758 0.369 1.559
Ulcers 
 
0.550 0.717 0.443 1.733 0.425 7.063
Provider interaction in the pre period 
PAAS enrollment -0.091 0.393 0.816 0.913 0.422 1.973
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.514 0.589 0.382 1.673 0.528 5.302
• Single pharmacy 0.208 0.237 0.380 1.231 0.774 1.960
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Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
Complexity of regimen 
Number of pills per day for 
chronic medications 
 
0.005 0.049 0.913 1.005 0.912 1.108
Number of prescriptions for 
chronic medications 
 
0.011 0.022 0.602 1.011 0.969 1.056
Number of pills per day for 
oral hypoglycemics 
 
-0.262 0.226 0.246 0.769 0.494 1.198
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 1.075 0.765 0.160 2.929 0.654 13.129
• Internal medicine         0.282 0.240 0.241 1.326 0.827 2.124
Total diabetes costs 0.000 0.000 0.435 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
-0.306 0.379 0.420 0.736 0.350 1.548
Gap between index diagnosis 
and prescription 
 
0.000 0.001 0.983 1.000 0.999 1.001
Initial polytherapy 0.172 0.462 0.709 1.188 0.480 2.939
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.531 0.416 0.201 1.701 0.753 3.843
• Biguanides  0.210 0.314 0.503 1.234 0.667 2.286
• Alpha-glucosidase 1.816 0.907 0.045* 6.147 1.038 36.393
• Sulfonyl-biguanides -0.607 0.906 0.503 0.545 0.092 3.215
• Meglitinides 0.740 1.202 0.538 2.095 0.199 22.099
Constant -2.113 1.128 0.061  
   
*Significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
Model fit statistics: 
 
Pseudo R-square = 20.0% 
-2 Log Likelihood = 3480.436; χ2  = 270.066; p= 0.000 
 
Table 17D: Multinomial Logistic regression for the impact of depression on 
adherence (Reg MPR-2) to oral hypoglycemics (Contd.) 
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Discussion for objective 6 
The study results indicated that newly diagnosed patients who continued oral 
hypoglycemic therapy had an adherence rate of 88.00%.  If patients who discontinued 
therapy were assumed to be non-adherent and included in the computation of adherence, 
rates of around 73.00% were found in the first year of oral hypoglycemic therapy.  
Results for adherence rates in the 12-month follow up period were found to be 
comparable to studies in the literature computing adherence rates for newly diagnosed 
patients using prescription claims data. In a study conducted by Spoelstra and 
associates161 using retrospective claims data of newly diagnosed type 2 diabetes patients, 
adherence rates of around 86.00% were found.  These numbers are very similar to the 
ones obtained in this study.  An adherence rate of 86.00% was also found in a study 
conducted in seniors in Nova Scotia, Canada.164 In more than 52,000 patients on 
sulfonylurea, Boccuzzi and associates16 determined an average adherence rate of 
approximately 79.00%.  Similar estimates of 70-80% were found for newly diagnosed 
type 2 diabetes patients in Tayside, Scotland.17 Slight differences in the reported 
adherence rates may reflect differences in methods, length of follow-up periods, inclusion 
criteria, and demographic distribution of the patient population. 
Results of this study indicated that patients with depression had significantly 
lower adherence (Reg MPR-1 = 86.00%; Reg MPR-2 = 66.00%) to oral hypoglycemics 
as compared to patients without depression (Reg MPR-1 = 89.00%; Reg MPR-2 = 
73.00%).  The impact of depression on adherence remained significant in the multivariate 
framework.  However, the magnitude of difference in adherence was not large.  In the 
only other study examining the impact of depression on adherence with oral 
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hypoglycemics, Ciechanowski and colleagues28 found that depressive symptom severity 
was significantly associated with decreased adherence to dietary recommendations and 
approximately twice as many interruptions in refills of oral hypoglycemics.  If these 
results are converted to make them comparable to findings from this study, rates of 
93.00% adherence were found for patients with low depressive symptomatology as 
compared to adherence rates of 85.00% for patients with high depression severity.  If 
patients with medium and high depression severity levels from this study are combined to 
form a group of depressed patients, adherence rates of 88% are estimated for depressed 
patients.  Thus, the difference in adherence rates between depressed and non-depressed 
patients in the study by Ciechanowski and associates was around 5.00%; similar to the 
results obtained from our study.  However, this study was not restricted to patients who 
were newly diagnosed patients and included a mix of type 1 and type 2 diabetes patients.  
Also, the study measured adherence with oral hypoglycemics over a 12-month period, 
including a period of six months before the assessment of depressive symptoms.  This 
study along with others in the literature demonstrating significantly lower adherence in 
depressed patients were co-relational in nature and failed to determine whether 
depression causes non-adherence or non-adherence causes depression.  The estimation 
models could be biased due to endogeneity and failed to control for a number of 
confounding variables. 
In addition to the study by Ciechanowski and associates28 in diabetes patients, 
depression has been reported to have an effect on adherence with other medications 
across a number of other disease conditions.  In a study of adherence with aspirin among 
elderly patients with coronary heart disease, depressed patients adhered to their regimen 
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on a significantly lower proportion of days (45.00%) than those without depression 
(69.00%).112  Studies of adherence in a variety of other conditions including AIDS, renal 
failure, and asthma have also identified depression as a risk factor for non-adherence.  In 
a study using prescription refill information from claims data of a large HMO and 
Veterans Affairs (VA) medical center, depression was significantly associated with 
adherence of antihypertensive medications.165 However, similar to this study’s results, the 
magnitude of decrease in adherence with every unit increase in depression severity was 
low.   
The strength of this study lies in the use of actual prescription refill information 
from claims data rather than patient reported adherence.  Using such an objective 
measure of adherence was especially important in this study as a pessimistic attitude in 
depressed patients can cause under-reporting of drug use among these patients and thus 
show an artificial association between depression and adherence.  In addition, data were 
adjusted for a range of baseline variables such as demographics, co-morbidity, diabetes 
severity, complexity of regimen, and interaction with health care providers that could 
confound the impact of depression on adherence with oral hypoglycemics.  The study 
design was also able to avoid the issue of endogeneity by examining adherence in newly 
diagnosed type 2 diabetes patients who had pre-existing depression.   
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Results for Objective 7 
To estimate the impact of preexisting depression on type 2 diabetes related utilization 
and costs 
 Claims including either a primary or secondary diagnosis code for type 2 diabetes 
and prescriptions for insulin, oral hypoglycemics and diabetic supplies were identified in 
assessing total resource utilization associated with type 2 diabetes.  In addition to total 
type 2 diabetes costs, separate costs in terms of ER/hospitalization costs, outpatient costs, 
and pharmacy costs were also assessed.  Along with expenditures in terms of dollar 
amounts, utilization related to type 2 diabetes such as number of ER/hospitalization 
episodes, number of physician office visits, and number of diabetes prescriptions were 
also compared between depressed and non-depressed patients.   
Type 2 diabetes related costs 
Univariate results for type 2 diabetes related costs are reported in Table 18.  
Results indicated that in the 12 month follow up period total type 2 diabetes related costs 
were significantly higher for depressed patients ($3,290.85 +7,060.05) as compared to 
non-depressed patients ($2,186.24 +5,142.13).  This difference in total type 2 diabetes 
costs was primarily due to difference in ER/hospitalization costs, with depressed patients 
incurring nearly twice the amount of ER/hospitalization costs as non-depressed patients.  
Type 2 diabetes related outpatient costs were also slightly higher for depressed patients 
($507.42 +678.48) as compared to non-depressed patients ($407.82 +629.57).  However, 
no differences in diabetes prescription costs were observed.  However, these effects could 
also be a result of confounders such as demographics, co-morbidity, diabetes severity, 
and interaction with health care providers.  Hence, multivariate econometric models were 
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used to determine the impact of depression on type 2 diabetes related expenditures 
controlling for baseline confounding factors.  
Semi-log Ordinary Least Squares (OLS) regression techniques were used for the 
estimation of the impact of preexisting depression on total costs associated with type 2 
diabetes controlling for other confounding factors.  The semi-log OLS model was found 
to be significant with a R-square value of 15.60%.  The model results are summarized in 
Table 19.  Results of the multivariate model indicated that controlling for confounding 
covariates, patients with depression incurred 21.30% higher type 2 diabetes costs as 
compared to non-depressed patients in the 12 month follow up period (p= 0.013).  These 
estimates were computed by applying the correction of Halverson and Palmquist with a 
modification by Kennedy.  This method was used for interpreting the estimates in all 
semi-log OLS models. Retransformation using smearing estimated that an excess of 
$451.27 in type 2 diabetes costs were attributable to depression.   
In models where the dependent variables are specific costs such as those due to 
ER/hospitalization visits and outpatient costs, a two-part model was used to estimate the 
impact of depression on diabetes related ER/hospitalization and outpatient costs.  Results 
for the two-part model estimating the impact of depression on ER/hospitalization costs 
are summarized in Table 20A-20B.  An initial multivariate logistic regression model to 
estimate the impact of depression on a type 2 diabetes related ER/hospitalization episode 
demonstrated that depressed patients were nearly 1.4 times more likely to have a 
ER/hospitalization episode as compared to non-depressed patients (p=0.028).  A 
subsequent semi-logarithmic OLS model, which was conducted only on those patients 
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incurring type 2 diabetes related ER/hospitalization revealed no significant differences in 
ER/hospitalization costs between depressed and non-depressed patients. 
Two-part models for type 2 diabetes related outpatient costs revealed no 
significant differences in either the probability or expenditures for type 2 diabetes related 
outpatient visits between patients with and without depression (Tables 21A-21B).  A 
semi-log OLS model in a multivariate framework also failed to reveal any significant 
differences in prescription costs between depressed and non-depressed patient controlling 
for baseline covariates (Table 22). 
Type 2 diabetes related utilization 
Univariate results for type 2 diabetes related utilization in the 12-month follow up 
period are presented in Table 18.   The most notable difference between the 2 groups was 
in the number of ER/Hospitalization episodes, with depressed patients (0.79 +1.57) 
having significantly higher ER/Hospitalization episodes as compared to non-depressed 
patients (0.40 +1.09).  Patients with depression (9.81 +5.49) had significantly less 
number of prescriptions for diabetes medications as compared to non-depressed patients 
(10.76 +6.01), primarily due to decreased adherence with medications.  However, the 
results did not indicate any differences in number of physician office visits between 
depressed and non-depressed patient.   
As the dependent variable in this case is count data, a Poisson or Negative 
binomial model could be used to estimate the impact of depression on type 2 diabetes 
related utilization in a multivariate framework.  In a Poisson regression, the probability of 
a count is determined by a Poisson distribution, which has the defining characteristic that 
the conditional mean of the outcome is equal to the conditional variance.  However, most 
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of the models for utilization were overdispersed (i.e the variance being greater than the 
mean) with a high proportion of zero counts.  Hence, a negative binomial model was used 
for estimation of all the utilization related variables. 
Results of the negative binomial models indicated that the only significant 
difference between the two groups in the multivariate framework was in terms of number 
of type 2 diabetes related ER/Hospitalizations with depressed patients incurring 57.78% 
higher number of visits as compared to non depressed patients (p= 0.000). Results of this 
negative binomial model and the fit statistics are summarized in Table 23.  Table 24 
reports the results of the negative binomial model, which demonstrates no significant 
impact of depression on number of diabetes related physician office visits. The 
multivariate framework also failed to reveal any significant impact of depression on 
number of diabetes related prescriptions in the 12-month follow up period (Table 25). 
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Table 18: Utilization and expenditures for type 2 diabetes in the 12-month follow up 
period 
        Depressed                Non-depressed        Mann-Whitney     Sig. 
      (Mean+ S.D.)               (Mean+ S.D.)               U test               (p) 
         (N = 471)          (N = 855)                                                               
 
Type 2 diabetes related costs  
 
Outpatient costs          507.42      407.82         184897.00  0.014* 
          +678.48            +629.57  
 
ER/Hosp costs        2,276.38                     1,271.08         174006.50  0.000* 
        +6,932.74        +4,939.85  
 
Pharmacy costs          507.05                        507.33     195443.00  0.376 
          +436.31           +475.01 
 
Total costs         3,290.85          2,186.24                173041.00  0.000* 
     +7,060.05       +5,142.13 
 
Type 2 diabetes related utilization  
 
Number of physician       2.76 +3.34         2.55 +3.08    197218.50  0.525 
office visits              
 
Number of ER/hosp       0.79 +1.57         0.40 +1.09    172425.50  0.000* 
visits 
     
Number of prescriptions   9.81 +5.49                  10.76 +6.01    182867.00     0.005* 
 
 
* significance at the 0.05 level 
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Table 19: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on total diabetes costs  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
     
Depression  0.196 0.079 2.492 0.013* 
Demographic characteristics 
Age (in years) 0.005 0.004 1.419 0.156 
 
Males (ref: females) 
 
0.048 0.075 0.633 0.527 
Whites (ref: non-whites) 0.078 0.155 0.505 0.614 
 
Urban (ref: rural) 
 
-0.184 0.129 -1.431 0.153 
Year of index prescription (ref: 2001) 
• 1998  0.044 0.187 0.233 0.815 
• 1999 0.478 0.177 2.705 0.007* 
• 2000 0.340 0.166 2.045 0.041* 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.050 0.014 3.509 0.000* 
Total health costs 
     
0.000 0.000 -1.370 0.171 
Charlson co-morbidity 
            
0.123 0.042 2.947 0.003* 
Number of therapeutic classes 
of medications 
 
0.077 0.022 3.443 0.001* 
Cardio-vascular 
 
0.074 0.079 0.935 0.350 
Cancer 
 
-0.409 0.197 -2.074 0.038* 
Asthma 
 
-0.017 0.106 -0.163 0.871 
Ulcers 
 
0.170 0.212 0.801 0.423 
Provider interaction in the pre period 
PAAS enrollment 0.125 0.109 1.146 0.252 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.035 0.179 -0.193 0.847 
• Single pharmacy -0.001 0.073 -0.020 0.984 
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Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.290 0.283 1.026 0.305 
• Internal medicine            0.061 0.076 0.803 0.422 
 
Total diabetes costs 0.000 0.000 0.608 0.543 
 
Number of diabetes related 
ER/hosp visits 
 
0.261 0.103 2.524 0.012* 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 1.605 0.109 
Initial polytherapy 0.696 0.155 4.486 0.000* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.611 0.149 4.108 0.000* 
• Biguanides  0.150 0.077 1.940 0.053* 
• Alpha-glucosidase -0.075 0.284 -0.264 0.792 
• Sulfonyl-biguanides -0.758 0.265 -2.863 0.004* 
• Meglitinides 0.464 0.277 1.672 0.095 
   
Constant 5.781 0.326 17.728 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
Model fit statistics 
R-square: 15.6%; F = 8.331; P = 0.000 
Durbin-Watson: 1.988  
White test for heteroskedasticity:  Chi-square= 409.1604; P = 0.1625 
 
 
 
 
 
 
 
 
 
 
 
 
Table 19: Semi-log Ordinary Least Squares (OLS) regression model for the 
impact of depression on total diabetes costs (Contd.) 
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TWO-PART MODEL-PART1 
Table 20A: Logistic regression for the impact of depression on having a diabetes 
related ER/hospitalization episode in the 12-month follow-up period 
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Depression 0.331 0.150 0.028* 1.392 1.037 1.868
Demographic characteristics 
Age (in years) 0.002 0.007 0.752 1.002 0.988 1.017
Males (ref: females) 
 
-0.047 0.150 0.753 0.954 0.712 1.279
Whites (ref: non-whites) 
 
-0.057 0.309 0.853 0.944 0.515 1.731
Urban (ref: rural) 
 
0.118 0.258 0.647 1.126 0.679 1.867
Year of index prescription (ref: 2001) 
• 1998  -0.274 0.370 0.459 0.760 0.368 1.570
• 1999 0.418 0.342 0.222 1.519 0.777 2.971
• 2000 0.316 0.323 0.328 1.372 0.728 2.583
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.230 0.038 0.000* 1.259 1.169 1.355
Total health costs 
     
0.000 0.000 0.510 1.000 1.000 1.000
Charlson co-morbidity 
            
0.139 0.077 0.071 1.149 0.988 1.337
Number of therapeutic classes 
of medications 
0.106 0.042 0.012* 1.111 1.023 1.207
Cardio-vascular 
 
-0.017 0.156 0.916 0.984 0.724 1.336
Cancer 
 
-0.474 0.385 0.217 0.622 0.293 1.323
Asthma 
 
0.242 0.193 0.209 1.274 0.873 1.858
Ulcers 
 
0.673 0.392 0.085 1.961 0.910 4.224
Provider interaction in the pre period 
PAAS enrollment -0.065 0.215 0.761 0.937 0.614 1.428
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.193 0.375 0.606 1.213 0.582 2.529
• Single pharmacy 0.065 0.144 0.649 1.068 0.806 1.415
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.306 0.517 0.553 1.359 0.493 3.742
• Internal medicine          0.150 0.146 0.304 1.162 0.873 1.547
Total diabetes costs 0.000 0.000 0.664 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.464 0.199 0.020* 1.590 1.077 2.348
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.978 1.000 0.999 1.001
Initial polytherapy 0.249 0.289 0.389 1.283 0.728 2.261
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.005 0.279 0.985 1.005 0.582 1.737
• Biguanides  -0.066 0.151 0.662 0.936 0.696 1.259
• Alpha-glucosidase -0.928 0.672 0.168 0.395 0.106 1.477
• Sulfonylurea-biguanide    -0.595 0.519 0.251 0.552 0.200 1.524
• Meglitinides -0.036 0.540 0.947 0.965 0.335 2.778
Constant -2.247 0.646 0.001 0.106  
       
* Significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
Model fit statistics: 
 
Pseudo R-square = 19.6% 
-2 Log Likelihood = 1350.585; χ2  = 189.547, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 4.653; p= 0.794 
 
 
 
 
 
 
 
 
 
 
 
Table 20A: Logistic regression for the impact of depression on having a diabetes 
related ER/Hosp episode the 12-month follow-up period (Contd.) 
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TWO-PART MODEL-PART 2 
Table 20B: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on diabetes related ER/hospitalization costs  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
     
Depression  0.232 0.209 1.109 0.268 
Demographic characteristics 
Age (in years) 
 
0.024 0.011 2.277 0.023* 
Males (ref: females) 
 
0.246 0.213 1.155 0.249 
Whites (ref: non-whites) 
 
0.025 0.448 0.056 0.955 
Urban (ref: rural) 
 
-0.618 0.377 -1.638 0.102 
Year of index prescription (ref: 2001) 
• 1998  0.610 0.483 1.263 0.208 
• 1999 0.599 0.440 1.360 0.175 
• 2000 0.256 0.421 0.610 0.543 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.015 0.027 0.550 0.583 
Total health costs 
     
0.000 0.000 0.645 0.519 
Charlson co-morbidity 
            
0.017 0.090 0.188 0.851 
Number of therapeutic classes 
of medications 
0.123 0.057 2.141 0.033* 
Cardio-vascular 
 
0.098 0.229 0.428 0.669 
Cancer 
 
-0.064 0.490 -0.131 0.896 
Asthma 
 
-0.194 0.246 -0.789 0.431 
Ulcers 
 
0.415 0.429 0.967 0.334 
Provider interaction in the pre period 
PAAS enrollment 0.184 0.295 0.623 0.534 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.444 0.560 0.793 0.428 
• Single pharmacy -0.036 0.200 -0.178 0.859 
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Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.035 0.652 0.053 0.957 
• Internal medicine        
   
-0.009 0.200 -0.044 0.965 
Total diabetes costs 
 
0.000 0.000 0.388 0.698 
Number of diabetes related 
ER/Hosp visits 
 
0.181 0.217 0.833 0.405 
Gap between index diagnosis 
and prescription 
 
0.000 0.001 0.792 0.429 
Initial polytherapy 
 
-0.711 0.417 -1.705 0.089 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.133 0.373 0.358 0.721 
• Biguanides  0.006 0.211 0.028 0.978 
• Alpha-glucosidase -2.114 0.928 -2.277 0.023* 
• Sulfonyl-biguanides 0.296 0.771 0.384 0.701 
• Meglitinides 0.478 0.772 0.619 0.536 
   
Constant 5.671 0.887 6.390 0.000 
* significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
Model fit statistics: 
 
R-square: 13.5%; F = 1.748; P = 0.010 
Durbin-Watson: 2.004 
White test for heteroskedasticity: Chi-square = 272.42; p= 0.7762 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 20B: Semi-log Ordinary Least Squares (OLS) regression model for the 
impact of depression on diabetes related ER/Hospitalization costs (Contd.) 
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TWO-PART MODEL-PART1 
Table 21A: Logistic regression for the impact of depression on having a diabetes 
related outpatient episode  
 Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
Depression -0.118 0.221 0.594 0.889 0.576 1.371
Demographic characteristics 
Age (in years) -0.008 0.010 0.402 0.992 0.972 1.011
Males (ref: females) 
 
0.223 0.215 0.299 1.250 0.821 1.903
Whites (ref: non-whites) 
 
0.289 0.381 0.448 1.335 0.633 2.814
Urban (ref: rural) 
 
-0.181 0.382 0.635 0.834 0.395 1.763
Year of index prescription (ref: 2001) 
• 1998  -0.995 0.612 0.104 0.370 0.111 1.228
• 1999 -0.013 0.598 0.983 0.987 0.306 3.188
• 2000 0.288 0.586 0.623 1.333 0.423 4.206
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.045 0.048 0.349 1.046 0.952 1.148
Total health costs 
     
0.000 0.000 0.000* 1.000 1.000 1.000
Charlson co-morbidity 
            
0.051 0.155 0.742 1.052 0.777 1.425
Number of therapeutic classes 
of medications 
-0.078 0.061 0.203 0.925 0.820 1.043
Cardio-vascular 
 
0.802 0.222 0.000* 2.230 1.444 3.446
Cancer 
 
0.910 0.832 0.274 2.484 0.487 12.675
Asthma 
 
-0.028 0.329 0.933 0.973 0.511 1.852
Ulcers 
 
-0.006 0.665 0.993 0.994 0.270 3.659
Provider interaction in the pre period 
PAAS enrollment 0.256 0.325 0.431 1.292 0.683 2.443
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.648 0.446 0.147 0.523 0.218 1.254
• Single pharmacy -0.414 0.210 0.049* 0.661 0.438 0.997
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Beta S.E. Sig. 
(p) 
Odds 
ratio
95% C.I. for 
Odds ratio
    Lower Upper
 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.607 1.065 0.568 1.836 0.228 14.788
• Internal medicine          0.334 0.230 0.147 1.396 0.890 2.192
Total diabetes costs 0.000 0.000 0.793 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
-0.068 0.332 0.838 0.934 0.487 1.791
Gap between index diagnosis 
and prescription 
 
0.001 0.001 0.504 1.001 0.999 1.002
Initial polytherapy 1.092 0.619 0.078 2.981 0.886 10.028
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -0.049 0.508 0.924 0.953 0.352 2.576
• Biguanides  -0.013 0.221 0.954 0.987 0.640 1.524
• Alpha-glucosidase -0.276 0.669 0.680 0.759 0.205 2.814
• Sulfonylurea-biguanide    -0.314 1.208 0.795 0.730 0.068 7.788
• Meglitinides -0.526 0.680 0.440 0.591 0.156 2.243
Constant 2.589 0.968 0.007 13.320  
  
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
Model fit statistics: 
 
Pseudo R-square = 14.9% 
-2 Log Likelihood = 759.410; χ2  = 97.180, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 5.411; p= 0.713 
 
 
 
 
 
 
 
 
 
Table 21A: Logistic regression for the impact of depression on having a diabetes 
related outpatient episode (Contd.) 
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TWO-PART MODEL-PART 2 
Table 21B: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on diabetes related outpatient costs  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
     
Depression  0.065 0.091 0.717 0.473 
Demographic characteristics 
Age (in years) -0.007 0.004 -1.519 0.129 
 
Males (ref: females) 
 
-0.054 0.087 -0.619 0.536 
Whites (ref: non-whites) 0.120 0.183 0.654 0.513 
 
Urban (ref: rural) 
 
-0.176 0.148 -1.190 0.234 
Year of index prescription (ref: 2001) 
• 1998  -0.095 0.214 -0.445 0.656 
• 1999 0.056 0.199 0.279 0.780 
• 2000 0.308 0.188 1.639 0.101 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.030 0.017 1.721 0.085 
Total health costs 
     
0.000 0.000 -1.157 0.247 
Charlson co-morbidity 
            
0.102 0.047 2.154 0.031 
Number of therapeutic classes 
of medications 
0.000 0.026 -0.012 0.990 
Cardio-vascular 
 
0.293 0.093 3.147 0.002* 
Cancer 
 
-0.036 0.222 -0.162 0.872 
Asthma 
 
0.005 0.122 0.043 0.966 
Ulcers 
 
0.123 0.243 0.508 0.611 
Provider interaction in the pre period 
PAAS enrollment 0.398 0.125 3.183 0.001* 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.329 0.212 -1.554 0.121 
• Single pharmacy -0.017 0.084 -0.201 0.841 
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Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.199 0.318 0.628 0.530 
• Internal medicine          -0.125 0.088 -1.427 0.154 
 
Total diabetes costs 0.000 0.000 0.921 0.357 
 
Number of diabetes related 
ER/Hosp visits 
 
-0.013 0.116 -0.116 0.908 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 1.823 0.069 
Initial polytherapy 0.428 0.175 2.455 0.014* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -0.175 0.168 -1.044 0.297 
• Biguanides  -0.104 0.089 -1.175 0.240 
• Alpha-glucosidase -0.072 0.336 -0.215 0.830 
• Sulfonyl-biguanides -0.813 0.296 -2.747 0.006* 
• Meglitinides -0.073 0.328 -0.222 0.824 
   
Constant 5.498 0.378 14.531 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
Model fit statistics: 
R-square: 7.6%; F = 3.080; P = 0.010 
Durbin-Watson: 2.009 
White test for heteroskedasticity: χ2= 328.00; p= 0.8161 
 
 
 
 
 
 
 
 
 
 
Table 21B: Semi-log Ordinary Least Squares (OLS) regression model for the 
impact of depression on diabetes related outpatient costs (Contd.) 
 202
Table 22: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on diabetes prescription costs  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
     
Depression  0.067 0.065 1.033 0.302 
Demographic characteristics 
Age (in years) 0.005 0.003 1.714 0.087 
 
Males (ref: females) 
 
0.040 0.062 0.649 0.517 
Whites (ref: non-whites) 0.124 0.127 0.972 0.331 
 
Urban (ref: rural) 
 
0.009 0.106 0.081 0.935 
Year of index prescription (ref: 2001) 
• 1998  0.315 0.154 2.046 0.041* 
• 1999 0.521 0.145 3.586 0.000* 
• 2000 0.200 0.137 1.463 0.144 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
-0.030 0.012 -2.554 0.011* 
Total health costs 
     
0.000 0.000 0.319 0.750 
Charlson co-morbidity 
            
0.010 0.034 0.279 0.780 
Number of therapeutic classes 
of medications 
 
0.042 0.018 2.285 0.022* 
Cardio-vascular 
 
0.028 0.065 0.427 0.670 
Cancer 
 
-0.218 0.162 -1.342 0.180 
Asthma 
 
-0.162 0.088 -1.848 0.065 
Ulcers 
 
-0.238 0.174 -1.363 0.173 
Provider interaction in the pre period 
PAAS enrollment 0.004 0.090 0.042 0.966 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.057 0.148 -0.388 0.698 
• Single pharmacy 0.058 0.060 0.954 0.340 
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Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.413 0.233 1.777 0.076 
• Internal medicine          0.047 0.063 0.742 0.458 
 
Total diabetes costs 0.000 0.000 0.873 0.383 
 
Number of diabetes related 
ER/Hosp visits 
 
0.063 0.085 0.746 0.456 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.680 0.497 
Initial polytherapy 1.210 0.128 9.482 0.000* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 1.270 0.122 10.368 0.000* 
• Biguanides  0.568 0.064 8.935 0.000* 
• Alpha-glucosidase 0.544 0.233 2.330 0.020* 
• Sulfonyl-biguanides -0.552 0.218 -2.534 0.011* 
• Meglitinides 0.893 0.228 3.913 0.000* 
   
Constant 4.527 0.268 16.868 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
 
 
Model fit statistics: 
 
R-square: 19.9%; F = 10.450; P = 0.00 
Durbin-Watson: 1.939 
White test for heteroskedasticity: χ2 = 398.14; p= 0.0705 
 
 
 
 
 
 
 
 
 
Table 22: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on diabetes prescription costs (Contd.) 
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Table 23: Negative binomial model for the impact of depression on number of 
diabetes related ER/Hosp episodes  
 Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
     
Depression  0.456 0.123 13.740 0.000* 
Demographic characteristics 
Age (in years) 0.001 0.006 0.020 0.902 
 
Males (ref: females) 
 
0.173 0.123 2.000 0.157 
Whites (ref: non-whites) -0.284 0.244 1.350 0.245 
 
Urban (ref: rural) 
 
0.146 0.225 0.420 0.517 
Year of index prescription (ref: 2001) 
• 1998  -0.090 0.300 0.090 0.764 
• 1999 0.364 0.275 1.750 0.186 
• 2000 0.368 0.264 1.940 0.164 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.149 0.024 37.880 0.000* 
Total health costs 
     
0.000 0.000 0.290 0.589 
Charlson co-morbidity 
            
0.059 0.058 1.050 0.306 
Number of therapeutic classes 
of medications 
 
0.062 0.034 3.280 0.070 
Cardio-vascular 
 
-0.060 0.131 0.210 0.648 
Cancer 
 
-0.308 0.299 1.060 0.303 
Asthma 
 
0.192 0.153 1.580 0.208 
Ulcers 
 
0.202 0.305 0.440 0.507 
Provider interaction in the pre period 
PAAS enrollment -0.095 0.175 0.290 0.587 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.081 0.306 0.070 0.792 
• Single pharmacy 0.076 0.119 0.410 0.524 
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Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.457 0.392 1.360 0.243 
• Internal medicine          0.197 0.120 2.710 0.100 
 
Total diabetes costs 0.000 0.000 1.060 0.303 
 
Number of diabetes related 
ER/Hosp visits 
 
0.452 0.135 11.210 0.001* 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.350 0.555 
Initial polytherapy 0.318 0.240 1.760 0.185 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.085 0.222 0.150 0.701 
• Biguanides  -0.070 0.123 0.320 0.572 
• Alpha-glucosidase -0.758 0.533 2.020 0.155 
• Sulfonyl-biguanides -0.573 0.452 1.600 0.205 
• Meglitinides 0.059 0.440 0.020 0.893 
   
Constant -1.782 0.523 11.620 0.001 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
 
Model fit statistics: 
 
-2log likelihood= 2281.1894; χ2= 205.37; p= 0.000 
Dispersion estimate: 1.4288; χ2= 236.39; p = 0.000 
 
 
 
 
 
 
 
 
 
 
 
Table 23: Negative binomial model for the impact of depression on number of diabetes 
related ER/Hosp episodes (Contd.) 
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Table 24: Negative binomial model for the impact of depression on number of 
diabetes related physician office visits  
 Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
     
Depression  0.063 0.081 0.610 0.435 
Demographic characteristics 
Age (in years) 0.008 0.004 4.070 0.044* 
 
Males (ref: females) 
 
-0.042 0.078 0.290 0.592 
Whites (ref: non-whites) 0.195 0.166 1.380 0.240 
 
Urban (ref: rural) 
 
0.037 0.137 0.070 0.788 
Year of index prescription (ref: 2001) 
• 1998  -0.374 0.193 3.750 0.053* 
• 1999 -0.031 0.180 0.030 0.865 
• 2000 0.080 0.170 0.220 0.639 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.006 0.016 0.150 0.694 
Total health costs 
     
0.000 0.000 5.420 0.020* 
Charlson co-morbidity 
            
0.031 0.043 0.520 0.469 
Number of therapeutic classes 
of medications 
 
-0.020 0.023 0.750 0.385 
Cardio-vascular 
 
0.055 0.085 0.420 0.517 
Cancer 
 
-0.029 0.198 0.020 0.886 
Asthma 
 
-0.030 0.108 0.080 0.782 
Ulcers 
 
0.138 0.211 0.430 0.512 
Provider interaction in the pre period 
PAAS enrollment 0.055 0.112 0.240 0.626 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.185 0.193 0.920 0.337 
• Single pharmacy -0.013 0.077 0.030 0.863 
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Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
Diabetes severity  
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.474 0.280 2.870 0.090 
• Internal medicine          0.149 0.080 3.480 0.062 
 
Total diabetes costs 0.000 0.000 0.550 0.457 
 
Number of diabetes related 
ER/Hosp visits 
 
-0.023 0.106 0.050 0.829 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.610 0.434 
Initial polytherapy 0.337 0.156 4.660 0.031* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.295 0.150 3.900 0.048* 
• Biguanides  0.074 0.080 0.840 0.358 
• Alpha-glucosidase 0.369 0.289 1.630 0.202 
• Sulfonyl-biguanides -0.217 0.268 0.650 0.419 
• Meglitinides -0.065 0.292 0.050 0.825 
   
Constant 0.332 0.348 0.910 0.340 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
Model fit statistics: 
 
-2loglikelihood= 5437.492; χ2= 58.82; p = 0.0013 
Dispersion estimate: 1.2206; χ2= 1510.38; p= 0.000 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 24: Negative binomial model for the impact of depression on number of 
diabetes related physician office visits (Contd.) 
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Table 25: Negative binomial model for the impact of depression on number of 
diabetes prescriptions  
 Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
     
Depression  -0.059 0.035 2.850 0.091 
Demographic characteristics 
Age (in years) 0.004 0.002 4.460 0.035* 
 
Males (ref: females) 
 
0.003 0.033 0.010 0.940 
Whites (ref: non-whites) 0.111 0.070 2.530 0.112 
 
Urban (ref: rural) 
 
0.044 0.057 0.580 0.446 
Year of index prescription (ref: 2001) 
• 1998  0.045 0.083 0.300 0.584 
• 1999 0.104 0.078 1.780 0.183 
• 2000 0.086 0.073 1.370 0.241 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
-0.023 0.007 11.490 0.001* 
Total health costs 
     
0.000 0.000 2.010 0.156 
Charlson co-morbidity 
            
-0.023 0.019 1.480 0.224 
Number of therapeutic classes 
of medications 
 
0.027 0.010 7.390 0.007* 
Cardio-vascular 
 
0.023 0.036 0.400 0.528 
Cancer 
 
-0.144 0.089 2.640 0.104 
Asthma 
 
-0.078 0.048 2.670 0.103 
Ulcers 
 
-0.063 0.096 0.420 0.515 
Provider interaction in the pre period 
PAAS enrollment 0.023 0.048 0.230 0.635 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.028 0.080 0.120 0.727 
• Single pharmacy 0.038 0.033 1.340 0.247 
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Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.241 0.122 3.920 0.048* 
• Internal medicine          0.001 0.034 0.000 0.985 
 
Total diabetes costs 0.000 0.000 4.060 0.044* 
 
Number of diabetes related 
ER/Hosp visits 
 
0.011 0.045 0.060 0.808 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 1.580 0.209 
Initial polytherapy 0.672 0.064 111.710 0.000* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.043 0.065 0.440 0.507 
• Biguanides  -0.065 0.034 3.530 0.060 
• Alpha-glucosidase 0.082 0.125 0.440 0.509 
• Sulfonyl-biguanides -0.627 0.114 30.380 0.000* 
• Meglitinides -0.115 0.125 0.840 0.359 
   
Constant 1.866 0.146 164.030 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
 
Model fit statistics: 
 
-2loglikelhiood = 7956.926; χ2= 197.66; p= 0.000 
Dispersion estimate: 0.1987; χ2 =943.91; p=0.000 
 
 
 
 
 
Table 25: Negative binomial model for the impact of depression on number of diabetes 
prescriptions (Contd.) 
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Discussion for Objective 7 
The study results demonstrated that patients with depression had nearly 21.00% 
higher type 2 diabetes related costs as compared to patients without depression.  These 
estimates were obtained after adjusting for a number of baseline confounding factors such 
as demographics, co-morbidity, diabetes severity, and interaction with health care 
providers.   This is to our knowledge the first study in literature to examine the impact of 
depression on type 2 diabetes related utilization and expenditures.  Adjusted smearing 
estimates indicated that an excess of $ 451.27 type 2 diabetes costs were attributable to 
presence of depression in the 12-month follow up period.  
Most of the studies in this area have examined the impact of depression on total 
health care costs.  One of the reasons that our study examined type 2 diabetes related 
costs was that we hypothesized that excess type 2 diabetes related costs in depressed 
patients could be attributable to the impact of depression on decreasing adherence with 
oral hypoglycemics. Also, our study examined the breakdown of these excess 
expenditures in detail. This can help us identify cost drivers and provide an explanation 
for any observed differences in type 2 diabetes expenditures.  Our results indicated that 
increased type 2 diabetes costs in patients with depression were primarily due to 
increased probability of diabetes related ER/hospitalization episodes.  This information 
may be an important lead for exploring future research in this area.  
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Results for Objective 8 
To estimate the impact of preexisting depression on overall health care utilization and 
costs  
All medical and prescription claims in the follow up period were identified for 
this analysis, irrespective of diagnosis codes (except those due to depressive diagnosis).  
The costs were also examined separately in terms of ER/ hospitalization costs, outpatient 
costs, and pharmacy costs.  Along with expenditures in terms of dollar amounts, overall 
utilization such as number of ER/hospitalization episodes, number of physician office 
visits, and number of prescriptions were also compared between depressed and non-
depressed patients.   
Overall health care costs 
Univariate results for the overall health care costs in the 12-month follow up 
period are reported in Table 26.  The results indicated that health care costs were 
significantly higher for depressed patients ($9,809.07 +12,293.26) as compared to non-
depressed patients ($6,833.37 +12,369.62).  Significant differences were observed in all 
categories of costs such as outpatient costs, ER/hospitalization costs, and prescription 
costs.  Patients with depression ($3,057.74 +7,764.26) had significantly higher 
ER/hospitalization costs as compared to non-depressed patients ($1,909.12 + 6,429.12). 
Outpatient costs were also higher for depressed patients ($3,654.98 +7087.62) as 
compared to non-depressed patients ($2,808.49 + 9,424.36).  Differences in prescription 
costs were also observed with depressed patients ($3,096.35 +2,479.97) incurring 
significantly higher prescription costs as compared to non-depressed patients ($2,115.76 
+ 1,912.47).   
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Semi-log Ordinary Least Squares (OLS) regression techniques were used for the 
estimation of the impact of preexisting depression on total costs associated with type 2 
diabetes controlling for other confounding factors.  The semi-log OLS model was found 
to be significant with a R-square value of 36.90%.  The model results are summarized in 
Tables 27.  Robust standard errors are reported as the model was found to be 
heteroskedastic.  Results of the multivariate model indicated that controlling for 
confounding covariates, patients with depression incurred 32.11% higher health care 
costs as compared to non-depressed patients in the 12-month follow up period (p= 0.000).  
Retransformation using smearing estimates indicated that an excess of $1,864.52 in total 
health care costs (excluding those due to depressive diagnosis) are due to depression.   
In models where the dependent variables are specific costs such as those due to 
ER/hospitalization visits, a two-part model was used in this case to estimate the impact of 
depression on ER/hospitalization (Tables 28A-28B).  An initial multivariate logistic 
regression model to estimate the impact of depression on a ER/hospitalization episode 
demonstrated that depressed patients were nearly 1.7 times more likely to have a 
ER/hospitalization episode as compared to non-depressed patients (p=0.000).  A 
subsequent semi-logarithmic OLS model, which was conducted only on those patients 
having an ER/hospitalization episode revealed no significant differences in 
ER/hospitalization costs between depressed and non-depressed patients. 
As all patients incurred outpatient and prescription costs, semi-log OLS models 
were used to estimate the impact of depression on these costs in a multivariate 
framework.   The semi-log OLS model for outpatient costs was found to be significant 
with a R-square value of 28.00%.  The model results are summarized in Table 29.  
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Results of the multivariate model indicated that controlling for confounding covariates, 
patients with depression incurred nearly 38.00% higher outpatient costs as compared to 
non-depressed patients in the 12-month follow up period (p= 0.000).  Retransformation 
using smearing estimates indicated that an excess of $732.65 in total outpatient costs 
(excluding those due to depressive diagnosis) were attributed to depression.   
The semi-log OLS model for prescription costs was found to be significant with a 
R-square value of 33.5%.  The model results are summarized in Table 30.  Results of the 
multivariate model indicated that controlling for confounding covariates, patients with 
depression incurred nearly 30.85% higher prescription costs as compared to non-
depressed patients in the 12-month follow up period (p= 0.000).  Retransformation using 
smearing estimates indicated that an excess of $627.75 in total prescription costs 
(excluding those due to depressive diagnosis) were attributed to depression.   
Health care utilization 
In the 12-month follow up period, significant differences were observed in terms 
of all the utilization related variables (Table 26).  Depressed patients (2.33 +3.88) had 
twice as many ER/hospitalization episodes as compared to non-depressed patients (1.14 
+2.20).  Patients with depression (71.35 +36.42) also had significantly higher number of 
prescriptions as compared to non-depressed patients (53.79 +32.99).  Univariate results 
also indicated that the number of physician office visits were significantly higher for 
depressed patients (10.44 +9.98) as compared to non-depressed patients (6.63 +6.27).   
Negative binomial models were used for estimation of all the utilization related 
variables.  Results of the negative binomial models indicated that significant differences 
were observed on all the utilization parameters between the two groups in a multivariate 
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framework (Tables 31-33).  Multivariate results indicated that controlling baseline 
covariates, patients with depression had 48.14% higher number of ER/Hospitalization 
episodes as compared to non-depressed patients (p= 0.000).  Patients with depression also 
had 28.78% higher number of physician office visits as compared to non-depressed 
patients (p=0.000).  Similar results were observed in terms of prescription utilization with 
depression patients filling 16.76% higher number of prescriptions in the 12-month follow 
up period (p=0.000). 
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Table 26: Utilization and expenditures for overall health care  
(excluding those due to depression ) in the 12-month follow up period  
        Depressed                Non-depressed        Mann-Whitney     Sig. 
      (Mean +S.D.)               (Mean + S.D.)            U test               (p) 
         (N = 471)          (N = 855)                                                               
 
Overall health care costs (in dollars) 
 
Outpatient costs                 3,654.98                       2,808.49          146647.00  0.000* 
     +7,087.62                     + 9,424.36 
 
ER/Hosp costs          3,057.74            1,909.12          158711.50  0.000* 
     +7,764.26            + 6,429.12 
 
Pharmacy costs                  3,096.35                       2,115.76      141544.00  0.000* 
   +2,479.97             + 1,912.47   
     
Total costs                   9,809.07             6,833.37          140387.00  0.000* 
  +12,293.26          +12,369.62 
 
Overall health care utilization  
 
Number of physician    10.44 +9.98                   6.63 +6.27                149043.50  0.000* 
office visits              
 
Number of ER/hosp        2.33 +3.88                   1.14 +2.20                154814.50  0.000*  
visits 
      
Number of Rxs             71.35 +36.42               53.79 +32.99                141781.50  0.000* 
 
*Significance at the 0.05 level 
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Table 27: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on total healthcare costs (excluding depression costs)  
 Beta Robust
S.E.
Test statistic 
(t) 
Sig. 
(p) 
     
Depression  0.280 0.055 5.133 0.000* 
Demographic characteristics 
Age (in years) 0.006 0.003 2.245 0.025* 
 
Males (ref: females) 
 
-0.025 0.055 -0.462 0.644 
Whites (ref: non-whites) 0.056 0.099 0.566 0.572 
 
Urban (ref: rural) 
 
-0.203 0.093 -2.185 0.029* 
Year of index prescription (ref: 2001) 
• 1998  0.164 0.121 1.350 0.177 
• 1999 0.174 0.115 1.520 0.129 
• 2000 0.156 0.103 1.523 0.128 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.023 0.012 1.935 0.053* 
Total health costs 
     
0.000 0.000 9.967 0.000* 
Charlson co-morbidity 
            
0.060 0.027 2.204 0.028* 
Number of therapeutic classes 
of medications 
0.107 0.015 7.162 0.000* 
Cardio-vascular 
 
0.029 0.055 0.524 0.601 
Cancer 
 
-0.134 0.114 -1.172 0.241 
Asthma 
 
0.108 0.066 1.654 0.098 
Ulcers 
 
0.209 0.138 1.515 0.130 
Provider interaction in the pre period 
PAAS enrollment 0.062 0.078 0.801 0.423 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.156 0.163 -0.960 0.337 
• Single pharmacy -0.043 0.050 -0.863 0.388 
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Beta Robust
S.E.
Test statistic 
(t) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.188 0.187 1.008 0.314 
• Internal medicine          0.053 0.053 0.989 0.323 
 
Total diabetes costs 0.000 0.000 -1.970 0.049* 
 
Number of diabetes related 
ER/Hosp visits 
 
0.141 0.066 2.133 0.033* 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 1.033 0.302 
Initial polytherapy 0.228 0.086 2.649 0.008* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.182 0.103 1.765 0.078 
• Biguanides  0.058 0.052 1.129 0.259 
• Alpha-glucosidase 0.060 0.143 0.423 0.672 
• Sulfonyl-biguanides -0.296 0.164 -1.804 0.071 
• Meglitinides 0.063 0.176 0.357 0.721 
   
Constant 7.357 0.231 31.907 0.000 
* Significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
Model fit statistics: 
 
R-square: 36.9%; F = 24.536; P = 0.000 
Durbin-Watson: 1.931  
White test for heteroskedasticity: Chi-square = 495.31; P= 0.0001 
 
 
 
 
 
 
 
 
 
 
 
Table 27: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on total healthcare costs (excluding depression costs) (Contd.) 
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TWO-PART MODEL-PART 1 
Table 28A: Logistic regression for the impact of depression on having an 
ER/Hospitalization episode (excluding depression)  
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Depression 0.524 0.139 0.000* 1.689 1.285 2.220
Demographic characteristics 
Age (in years) -0.005 0.007 0.406 0.995 0.982 1.007
Males (ref: females) 
 
-0.170 0.133 0.200 0.844 0.651 1.094
Whites (ref: non-whites) 
 
-0.124 0.272 0.648 0.883 0.518 1.505
Urban (ref: rural) 
 
-0.080 0.225 0.722 0.923 0.594 1.435
Year of index prescription (ref: 2001) 
• 1998  0.103 0.337 0.761 1.108 0.572 2.147
• 1999 0.239 0.319 0.453 1.270 0.680 2.371
• 2000 0.241 0.300 0.422 1.273 0.707 2.294
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.411 0.053 0.000* 1.508 1.359 1.674
Total health costs 
     
0.000 0.000 0.511 1.000 1.000 1.000
Charlson co-morbidity 
            
0.198 0.085 0.019* 1.219 1.033 1.440
Number of therapeutic classes 
of medications 
0.041 0.040 0.310 1.041 0.963 1.126
Cardio-vascular 
 
-0.238 0.140 0.090 0.788 0.599 1.038
Cancer 
 
-0.449 0.364 0.217 0.638 0.313 1.303
Asthma 
 
0.355 0.198 0.073 1.427 0.968 2.103
Ulcers 
 
0.291 0.435 0.504 1.338 0.570 3.140
Provider interaction in the pre period 
PAAS enrollment 0.157 0.195 0.422 1.169 0.798 1.713
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.119 0.308 0.699 1.126 0.616 2.058
• Single pharmacy -0.131 0.129 0.309 0.877 0.681 1.129
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.013 0.509 0.980 1.013 0.373 2.747
• Internal medicine          0.155 0.137 0.259 1.168 0.892 1.529
Total diabetes costs 0.000 0.000 0.902 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.015 0.216 0.945 1.015 0.665 1.549
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.457 1.000 0.999 1.000
Initial polytherapy 0.112 0.268 0.676 1.119 0.661 1.892
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.155 0.268 0.564 1.167 0.691 1.972
• Biguanides  0.103 0.137 0.450 1.109 0.848 1.451
• Alpha-glucosidase -0.374 0.522 0.474 0.688 0.247 1.915
• Sulfonylurea-biguanide    -0.189 0.459 0.681 0.828 0.336 2.036
• Meglitinides 0.104 0.476 0.827 1.109 0.436 2.821
Constant -0.378 0.584 0.517 0.685  
    
*Significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
 
Model fit statistics: 
 
Pseudo R-square = 21.8% 
-2 Log Likelihood = 1559.939; χ2  = 230.150, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 16.207; p= 0.040 
 
 
 
 
 
 
 
 
 
Table 28A: Logistic regression for the impact of depression on having an 
ER/hospitalization episode (excluding depression) (Contd.) 
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TWO-PART MODEL-PART 2 
Table 28B: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on total ER/hospitalization costs (excluding depression)  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
     
Depression  0.154 0.155 0.994 0.321 
Demographic characteristics 
Age (in years) 0.022 0.007 2.890 0.004* 
 
Males (ref: females) 
 
0.194 0.159 1.217 0.224 
Whites (ref: non-whites) 0.238 0.316 0.752 0.452 
 
Urban (ref: rural) 
 
-0.170 0.265 -0.643 0.520 
Year of index prescription (ref: 2001) 
• 1998  0.605 0.379 1.599 0.110 
• 1999 0.462 0.356 1.300 0.194 
• 2000 0.267 0.339 0.786 0.432 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.087 0.023 3.774 0.000* 
Total health costs 
     
0.000 0.000 2.119 0.034* 
Charlson co-morbidity 
            
0.079 0.075 1.056 0.291 
Number of therapeutic classes 
of medications 
0.115 0.044 2.622 0.009* 
Cardio-vascular 
 
0.157 0.162 0.966 0.334 
Cancer 
 
-0.442 0.383 -1.155 0.248 
Asthma 
 
-0.030 0.190 -0.155 0.877 
Ulcers 
 
0.873 0.365 2.388 0.017* 
Provider interaction in the pre period 
PAAS enrollment -0.009 0.214 -0.043 0.966 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.543 0.401 1.355 0.176 
• Single pharmacy -0.045 0.150 -0.300 0.764 
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Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.516 0.536 0.963 0.336 
• Internal medicine          -0.007 0.151 -0.045 0.964 
 
Total diabetes costs 0.000 0.000 -0.091 0.928 
 
Number of diabetes related 
ER/Hosp visits 
 
0.288 0.189 1.526 0.128 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.503 0.615 
Initial polytherapy -0.230 0.323 -0.711 0.478 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.265 0.291 0.911 0.363 
• Biguanides  0.019 0.158 0.123 0.902 
• Alpha-glucosidase -0.935 0.587 -1.593 0.112 
• Sulfonyl-biguanides 0.062 0.559 0.111 0.912 
• Meglitinides -0.461 0.563 -0.819 0.413 
   
Constant 4.436 0.660 6.722 0.000 
*Significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
Model fit statistics: 
 
R-square: 17.0%; F = 4.321; P = 0.000 
Durbin-Watson: 2.109 
White test for heteroskedasticity: χ2= 408.66; p= 0.3850 
  
 
 
 
 
 
 
 
 
 
 
Table 28B: Semi-log Ordinary Least Squares (OLS) regression model for the 
impact of depression on total ER/hospitalization costs (excluding depression) 
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Table 29: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on total outpatient costs (excluding depression)  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
      
Depression  0.325 0.077 4.226 0.000* 
Demographic characteristics 
Age (in years) -0.006 0.004 -1.607 0.108 
 
Males (ref: females) 
 
-0.168 0.074 -2.278 0.023* 
Whites (ref: non-whites) 0.070 0.151 0.464 0.643 
 
Urban (ref: rural) 
 
-0.271 0.126 -2.158 0.031* 
Year of index prescription (ref: 2001) 
• 1998  0.315 0.183 1.720 0.086 
• 1999 0.203 0.172 1.177 0.240 
• 2000 0.294 0.162 1.808 0.071 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.013 0.014 0.951 0.342 
Total health costs 
     
0.000 0.000 14.360 0.000* 
Charlson co-morbidity 
            
0.092 0.041 2.256 0.024* 
Number of therapeutic classes 
of medications 
 
0.008 0.022 0.345 0.730 
Cardio-vascular 
 
0.187 0.078 2.401 0.017* 
Cancer 
 
0.073 0.192 0.379 0.705 
Asthma 
 
0.233 0.104 2.243 0.025* 
Ulcers 
 
0.363 0.209 1.736 0.083 
Provider interaction in the pre period 
PAAS enrollment 0.312 0.106 2.937 0.003* 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.263 0.176 -1.494 0.135 
• Single pharmacy -0.051 0.072 -0.712 0.476 
 223
 
 
Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.183 0.276 0.665 0.506 
• Internal medicine          0.033 0.075 0.435 0.663 
 
Total diabetes costs 0.000 1.6E-05 -1.291 0.197 
 
Number of diabetes related 
ER/Hosp visits 
 
0.046 0.10086 0.456 0.648 
Gap between index diagnosis 
and prescription 
 
0.000 0.0002 1.455 0.146 
Initial polytherapy 0.277 0.15132 1.834 0.067 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -0.099 0.14598 -0.676 0.499 
• Biguanides  -0.046 0.07555 -0.614 0.539 
• Alpha-glucosidase 0.244 0.27655 0.881 0.379 
• Sulfonyl-biguanides -0.430 0.25836 -1.665 0.096 
• Meglitinides -0.094 0.27056 -0.346 0.729 
   
Constant 6.640 0.319 20.845 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
Model fit statistics: 
 
R-square: 28.0%; F = 16.254; P = 0.000 
Durbin-Watson: 1.925 
White test for heteroskedasticity: χ2 = 390.70; p= 0.9330 
 
 
 
 
 
 
 
 
 
 
 
Table 29: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on total outpatient costs (excluding depression) (Contd.) 
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Table 30: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on total prescription costs (excluding depression)  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
     
Depression   0.270 0.048 5.668 0.000* 
Demographic characteristics 
Age (in years) 0.009 0.002 3.969 0.000* 
 
Males (ref: females) 
 
-0.006 0.046 -0.132 0.895 
Whites (ref: non-whites) 0.030 0.094 0.319 0.750 
 
Urban (ref: rural) 
 
-0.057 0.078 -0.735 0.463 
Year of index prescription (ref: 2001) 
• 1998  0.018 0.113 0.159 0.874 
• 1999 0.121 0.107 1.134 0.257 
• 2000 0.068 0.101 0.673 0.501 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
-0.006 0.009 -0.700 0.484 
Total health costs 
     
0.000 0.000 5.715 0.000* 
Charlson co-morbidity 
            
0.008 0.025 0.327 0.743 
Number of therapeutic classes 
of medications 
 
0.183 0.013 13.533 0.000* 
Cardio-vascular 
 
0.068 0.048 1.406 0.160 
Cancer 
 
-0.129 0.119 -1.081 0.280 
Asthma 
 
0.059 0.064 0.910 0.363 
Ulcers 
 
0.010 0.128 0.079 0.937 
Provider interaction in the pre period 
PAAS enrollment -0.050 0.066 -0.757 0.449 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.275 0.109 -2.528 0.012* 
• Single pharmacy -0.048 0.044 -1.087 0.277 
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Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.133 0.171 0.776 0.438 
• Internal medicine          0.014 0.046 0.298 0.766 
 
Total diabetes costs 0.000 0.000 0.028 0.978 
 
Number of diabetes related 
ER/Hosp visits 
 
0.025 0.063 0.396 0.692 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.979 0.328 
Initial polytherapy 0.386 0.094 4.110 0.000* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.336 0.090 3.728 0.000* 
• Biguanides  0.126 0.047 2.680 0.007* 
• Alpha-glucosidase 0.117 0.172 0.682 0.495 
• Sulfonyl-biguanides -0.223 0.160 -1.391 0.164 
• Meglitinides 0.224 0.168 1.334 0.182 
   
Constant 6.281 0.198 31.796 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
Model fit statistics: 
 
R-square: 33.5%; F = 21.204; P = 0.000 
Durbin-Watson: 2.004 
White test for heteroskedasticity: χ2 = 459.76; p= 0.1633 
 
 
 
 
 
 
 
 
 
 
 
Table 30: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of depression on total prescription costs (excluding depression) (Contd.) 
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Table 31: Negative binomial model for the impact of depression on number of 
overall ER/hospitalization episodes (excluding depression)  
 Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
     
Depression  0.393 0.085 21.200 0.000* 
Demographic characteristics 
Age (in years) -0.002 0.004 0.290 0.592 
 
Males (ref: females) 
 
-0.002 0.085 0.000 0.981 
Whites (ref: non-whites) 0.044 0.181 0.060 0.810 
 
Urban (ref: rural) 
 
-0.009 0.146 0.000 0.948 
Year of index prescription (ref: 2001) 
• 1998  0.126 0.216 0.340 0.560 
• 1999 0.059 0.204 0.080 0.773 
• 2000 0.132 0.195 0.460 0.499 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.197 0.017 127.470 0.000* 
Total health costs 
     
0.000 0.000 0.160 0.688 
Charlson co-morbidity 
            
0.089 0.043 4.390 0.036* 
Number of therapeutic classes 
of medications 
 
0.052 0.024 4.630 0.031* 
Cardio-vascular 
 
-0.185 0.089 4.350 0.037* 
Cancer 
 
-0.210 0.216 0.950 0.330 
Asthma 
 
0.073 0.110 0.440 0.508 
Ulcers 
 
0.099 0.219 0.210 0.650 
Provider interaction in the pre period 
PAAS enrollment -0.060 0.123 0.240 0.626 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.201 0.204 0.970 0.324 
• Single pharmacy -0.173 0.083 4.350 0.037* 
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Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.118 0.298 0.160 0.692 
• Internal medicine          0.103 0.085 1.450 0.229 
 
Total diabetes costs 0.000 0.000 2.130 0.144 
 
Number of diabetes related 
ER/Hosp visits 
 
0.206 0.102 4.100 0.043* 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.270 0.604 
Initial polytherapy 0.230 0.170 1.840 0.175 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.172 0.161 1.140 0.286 
• Biguanides  -0.003 0.086 0.000 0.971 
• Alpha-glucosidase -0.641 0.355 3.260 0.071 
• Sulfonyl-biguanides -0.500 0.309 2.620 0.106 
• Meglitinides -0.134 0.323 0.170 0.678 
   
Constant -0.306 0.369 0.690 0.407 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
Model fit statistics: 
 
-2loglikelihood = 3948.0036 χ2= 377.59; p= 0.00 
Dispersion estimate: 1.0099; χ2= 799.89; p = 0.000 
 
 
 
 
 
 
 
 
 
 
 
 
Table 31: Negative binomial model for the impact of depression on number of overall 
ER/hospitalization episodes (excluding depression) (Contd.) 
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Table 32: Negative binomial model for the impact of depression on number of 
overall physician office visits (excluding depression)  
 Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
     
Depression  0.253 0.060 17.770 0.000* 
Demographic characteristics 
Age (in years) 0.002 0.003 0.260 0.613 
 
Males (ref: females) 
 
-0.121 0.058 4.330 0.037* 
Whites (ref: non-whites) 0.107 0.121 0.770 0.380 
 
Urban (ref: rural) 
 
-0.083 0.100 0.690 0.406 
Year of index prescription (ref: 2001) 
• 1998  -0.077 0.145 0.280 0.596 
• 1999 0.021 0.136 0.020 0.879 
• 2000 0.059 0.129 0.210 0.649 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.038 0.012 10.700 0.001* 
Total health costs 
     
0.000 0.000 3.250 0.072 
Charlson co-morbidity 
            
0.046 0.030 2.350 0.125 
Number of therapeutic classes 
of medications 
 
0.043 0.017 6.820 0.009* 
Cardio-vascular 
 
0.069 0.061 1.310 0.253 
Cancer 
 
0.042 0.150 0.080 0.781 
Asthma 
 
0.053 0.078 0.470 0.495 
Ulcers 
 
0.402 0.156 6.630 0.010* 
Provider interaction in the pre period 
PAAS enrollment 0.076 0.083 0.830 0.362 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.316 0.146 4.720 0.030* 
• Single pharmacy -0.089 0.057 2.420 0.120 
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Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.501 0.210 5.710 0.017* 
• Internal medicine          0.138 0.059 5.440 0.020* 
 
Total diabetes costs 0.000 0.000 0.000 0.951 
 
Number of diabetes related 
ER/Hosp visits 
 
0.008 0.080 0.010 0.925 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.690 0.405 
Initial polytherapy 0.115 0.120 0.920 0.336 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.204 0.114 3.190 0.074 
• Biguanides  0.076 0.060 1.600 0.206 
• Alpha-glucosidase 0.396 0.213 3.460 0.063 
• Sulfonyl-biguanides -0.014 0.203 0.000 0.946 
• Meglitinides 0.096 0.214 0.200 0.653 
   
Constant 1.522 0.252 36.590 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
 
 
Model fit statistics: 
 
-2loglikelihood= 7909.38; χ2= 205.05; p= 0.000 
Dispersion estimate: 0.7588; χ2 = 3819.72; p= 0.000 
 
 
 
 
 
 
 
 
 
Table 32: Negative binomial model for the impact of depression on number of overall 
physician office visits (excluding depression) (Contd.) 
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Table 33: Negative binomial model for the impact of depression on number of 
overall prescriptions (excluding depression)  
 Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
     
Depression  0.155 0.031 25.390 0.000* 
Demographic characteristics 
Age (in years) 0.008 0.002 28.870 0.000* 
 
Males (ref: females) 
 
-0.079 0.029 7.240 0.007* 
Whites (ref: non-whites) 0.028 0.061 0.210 0.643 
 
Urban (ref: rural) 
 
-0.022 0.050 0.180 0.669 
Year of index prescription (ref: 2001) 
• 1998  -0.027 0.074 0.140 0.710 
• 1999  0.003 0.069 0.000 0.968 
• 2000 -0.042 0.065 0.420 0.518 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.001 0.006 0.030 0.862 
Total health costs 
     
0.000 0.000 18.150 0.000* 
Charlson co-morbidity 
            
-0.002 0.016 0.010 0.916 
Number of therapeutic classes 
of medications 
 
0.153 0.009 303.320 0.000* 
Cardio-vascular 
 
0.048 0.031 2.410 0.120 
Cancer 
 
-0.146 0.077 3.620 0.057 
Asthma 
 
0.051 0.041 1.540 0.215 
Ulcers 
 
0.060 0.082 0.540 0.464 
Provider interaction in the pre period 
PAAS enrollment 0.012 0.043 0.070 0.786 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.181 0.072 6.260 0.012* 
• Single pharmacy -0.059 0.029 4.170 0.041* 
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Estimate S.E. Test statistic 
(Chi-square) 
Sig. 
(p) 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.142 0.110 1.670 0.197 
• Internal medicine          0.034 0.030 1.320 0.251 
 
Total diabetes costs 0.000 0.000 0.080 0.775 
 
Number of diabetes related 
ER/Hosp visits 
 
0.019 0.041 0.220 0.637 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.210 0.648 
Initial polytherapy 0.246 0.061 16.380 0.000* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -0.024 0.058 0.170 0.683 
• Biguanides  -0.025 0.030 0.690 0.406 
• Alpha-glucosidase 0.027 0.111 0.060 0.805 
• Sulfonyl-biguanides -0.272 0.104 6.880 0.009* 
• Meglitinides -0.132 0.108 1.480 0.224 
   
Constant 3.205 0.128 632.110 0.000 
*Significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
Model fit statistics: 
-2loglikelhood: 1192.86; χ2= 664.45; p= 0.000 
Dispersion estimate: 0.2128 (0.1956 – 02316); χ2= 3599.54; p= 0.000 
 
 
 
 
 
 
 
 
 
 
 
Table 33: Negative binomial model for the impact of depression on number of overall 
prescriptions (excluding depression) (Contd.) 
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Discussion for Objective 8 
Our study results indicated that patients with depression had nearly 32.10% higher 
health care costs as compared to patients without depression.  These estimates were 
obtained after adjusting for a number of baseline confounding factors such as 
demographics, co-morbidity, diabetes severity, and interaction with health care providers.      
A few studies in the literature have examined the impact of depression on health care 
costs in patients with type 2 diabetes.  Ciechanowski and associates28 showed that after 
controlling for demographics, medical comorbidity, and diabetes severity, higher levels 
of depression severity were associated with a significantly greater probability of having 
an emergency department, primary care, specialty care, medical inpatient, and mental 
health costs compared to patients with low severity depression.  The total costs of the 
high tertile group were $3,654 versus $ 2,653 in the medium depression tertile and 
$2,094 in the low tertile groups.  However, these reported costs were unadjusted and 
were calculated for a six-month period.  Also, it was a population-based study from two 
primary care clinics with relatively small sample sizes, especially for assessing costs.  
Egede and associates125 used the Medical Expenditure Panel Survey (MEPS) and showed 
that patients with depression and diabetes incurred 4.5 times greater health care costs than 
patients with diabetes alone. However, the numbers reported for excess costs seemed 
unreasonably large thus raising concerns regarding the validity of the study results.  Both 
the above studies relied on self-reported data and had small sample sizes.  Most 
importantly, these studies examined total health care costs that included costs due to 
depressive diagnosis, which will be higher for depressed patients irrespective of the 
impact of depression on other chronic illnesses.  
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The only study in literature which examined the impact of depression on non-
depression related health care costs in type 2 diabetes patients was conducted by 
Finklestein and associates127 using claims data from the 1997 Medicare 5% Standard 
Analytic Files.  The study results indicated that controlling for age, gender, race, and 
comorbidities non-mental health care costs were approximately 21.00% higher for 
depressed diabetics as compared to non-depressed diabetics.  The authors also concluded 
that depressed patients seek treatment for more services and when admitted, spend more 
time in inpatient facilities than patients without depression.  These differences in terms of 
non-depression health costs between depressed and non-depressed diabetic patients were 
lower than those obtained in our study (32.10%).  Numbers in this study may be higher 
since a more comprehensive utilization data was available for the study population as 
opposed to Medicare claims which may not be furnish information related to some 
expenditures such as prescription costs.  The cost differences may also be due to a 
younger population in this study (18-64 years of age) comprising of only newly 
diagnosed type 2 diabetes patients.    
The findings of higher health care costs among depressed patients in this study 
corresponds with the literature that in patients with diverse medical illnesses, depression 
makes a significant independent contribution to increased health care costs.113 Studies 
have shown depression to be a good predictor of symptoms commonly associated with 
worsening glucose control such as polyphagia and polydipsia.  Depressive symptoms 
may also be associated with a perception of impaired health and thus simulate worsening 
diabetes symptoms.119 Such perceptions on the part of the patient may prompt both the 
patient and provider to increase diagnostic testing, medical testing, and pursue aggressive 
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treatment strategies.  Adherence to medications and other behaviors can also be a 
mediator between depression and health care expenditures.      
 
Results for Objective 9 
 
To examine the causal pathways between preexisting depression, adherence, and 
outcomes such as resource utilization and costs for type 2 diabetes 
Earlier objectives have examined the role that depression can play in affecting 
adherence to oral hypoglycemics and type 2 diabetes related utilization and expenditures.  
The following 4 steps were used to identify whether adherence with oral hypoglycemics 
mediates the relationship between depression and type 2 diabetes outcomes.  The 
mediating relation is going to be tested using the four steps mentioned in the 
methodology section. 
 
Step 1:  If depression is a significant predictor of type 2 diabetes outcomes   
Results of a multivariate Semi-log Ordinary Least Squares (OLS) model indicated 
that controlling for confounding covariates, patients with depression incurred 21.27% 
higher type 2 diabetes costs as compared to non-depressed patients in the 12 month 
follow up period (Table 19). These cost differences were primarily due to increased 
likelihood of ER/hospitalization episodes for depressed patients.  Results from a 
multivariate logistic regression model indicated that depressed patients were nearly 1.4 
times more likely to have an ER/hospitalization episode as compared to non-depressed 
patients (Table 20A). 
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Step 2:  If depression significantly predicts adherence with oral hypoglycemics 
Results indicated that patients with depression had significantly lower adherence 
to oral hypoglycemics than non-depressed patients on the basis of both Reg MPR-1 and 
Reg MPR-2.  However, although the differences were significant the magnitude of 
difference was not large with depressed patients being only 3.00% and 6.00% less 
adherent than non-depressed patients on the Reg MPR-1 and Reg MPR-2 index 
respectively.  These estimates were found to be similar in both the univariate and 
multivariate framework (Tables 14 and 15). 
The multinomial logistic regression model for the impact of depression on 
categories of adherence (Reg MPR-1 and Reg MPR-2) also indicated similar results.  
Results of the multivariate model for Reg MPR-1 indicated that controlling for 
confounding covariates, patients with depression were 1.9 times more likely to have low 
adherence to oral hypoglycemics as compared non-depressed patients (Table 16B).  
Results from the model for Reg MPR-2 demonstrated that depressed patients were 1.6 
times more likely to be in the very low adherence group as compared to non-depressed 
patients (Table 17A).  
 
Step 3: If adherence significantly predicts outcomes while controlling for depression. 
Results from the semi-log OLS models for the effect of adherence (Reg MPR-1 
and Reg MPR-2) on type 2 diabetes related total costs were inconclusive.  A non-linear 
pattern of the effect of adherence on costs was observed with results indicating that 
patients who had very low adherence have lower costs and patients with over adherence 
have higher costs than patients with good adherence. 
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The semi-log OLS model for the impact of Reg MPR-1 on type 2 diabetes costs 
indicated that patients who were over adherent to their oral hypoglycemics medications 
incurred nearly 65.00% greater type 2 diabetes related costs than patients who were 
adherent to their medications (p=0.004) (Table 34).   However, adherence with oral 
hypoglycemics was not associated with the probability of a type 2 diabetes related 
ER/hospitalization episode (Tables 35).   
The semi-log OLS model estimating the impact of Reg MPR-2 on type 2 diabetes 
costs demonstrated that patients with very low adherence had nearly 57.00% lower costs 
as compared to patients who were adherent to their medications (p=0.000)(Table 36).  
The logistic regression model to estimate the impact of adherence (Reg MPR-2) on 
ER/hospitalization costs (Table 37) demonstrated that patients with low adherence were 
nearly 1.6 times more likely to have a diabetes related ER/hospitalization episode 
(p=0.029).  
 
Step 4: If adherence mediates the impact of depression on type 2 diabetes outcomes 
To establish that adherence completely mediates the relationship between 
depression and outcomes, the effect of depression on outcomes controlling for adherence 
should be zero. If partial mediation is exhibited then the effect of depression on outcomes 
controlling for adherence should reduce in size.  However, in both the models to estimate 
effect of adherence on type 2 diabetes costs, depression demonstrated a significant effect 
on outcomes without reducing its effect size as compared to models not controlling for 
the effect of adherence.    
A multivariate model indicated that controlling for confounding covariates other 
than adherence, patients with depression incurred 21.27% higher type 2 diabetes costs as 
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compared to non-depressed patients (Table 19).  The impact of depression on type 2 
diabetes costs remained significant even in models adjusted for adherence.  The effect 
size of depression also remained similar to the original model with adherence-adjusted 
models indicating that patients with depression incurred 23%-31% higher costs than non-
depressed patients (Table 34, 36).   
Controlling for confounding covariates other than adherence, depressed patients 
were nearly 1.4 times more likely to have an ER/hospitalization episode as compared to 
non-depressed patients (p=0.028).  (Table 20A)  This effect of depression was maintained 
in adherence-adjusted models with odds ratio of 1.537 and 1.390 for Reg MPR-1 and Reg 
MPR-2 adjusted models respectively (Table 35, 37).  The presence of mediation was 
statistically tested by comparing the estimated effects of depression on type 2 diabetes 
outcomes with and without controlling for adherence using a Hausman type statistic.  
This statistic displayed no significant differences between the estimates confirming the 
absence of adherence to oral hypoglycemic agents as a mediator between depression and 
type 2 diabetes outcomes. 
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Table 34: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of adherence (MPR-1) on total diabetes related costs  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
     
Depression  0.210 0.081 2.579 0.010* 
 
Adherence (Ref: Good adherence) 
• Very low adherence   -0.199 0.248 -0.801 0.423 
• Low adherence    -0.164 0.129 -1.263 0.207 
• Average adherence   -0.024 0.087 -0.277 0.782 
• Over adherence   0.520 0.181 2.870 0.004* 
 
Demographic characteristics 
Age (in years) 0.001 0.004 0.221 0.825 
 
Males (ref: females) 
 
0.024 0.075 0.324 0.746 
Whites (ref: non-whites) -0.027 0.163 -0.165 0.869 
 
Urban (ref: rural) 
 
-0.157 0.128 -1.225 0.221 
Year of index prescription (ref: 2001) 
• 1998  -0.252 0.190 -1.325 0.185 
• 1999 0.184 0.178 1.032 0.303 
• 2000 0.093 0.167 0.555 0.579 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.059 0.019 3.068 0.002* 
Total health costs 
     
0.000 0.000 -2.091 0.037* 
Charlson co-morbidity 
            
0.141 0.045 3.127 0.002* 
Number of therapeutic classes 
of medications 
0.043 0.023 1.910 0.057 
Cardio-vascular 
 
0.031 0.083 0.371 0.711 
Cancer 
 
-0.078 0.215 -0.363 0.716 
Asthma 
 
0.050 0.111 0.453 0.651 
Ulcers 
 
0.352 0.231 1.521 0.129 
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Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
Provider interaction in the pre period 
PAAS enrollment 0.252 0.111 2.268 0.024* 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.059 0.194 -0.306 0.760 
• Single pharmacy -0.024 0.074 -0.324 0.746 
   
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.292 0.274 1.066 0.287 
• Internal medicine          0.044 0.079 0.564 0.573 
 
Total diabetes costs 0.000 0.000 1.399 0.162 
 
Number of diabetes related 
ER/Hosp visits 
 
0.125 0.104 1.203 0.229 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.467 0.641 
Initial polytherapy 0.565 0.140 4.030 0.000* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.553 0.151 3.665 0.000* 
• Biguanides  0.279 0.079 3.534 0.000* 
• Alpha-glucosidase 0.177 0.282 0.627 0.531 
• Sulfonyl-biguanides -0.643 0.248 -2.597 0.010* 
• Meglitinides 0.676 0.285 2.370 0.018* 
   
Constant 6.646 0.339 19.602 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
Model fit statistics: 
R-square: 20.8%; F = 6.422; P = 0.000 
Durbin-Watson: 2.050 
White test for heteroskedasticity: χ2 = 465.86; p= 0.7675 
 
 
 
 
Table 34: Semi-log Ordinary Least Squares (OLS) regression model for the impact of 
adherence (Reg MPR-1) on total diabetes related costs (Contd.) 
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Table 35: Logistic regression for the impact of adherence (Reg MPR-1) on having a 
type 2 diabetes related ER/hospitalization episode  
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Depression 0.430 0.189 0.023* 1.537 1.061 2.226
Adherence (Ref: Good adherence) 
• Very low adherence   0.566 0.555 0.307 1.761 0.594 5.223
• Low adherence    0.137 0.305 0.653 1.147 0.630 2.088
• Average adherence   0.266 0.208 0.202 1.304 0.867 1.961
• Over adherence   0.378 0.415 0.362 1.459 0.647 3.290
Demographic characteristics 
Age (in years) 0.006 0.010 0.520 1.006 0.987 1.026
Males (ref: females) 
 
-0.125 0.185 0.499 0.882 0.614 1.268
Whites (ref: non-whites) 
 
0.141 0.420 0.738 1.151 0.505 2.625
Urban (ref: rural) 
 
-0.033 0.310 0.915 0.968 0.527 1.776
Year of index prescription (ref: 2001) 
• 1998  -0.513 0.461 0.266 0.599 0.243 1.477
• 1999 0.261 0.424 0.539 1.298 0.565 2.981
• 2000 0.049 0.398 0.902 1.050 0.481 2.294
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.276 0.055 0.000* 1.318 1.183 1.468
Total health costs 
     
0.000 0.000 0.971 1.000 1.000 1.000
Charlson co-morbidity 
            
0.161 0.105 0.126 1.175 0.956 1.445
Number of therapeutic classes 
of medications 
0.106 0.053 0.043* 1.112 1.003 1.233
Cardio-vascular 
 
0.009 0.203 0.965 1.009 0.678 1.501
Cancer 
 
-0.623 0.525 0.236 0.536 0.191 1.502
Asthma 
 
0.376 0.247 0.127 1.457 0.898 2.364
Ulcers 1.125 0.529 0.034* 3.081 1.091 8.697
 241
 
 
Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
   Lower Upper
Provider interaction in the pre period 
PAAS enrollment 0.114 0.265 0.666 1.121 0.667 1.883
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy -0.037 0.550 0.946 0.963 0.328 2.829
• Single pharmacy 0.170 0.179 0.343 1.185 0.834 1.683
 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.341 0.610 0.577 1.406 0.425 4.646
• Internal medicine          0.178 0.185 0.334 1.195 0.832 1.716
Total diabetes costs 0.000 0.000 0.978 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.409 0.241 0.090 1.505 0.938 2.414
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.825 1.000 0.999 1.001
Initial polytherapy 0.249 0.321 0.438 1.283 0.683 2.408
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -0.158 0.365 0.666 0.854 0.418 1.746
• Biguanides  0.128 0.189 0.499 1.137 0.784 1.648
• Alpha-glucosidase -1.008 0.871 0.247 0.365 0.066 2.012
• Sulfonylurea-biguanide    -0.484 0.602 0.422 0.616 0.189 2.006
• Meglitinides 0.420 0.630 0.505 1.521 0.443 5.230
Constant -2.671 0.834 0.001 0.069  
    
*Significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
 
Model fit statistics: 
 
Pseudo R-square = 23.5% 
-2 Log Likelihood = 871.069; χ2  = 153.705, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 8.552; p= 0.381 
 
Table 35: Logistic regression for the impact of adherence (Reg MPR-1) on having a 
type 2 diabetes related ER/Hospitalization episode 
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Table 36: Semi-log Ordinary Least Squares (OLS) regression model for the impact 
of adherence (Reg MPR-2) on total diabetes related costs  
 Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
     
Depression  0.275 0.076 3.639 0.000* 
 
Adherence (Ref: Good adherence) 
• Very low adherence  -0.840 0.084 -9.980 0.000* 
• Low adherence   0.023 0.115 0.197 0.844 
• Average adherence  -0.061 0.103 -0.593 0.554 
• Over adherence  0.166 0.128 1.294 0.196 
 
Demographic characteristics 
Age (in years) 0.003 0.004 0.753 0.452 
 
Males (ref: females) 
 
0.056 0.072 0.776 0.438 
Whites (ref: non-whites) 0.066 0.148 0.449 0.653 
 
Urban (ref: rural) 
 
-0.197 0.123 -1.600 0.110 
Year of index prescription (ref: 2001) 
• 1998  -0.014 0.179 -0.077 0.938 
• 1999 0.393 0.168 2.331 0.020* 
• 2000 0.306 0.159 1.932 0.054* 
 
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.072 0.014 5.206 0.000* 
Total health costs 
     
0.000 0.000 -2.343 0.019* 
Charlson co-morbidity 
            
0.137 0.040 3.438 0.001* 
Number of therapeutic classes 
of medications 
0.053 0.021 2.489 0.013* 
Cardio-vascular 
 
0.026 0.076 0.339 0.735 
Cancer 
 
-0.337 0.188 -1.797 0.073 
Asthma 
 
0.052 0.102 0.513 0.608 
Ulcers 
 
0.235 0.202 1.165 0.244 
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Beta S.E. Test statistic 
(t) 
Sig. 
(p) 
 
Provider interaction in the pre period 
PAAS enrollment 0.128 0.104 1.235 0.217 
 
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.031 0.171 0.182 0.855 
• Single pharmacy -0.034 0.070 -0.484 0.628 
   
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.307 0.270 1.137 0.256 
• Internal medicine          0.057 0.073 0.781 0.435 
 
Total diabetes costs 0.000 0.000 0.467 0.641 
 
Number of diabetes related 
ER/Hosp visits 
 
0.217 0.099 2.205 0.028* 
Gap between index diagnosis 
and prescription 
 
0.000 0.000 1.309 0.191 
Initial polytherapy 0.665 0.148 4.496 0.000* 
 
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione 0.612 0.142 4.312 0.000* 
• Biguanides  0.192 0.074 2.593 0.010* 
• Alpha-glucosidase -0.073 0.271 -0.269 0.788 
• Sulfonyl-biguanides -0.735 0.252 -2.914 0.004* 
• Meglitinides 0.506 0.265 1.914 0.056 
   
Constant 6.259 0.316 19.794 0.000 
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
Model fit statistics: 
 
R-square: 23.7%; F = 11.479; P = 0.000 
Durbin-Watson: 1.995 
White test for heteroskedasticity: χ2= 596.11; p= 0.0678 
 
 
 
 
Table 36: Semi-log Ordinary Least Squares (OLS) regression model for the impact of 
adherence (Reg MPR-2) on total diabetes related costs (Contd.) 
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Table 37: Logistic regression for the impact of adherence (Reg MPR-2) on having a 
type 2 diabetes related ER/hospitalization episode  
 Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
     Lower Upper
Depression 0.330 0.151 0.029* 1.390 1.034 1.871
Adherence (Ref: Good adherence) 
• Very low adherence   -0.025 0.175 0.885 0.975 0.692 1.374
• Low adherence    0.485 0.222 0.029* 1.624 1.051 2.510
• Average adherence   -0.070 0.217 0.748 0.932 0.609 1.428
• Over adherence   0.037 0.267 0.890 1.038 0.615 1.752
 
Demographic characteristics 
Age (in years) 0.002 0.007 0.804 1.002 0.987 1.016
Males (ref: females) 
 
-0.038 0.150 0.802 0.963 0.718 1.292
Whites (ref: non-whites) 
 
-0.013 0.311 0.965 0.987 0.536 1.815
Urban (ref: rural) 
 
0.095 0.258 0.713 1.100 0.663 1.824
Year of index prescription (ref: 2001) 
• 1998  -0.287 0.372 0.439 0.750 0.362 1.554
• 1999 0.419 0.344 0.223 1.520 0.775 2.983
• 2000 0.320 0.324 0.323 1.377 0.730 2.598
Co-morbid conditions in the pre period 
Number of ER/hosp visits 
 
0.232 0.038 0.000* 1.261 1.170 1.359
Total health costs 
     
0.000 0.000 0.493 1.000 1.000 1.000
Charlson co-morbidity 
            
0.143 0.077 0.065 1.154 0.991 1.343
Number of therapeutic classes 
of medications 
0.104 0.042 0.014* 1.110 1.021 1.206
Cardio-vascular 
 
-0.034 0.157 0.831 0.967 0.711 1.316
Cancer 
 
-0.483 0.388 0.213 0.617 0.288 1.319
Asthma 
 
0.238 0.194 0.220 1.268 0.868 1.854
Ulcers 
 
0.663 0.394 0.092 1.941 0.898 4.199
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Beta S.E. Sig. 
(p) 
Odds 
ratio 
95% C.I. for 
Odds ratio
   Lower Upper
Provider interaction in the pre period 
PAAS enrollment -0.047 0.216 0.828 0.954 0.625 1.457
Number of pharmacies visited (ref: multiple pharmacies) 
• No pharmacy 0.197 0.376 0.601 1.217 0.583 2.541
• Single pharmacy 0.063 0.145 0.664 1.065 0.802 1.413
 
Diabetes severity 
Index oral hypoglycemic prescription by: (ref: Family medicine) 
• Endocrinologist 0.370 0.519 0.476 1.447 0.523 4.002
• Internal medicine          0.139 0.147 0.344 1.149 0.862 1.532
Total diabetes costs 0.000 0.000 0.720 1.000 1.000 1.000
Number of diabetes related 
ER/Hosp visits 
 
0.455 0.199 0.022* 1.577 1.067 2.329
Gap between index diagnosis 
and prescription 
 
0.000 0.000 0.955 1.000 0.999 1.001
Initial polytherapy 0.213 0.290 0.463 1.237 0.701 2.184
Index class of oral hypoglycemic (ref: Sulfonyl urea) 
• Thiazolidenedione -0.006 0.280 0.983 0.994 0.574 1.722
• Biguanides  -0.085 0.152 0.577 0.918 0.681 1.238
• Alpha-glucosidase -0.918 0.672 0.172 0.399 0.107 1.491
• Sulfonylurea-biguanide    -0.572 0.520 0.271 0.564 0.204 1.563
• Meglitinides -0.078 0.546 0.887 0.925 0.317 2.698
Constant -2.266 0.658 0.001 0.104  
    
*significance at the 0.05 level 
PAAS: Physician Assured Access System 
 
 
Model fit statistics: 
 
Pseudo R-square = 20.2% 
-2 Log Likelihood = 1344.536; χ2  = 195.596, p= 0.000 
Hosmer and Lemeshow’s goodness of fit: χ2  = 4.848; p= 0.774 
 
 
 
Table 37: Logistic regression for the impact of adherence (Reg MPR-2) on having a 
type 2 diabetes related ER/hospitalization episode (Contd.) 
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Discussion for Objective 9 
The four step method for determining mediation indicated that adherence to oral 
hypoglycemics is not a mediator in the relationship between depression and type 2 
diabetes.  Lustman and associates122,123 and Gary and associates131 conducted studies 
using different methodological approaches to determine the mediating role of adherence 
in the impact of depression on diabetes outcomes.  Their findings were similar to our 
study results with depression affecting diabetes outcomes without adherence being a 
mediating variable.   
As for the effect of adherence on type 2 diabetes related costs, our results 
indicated lack of a strong association.  However, the effect was non-linear with results 
indicating that patients who had very low adherence have lower costs and patients with 
over adherence have higher costs than patients with good adherence.  For the middle 
group, there seemed to be a linear trend with improving adherence decreasing type 2 
diabetes costs.  An interesting finding is the effect of over adherence on costs.  Over 
adherence is ignored in a lot of adherence studies by truncating the adherence levels at 
1.0.   In some situations over adherence may not be serious, while in other situations it 
may result in serious conditions such as hypoglycemia or may be indicative of over 
aggressive pharmacotherapy.  The study also examined the effect of over adherence 
separately on non-prescription type 2 diabetes costs.  The effects remained the same 
indicating higher type 2 diabetes costs in patients who are over adherent to their oral 
hypoglycemics.  Low costs for patients with low adherence may possibly be due to the 
fact that these patients have achieved glycemic control through diet and exercise and 
hence did not regularly filled their prescriptions.  These results were similar to those of a 
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recent retrospective cohort study conducted in a non-managed care setting, wherein a 
non-linear effect was observed with significantly lower costs for patients with less than 
20% adherence and significantly higher costs for patients with more than 100% 
adherence.  Adherence levels somewhere in between showed a weak negative linear 
association with type 2 diabetes costs.84  
The study had a short follow up period of one year.  Diabetes is a chronic illness 
and complications of diabetes normally arise years after diagnosis.  Improved adherence 
with oral hypoglycemics is likely to increase pharmaceutical costs in the short term.  The 
decreases in medical costs due to improved adherence may not be enough to offset the 
high costs of pharmaceuticals in the short term.  However, a couple of sub-analyses were 
conducted to explore these issues.  The objectives were examined in a sub-sample with a 
24-month follow up period.  Also, the impact of adherence on type 2 diabetes related 
costs excluding those due to pharmaceutical expenditures were examined.  However, 
these sub-analyses provided identical results.  It may take many years of improved 
glycemic control through adherence to oral hypoglycemics to reduce medical costs 
associated with treatment of long-term complications.  Thus, the relationship between 
depression, adherence, and type 2 diabetes related expenditures might differ with a longer 
measurement period. 
These results of this study could be possible as one failed to measure adherence to 
other aspects of diabetes therapy such as diet, exercise, or glucose monitoring.  Also, the 
relation between depression and type 2 diabetes outcomes might occur via physiological 
pathways that are independent of behavioral factors.  It is possible that a common 
neuroendocrine factor leads to both depression and diabetes.  The increased expenditures 
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may be a direct result of worsening glucose control due to changes in the autonomic 
nervous system, the hypothalamic-pituitary adrenal axis, or neurotransmitters.   
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CHAPTER FIVE 
SUMMARY AND CONCLUSIONS 
This chapter provides and overview of the study findings, draws conclusions, 
presents implications of the study, lists limitations, and provides recommendations for 
future research. 
Phase 1 
The potential effects of depression on outcomes associated with management of 
type 2 diabetes may be significant when one considers that depression is highly prevalent 
in patients with diabetes.  In addition to the increased prevalence of co-morbid depression 
in patients with type 2 diabetes, a few studies have also indicated an increased incidence 
of type 2 diabetes in patients with depression.  Depression is related to changes in 
nutrition and exercise that may contribute to risk for diabetes; and there may be somatic 
aspects of depression such as a change in the immune or vascular system that contributes 
to enhanced risk for diabetes onset.  Phase 1 of the study examined the epidemiological 
relationship between depression and type 2 diabetes.  Objectives of this phase included 
determining the prevalence of co-morbid depression in patients with type 2 diabetes and 
the incidence of type 2 diabetes in patients with pre-existing depression. 
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Conclusions for Phase 1 
Objective 1: To estimate prevalence of co-morbid depression in patients with type 2 
diabetes 
The null hypothesis for this objective was that there is no difference between the 
prevalence of co-morbid depression in patients with type 2 diabetes and without type 2 
diabetes.  The study results indicated that co-morbid depression was more prevalent in 
patients with type 2 diabetes as compared to enrollees without type 2 diabetes.  The 
higher prevalence of depression was primarily due to the higher number of co-morbid 
conditions associated with type 2 diabetes.  However, one can attribute these co-morbid 
conditions and subsequent depression to type 2 diabetes and thus reasonably conclude 
that type 2 diabetes is associated with a higher prevalence of co-morbid depression.   
 
Objective 2:  To estimate the incidence of type 2 diabetes in patients with pre-existing 
depression 
The null hypothesis for this objective was that there is no difference in the 
incidence rate of type 2 diabetes in patients with pre-existing depression as compared to 
patients without pre-existing depression.  The results indicated that female patients with 
pre-existing depression are more likely to develop type 2 diabetes as compared to 
enrollees without pre-existing depression controlling for baseline confounding factors 
such as demographics and co-morbidity.  No differences in incident rates were observed 
in males. 
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Phase 2 
Phase 2 of the study examined the impact of depression on patterns of oral 
hypoglycemic use, initiation of insulin therapy, and adherence with oral hypoglycemics.  
The effect of depression on utilization and expenditures related to type 2 diabetes and 
overall health care (excluding those due to depressive diagnosis) was also estimated.   In 
addition, the study also tested the mediating influence of adherence with oral 
hypoglycemics between depression and outcomes related to management of type 2 
diabetes. 
 
Conclusions for Phase 2 
Objective 3:  To examine the impact of preexisting depression on patterns of oral 
hypoglycemic use in new patients with type 2 diabetes  
The null hypothesis for this objective was that there is no difference in the pattern 
of oral hypoglycemic use between newly diagnosed type 2 diabetes patients who have 
pre-existing depression and those who do not have pre-existing depression.  The study 
findings indicated that patients without depression had a significantly favorable pattern of 
oral hypoglycemic use as compared to non-depressed patients.  A significantly higher 
proportion of depressed patients, switched, augmented or discontinued their index oral 
hypoglycemic therapy as compared to non –depressed patients. 
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Objective 4:  To examine the impact of preexisting depression on modification of oral 
hypoglycemic therapy 
The null hypothesis for this objective was that there is no difference in the rate of 
modification of oral hypoglycemics between newly diagnosed type 2 diabetes patients 
who have pre-existing depression and those who do not have pre-existing depression.  
The results indicated that patients with depression had a significantly higher rate of 
modification of oral hypoglycemic therapy and had a relatively shorter time to 
modification as compared to non-depressed patients.   
 
Objective 5: To estimate the impact of preexisting depression on initiation of insulin 
therapy in patients with type 2 diabetes 
The null hypothesis for this objective was that there is no difference in the rate of 
initiation of insulin therapy between newly diagnosed type 2 diabetes patients who have 
pre-existing depression and those who do not have pre-existing depression.  The null 
hypothesis for this objective was accepted as no differences were seen in rates of insulin 
initiation and time to insulin therapy between depressed and non-depressed patients in the 
12-month follow up period.   
 
Objective 6: To estimate the impact of preexisting depression on adherence to oral 
hypoglycemic agents 
The null hypothesis for this objective was that there is no difference in adherence 
to oral hypoglycemics between newly diagnosed type 2 diabetes patients who have pre-
existing depression and those who do not have pre-existing depression.  The findings 
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demonstrated that depressed patients had significantly lower adherence to oral 
hypoglycemic agents as compared to non-depressed patients.  However, the magnitude of 
difference was not large with results indicating that patients with depression were 3-6% 
less adherent than non-depressed patients.  
 
Objective 7: To estimate the impact of preexisting depression on type 2 diabetes related 
utilization and costs  
The null hypothesis for this objective was that there is no difference in type 2 
diabetes related utilization and costs between newly diagnosed type 2 diabetes patients 
who have pre-existing depression and those who do not have pre-existing depression.  
Patients with depression had significantly higher type 2 diabetes related costs as 
compared to non-depressed patients.  Results indicated that controlling for confounding 
covariates, patients with depression incurred around 21.30% higher type 2 diabetes costs 
as compared to non-depressed patients.  These cost differences were primarily due to a 
higher probability of an ER/hospitalization episode in depressed patients as compared to 
non-depressed patients.  Also, a significant difference between the two groups was in 
terms of number of type 2 diabetes related ER/hospitalizations with depressed patients 
incurring nearly 57.80% higher number of visits as compared to non depressed patients. 
 
Objective 8: To estimate the impact of preexisting depression on overall health care 
utilization and costs (excluding those due to depressive diagnosis) 
The null hypothesis for this objective was that there is no difference in overall 
health care utilization and costs between newly diagnosed type 2 diabetes patients who 
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have pre-existing depression and those who do not have pre-existing depression.  Patients 
with depression had nearly 32.10% higher overall health care costs (excluding those due 
to depressive diagnosis) as compared to patients without depression.  Depression was 
associated with increased costs in all areas of health care such as ER/hospitalization, 
outpatient, and prescription costs.  A similar increase in health care utilization was 
observed for depressed patients in terms of number of ER/hospitalization episodes, 
physician office visits, and prescriptions in the 12-month follow up period. 
 
 Objective 9:  To examine the causal pathways between preexisting depression, 
adherence, and outcomes such as resource utilization and costs for type 2 diabetes 
The null hypothesis for this objective was that adherence to oral hypoglycemics is 
not a mediating variable between the presence of pre-existing depression and outcomes 
related to management of type 2 diabetes.  Mediation analysis indicated that depression 
had a significant impact on both, type 2 diabetes related expenditures and adherence with 
oral hypoglycemics.  However, adherence to oral hypoglycemics was not a mediator 
between depression and type 2 diabetes related expenditures.  Depression could have 
impacted type 2 diabetes related outcomes directly through a physiological effect on 
glycemic levels or indirectly through its impact on adherence to other behaviors such as 
diet or exercise. 
Limitations 
Although our database study revealed the patterns of oral hypoglycemic use such 
as switching, augmentation, discontinuation, it gives no indication of the reasons for 
these patterns.  These patterns could be a result of variety of reasons such as side effects, 
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lack of efficacy, adequate glycemic control, or co-morbid conditions.  Determining these 
reasons from claims data without additional clinical or patient/physician reported 
information is not possible.  The study could have classified some patients who achieved 
glycemic control through diet and exercise and were taken off their oral hypoglycemic 
prescriptions as discontinuers and non-adherent.  Also, the adherence measures were 
based on refill information from prescription claims data.  Hence, the study makes the 
assumption that the prescriptions filled by patients were used appropriately.  These 
indirect measures of adherence from claims data may not be considered the most accurate 
and reliable, but several studies have found significant associations between adherence 
measured from refill information and other methods such as self-report, pill count, 
medication diary.166 
Adherence to medications can be affected by a number of factors, which were not 
measured in this study such as social support, perceived risk of the outcomes of being 
non-adherent, and others.  One of the primary factors affecting adherence to oral 
hypoglycemics is diabetes severity.  All our estimation models were controlled for 
severity of diabetes, which was measured from the information available from claims 
data.  Although large variations in diabetes severity were not expected in this study 
population of newly diagnosed type 2 diabetes patients, additional laboratory values such 
as A1C and blood glucose levels would have been helpful in determining disease 
severity.  These laboratory values could also have been very useful as clinical outcome 
measures of diabetes therapy in addition to economic outcomes such as type 2 diabetes 
related expenditures.   
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 One of the primary limitations of this study is the absence of measurement of 
depression severity though a structured diagnostic interview.  Depressed patients in this 
study are identified on the basis of seeking treatment for depression.  Hence, it is possible 
that patients in this study classified as non-depressed may have depression 
symptomatology but not been diagnosed with depression.  This issue of 
undiagnosed/unrecognized depression can potentially lead to misclassification bias as 
patient classified as non-depressed could be patients with undiagnosed depression.  
However, one can assume that diagnosed patients will have more severe depressive 
symptoms as compared to an undiagnosed population.  Also, this misclassification could 
only lead to underestimation of the effect of depression on adherence to medications and 
related outcomes.  The significant impact of depression found in this study’s results 
would remain significant, but have a bigger magnitude of effect in absence of this 
misclassification.   
The mediation analyses indicated that adherence to oral hypoglycemics had a 
non-linear and insignificant impact on type 2 diabetes related costs.  However, diabetes is 
a chronic illness and complications of diabetes arise after several years of diagnosis.  
Improved adherence with oral hypoglycemics is likely to increase pharmaceutical costs in 
the short term.  The decreases in medical costs due to improved adherence may not be 
enough to offset the high costs of pharmaceuticals in the short term.  This study used a 
12-month follow up period since the initial diagnosis of type 2 diabetes.  It may take 
many years of improved glycemic control through adherence to oral hypoglycemics to 
reduce medical costs associated with treatment of long-term complications.  Thus the 
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relationship between depression, adherence, and type 2 diabetes related expenditures 
might differ with a longer measurement period. 
 
 
Implications 
 
Study results indicated that depression is associated with significantly higher type 
2 diabetes and overall health care costs.  Also, the rate of occurrence of depression in 
patients with type 2 diabetes was significantly higher as compared to Medicaid enrollees 
without type 2 diabetes.  These results should encourage West Virginia Medicaid, 
national credentialing committees, large insurers, and employers to screen for depression 
in patients with type 2 diabetes and improve clinical management of depression in these 
patients.  The implications of untreated depression on long-term type 2 diabetes 
complications can be even more significant when one considers that depression may be 
recurrent in diabetes patients.  This data suggests that interventions are needed to screen 
diabetes patients for depression and use effective and aggressive therapies for treatment 
of depression.  These data may provide an impetus for improving the detection and 
treatment of depression.  Such increased effort in detecting and treating depression may 
be associated with additional non-psychiatric health benefits due to improved adherence, 
glycemic control, and decreased health care utilization. 
Also, the observed higher risk of type 2 diabetes among female patients with 
depression may suggest that physicians need to monitor diabetic metabolic changes in 
females with depression for early detection and treatment of type 2 diabetes.  Undetected 
and untreated type 2 diabetes can aggravate diabetic complications thus resulting in 
increased costs associated with management of type 2 diabetes.   Considering the high 
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prevalence of depression in West Virginia Medicaid, an improved screening and 
detection of type 2 diabetes may result in better disease management and cost saving. 
In addition to improving depression screening for patients with type 2 diabetes, 
one must systematically identify patients who have both type 2 diabetes and depression to 
ensure appropriate quality of care and the need for more aggressive treatment.  The 
recognition of depression as a risk factor for decreasing adherence with oral 
hypoglycemics and increasing type 2 diabetes related expenditures has the potential to 
improve diabetes management and related outcomes.  A potential barrier to effective 
depression management among type 2 diabetes patients is the lack of an overall unified 
view of a patient’s condition encompassing both the conditions.  Although the Health 
Plan Employer Data and Information Set (HEDIS) has included performance measures 
for both depression and diabetes care, separate standards should also be set for the 
treatment of type 2 diabetes with co-morbid depression.  Programs addressing such 
multiple disorders must search for commonalities in treatment.167 A good example can be 
the emphasis on increased physical activity for management of both diabetes and 
depression. Also, given the crucial role of depression in diabetes, mental health 
professionals can play an important role in the care of these patients.  This also calls for 
mental health professionals to create working relations with diabetes health care 
providers, including physicians, nurses, dietitians, pharmacists, and others. 
Physicians can help improve patient adherence to treatment regimens by 
addressing adherence issues with their patients regularly and providing them with 
educational materials.  Pharmacists can also assume a proactive role, especially in type 2 
diabetes patients with co-morbid depression.  These data suggest that patients with 
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depressive symptoms should have their adherence to oral hypoglycemics monitored 
particularly closely and may require special encouragement from health care providers.   
Recognizing that a patient might be depressed could help a physician fathom the reasons 
for a patient’s non-adherence and thus improve patient-physician relationship.  For 
patients initiating treatment for type 2 diabetes, presence of depression might prove to be 
a useful indicator of possible future non-adherence and might suggest closer monitoring 
and assistance to achieve adherence to treatment.  Alternatively, a lack of adherence with 
diabetes pharmacotherapy should cause concern for a possible presence of co-morbid 
depression.   
 
Directions for Future Research 
 
One of the main limitations of this study was the lack of clinical information 
regarding glycemic control and depression severity.  The study also failed to measure 
adherence to other behaviors such as diet, exercise, and glucose monitoring that can 
affect management of type 2 diabetes.  Incorporation of this clinical and adherence 
information in the study design can increase the validity of the findings.  The relationship 
between depression and type 2 diabetes can be better explained in such a large scale 
longitudinal study that measure indicators such as adherence to medications, diet, and 
exercise, alterations in neurohormonal levels, depression severity, and glycemic levels at 
several points in time.  Similar research can be conducted in patients with type 2 diabetes 
developing depression over the course of their diabetes management.  The effect of the 
onset of depression on changing adherence with oral hypoglycemics and related 
outcomes in a prevalent type 2 diabetes patient should also be examined.   
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There are a number of approaches to measure adherence with medications.  Refill 
information using claims data seems a relatively valid and non-intrusive method to 
measure adherence.  However, future studies can use multiple methods of adherence 
measurement such as pill count, self-report, or MEMS cap to validate the results from 
refill information.  One of the main problems with refill data is the absence of 
information on free samples provided by physicians, which can especially invalidate the 
patterns of oral hypoglycemic use computed in our study.  Similar studies in literature 
have measured patterns of use in terms of discontinuation, augmentation, modification, 
and switching from claims data.  Future research needs to examine the extent of free 
samples being provided by physicians and adjustments be made to findings from claims 
data.   
The excess costs attributable to depression in patients with type 2 diabetes or 
other chronic illness may be more significant if costs due to sick leave, missed 
productivity, or absenteeism from the work force are accounted.  Thus, the impact of 
depression may more substantial from a societal perspective, which includes costs outside 
of the health care system.  In future research, the policy discussion related to the impact 
of depression on costs should be expanded to include such indirect costs.    
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